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ABSTRACT

Conley, Jason M. Ph.D., Purdue University, December 2013. Novel Modulation
of Adenylyl Cyclase Type 2. Major Professor: Val J. Watts.

Adenylyl cyclase isoforms are distinctly modulated by G protein subunits
and are therefore hypothesized to be uniquely regulated by proteins that
influence G protein signaling. Activator of G protein signaling 3 (AGS3) is a G
protein modulator that binds Gαi subunits in the GDP-bound state, implicating
AGS3 as an important regulator of Gi-coupled receptor signaling. We studied the
ability of AGS3 to modulate recombinant adenylyl cyclase (AC) type 1 and 2
signaling in HEK293 cells following both acute and persistent activation of the D2L
dopamine receptor (D2LDR). AGS3 expression modestly enhanced the potency
of acute quinpirole-induced D2LDR modulation of AC1 or AC2 activity. AGS3
also promoted desensitization of D2LDR-mediated inhibition of AC1, whereas
desensitization of D2LDR-mediated AC2 activation was significantly attenuated.
Additionally, AGS3 reduced D2LDR-mediated heterologous sensitization of AC1
and AC2. Our results suggest that AGS3 alters G protein signaling in a complex
fashion that is effector-specific and dependent on the duration of receptor
activation. The present work also addressed the role of Gβγ subunits in the
development of D2LDR-mediated sensitization of AC2. The molecular signaling
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components that contribute to the development of heterologous sensitization are
largely unknown, but G protein subunits are strongly implicated in this adaptive
process. We utilized Gβγ subunit sequestering proteins, small molecule and
peptide Gβγ signaling inhibitors, and pharmacological Gβγ effector and kinase
inhibitors to study the role of Gβγ subunit signaling pathways in the development
of AC2 sensitization in HEK293 cells. Our results suggest that Gβγ subunit
signaling is necessary for D2LDR-mediated sensitization of AC2. The multitude
and diversity of Gβγ signaling pathways that may underlie AC sensitization
prompted us to develop a high-throughput cAMP assay platform to facilitate
future unbiased approaches for the study of AC sensitization, such as siRNA
library screening. As an intermediate step to the development of such assays,
we addressed the lack of potent and selective small molecule modulators of AC.
Identification of chemical probes for AC2 is particularly important because there
are no published genetic deletion studies and few small molecule modulators.
Therefore, we developed and executed an intact-cell small molecule screening
approach and subsequent validation paradigm for the discovery of AC2 inhibitors.
The NIH clinical collections I and II were screened for inhibitors of AC2 activity,
using PMA-stimulated cAMP accumulation as a functional readout. Active
compounds were subsequently confirmed and validated as direct AC2 inhibitors
using orthogonal and counter screening assays. The screening effort identified
SKF-83566 as a selective AC2 inhibitor with superior pharmacological properties
for selective modulation of AC2 when compared to currently available AC

x
inhibitors. The utility of SKF-83566 as a small molecule probe to study the
function of endogenous ACs was demonstrated in C2C12 mouse skeletal muscle
cells.
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CHAPTER 1. INTRODUCTION

1.1

The foundation of second messenger signaling: A historical perspective
Cyclic AMP (cAMP) is the prototypical second messenger signaling

molecule and the impact of cAMP signaling research is highlighted by the fact
that four Nobel prizes have been awarded for the study of cAMP signaling
components (Sutherland in 1971, Krebs and Fischer in 1992, Gilman and
Rodbell in 1994, and Lefkowitz and Kobilka in 2012). The identification of cAMP
was first reported in the late 1950s by Earl Sutherland and colleagues while
studying the relationship of the hormones epinephrine and glucagon to the
activation of liver phosphorylase (Rall et al., 1957; Sutherland and Rall, 1958).
Specifically, hormone treatment resulted in activation of liver phsophorylase and
a heat-stable molecule was isolated from the particulate fraction of the tissue
homogenate following fractionation (Sutherland and Rall, 1958). Remarkably,
the heat-stable factor was able to activate liver phosphorylase in the supernatant
fraction, while hormone treatment had no effect on the liver phosphorylase in the
supernatant fraction (Rall et al., 1957; Sutherland and Rall, 1958; Sutherland and
Rall, 1960). Ultimately, the heat-stable factor was found to be cAMP and the
enzyme that synthesizes cAMP was termed the adenylyl cyclase (AC) enzyme
(Rall and Sutherland, 1958; Sutherland et al., 1962). Cyclic AMP was
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considered a second messenger because their results suggested that the
hormone-mediated activation of liver phosphorylase occurs in two distinct steps
(Rall et al., 1957). For example, the first messenger (hormone) was unable to
activate liver phosphorylase on its own, but stimulated AC to produce cAMP
(second messenger), which was capable of activating liver phosphorylase in the
supernatant fraction (Sutherland and Rall, 1960). It was subsequently realized
that a variety of hormones and catecholamines were able to stimulate cAMP
responses in multiple tissue types (and elicit specific physiological responses),
suggesting a common mechanism of signal relay (Robison et al., 1968;
Sutherland and Rall, 1960). Nonetheless, until the early 1970s, it was unclear if
adenylyl cyclases were responsible for both hormone-binding and cAMP
synthesis or if intermediates between hormone and adenylyl cyclase existed
(Robison et al., 1968). The requirement of GTP for hormonal activation of AC
was the first explicit suggestion that intermediate signal transducers were
involved in hormone-mediated AC activity (Rodbell et al., 1971a; Rodbell et al.,
1971b). It was further observed that a stimulatory regulator (the guanine
nucleotide-binding protein, Gs) was necessary for significant adenylyl cyclase
activity under physiological conditions and that binding of GTP to the G protein
promoted its association with the catalytic moieties (Pfeuffer, 1979; Ross and
Gilman, 1977). It was also demonstrated that agonist binding of receptor
increased the receptor size as measured by gel exclusion chromatography, but
was not due to interaction of the AC catalytic moieties, as they eluted
independently. (Limbird and Lefkowitz, 1978). Soon after, it was then
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demonstrated that agonist-activated receptor coupled with G protein (Limbird et
al., 1980), leading to the conclusion that the G protein is a communicator
between the agonist-activated receptor and the AC enzyme (Figure 1.1). These
studies intimately link receptor and G proteins to AC/cAMP-mediated
physiological responses and form the backbone of the signaling pathway
mechanism for how a hormone or catecholamine ligand is transduced into a
physiological response.

4

Figure 1.1 Schematic of hormone-stimulated cAMP signaling.
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1.2

Adenylyl cyclase topology and catalytic mechanism

Early studies of cAMP suggested that the enzyme that catalyzes the
formation of cAMP is membrane-bound (Sutherland and Rall, 1958). The
topology of AC, however, was not realized until over three decades later, upon
the cloning of the first AC isoform (Krupinski et al., 1989). Specifically,
hydropathy analysis of the primary sequence suggested that the enzyme could
be conceptually divided into two large sets of alternating hydrophobic and
hydrophilic domains, where each of the hydrophobic domains consisted of six
transmembrane spans and each of the hydrophilic domains was homologous to
the cytoplasmic domain of guanylyl cyclase (Krupinski et al., 1989). The cloning
of eight additional transmembrane AC isoforms suggested similar overall
topology. The proposed structure of AC is thought to have a short, variable
cytoplasmic N-terminus that is followed sequentially by the first sixtransmembrane cassette (M1), the first large cytoplasmic domain (C1a and C1b),
the second six-transmembrane cassette (M2), and finally another large
cytoplasmic domain (C2a and C2b) (Figure 1.2) (Sunahara et al., 1996). The
most conserved stretches of primary sequences reside in the N-terminal
segments the large cytoplasmic domains, specifically in C1a and C2a, whereas
the sequences are most divergent in the N-terminus and C1b and C2b domains
(Sadana and Dessauer, 2009).
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Figure 1.2 Topology of adenylyl cyclase.
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A complete understanding of the structure of AC has remained elusive, as
a crystal structure of an entire AC enzyme remains to be reported. However,
much of what we know about the structure and function of AC stems from
biochemical studies of the C1a and C2a cytoplasmic domains. For example,
these regions can be expressed independently of other domains and possess
catalytic activity (Dessauer and Gilman, 1996; Whisnant et al., 1996; Yan et al.,
1996) and such biochemical studies of the catalytic domains provided the basis
for the crystal structures of AC. Specifically, high resolution crystal structures of
a C2 domain homodimer from AC2 (Zhang et al., 1997) and an AC5-C1a/AC2C2a heterodimer (Tesmer et al., 1997) have been described. The crystal
structures of the two cytoplasmic domains suggest that they interact to form a
“pseudosymmetrical” structure that makes up the catalytic core of AC (Tesmer et
al., 1997; Zhang et al., 1997). The interface of the C1a and C2a domains is
expected to have conformational flexibility that allows for the relative orientation
of the domains to change, while remaining associated (Tesmer et al., 1997). For
example, the catalytic core is thought to exist in at least two states: an open state
that is thought to be unable to accommodate ATP, and a closed state where
domains collapse around ATP to form the active site (Tesmer et al., 1997). The
mechanism of catalysis of ATP to cAMP is thought to be a two-metal-ion
catalysis mechanism (similar to that utilized by Pol I DNA polymerases) where
two metal ions coordinate with ATP in the active site to stabilize a pentavalent
transition state, facilitating the conversion of ATP to cAMP (Tesmer et al., 1999).
Additionally, the crystal structures of the catalytic domains of AC suggest that
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Gαs and the small molecule AC activator, forskolin, (see below for discussion of
AC modulation by forskolin) act allosterically to influence the orientation of the
C1a/C2a interface, thus priming the active site for catalysis (Tesmer et al., 1999).
In contrast, the Gαi subunit of the inhibitory G protein (Gi) is thought to
allosterically influence the relative orientation of the C1a/C2a interface in an
opposite manner, thereby inhibiting the collapse of catalytic residues around ATP
(Dessauer et al., 1998; Tesmer and Sprang, 1998). The crystal structures of the
AC catalytic domains, together with biochemical studies have provided a great
deal of insight into the mechanism of AC modulation by forskolin, Gαs, and Gαi
subunits. However, the nine membrane-bound ACs are distinctly modulated by
many signaling molecules (including Gαi/o subunits, Gβγ protein subunits, Ca2+,
and protein kinases) that are downstream components of G protein coupledreceptor signaling (Hanoune and Defer, 2001). Each of these signaling
molecules may affect catalysis by allosterically modulating the C1a/C2a interface,
but the precise molecular details that contribute to the differential modulation of
AC isoforms are currently not well understood (Tesmer and Sprang, 1998).

1.3

Overview of cAMP signaling: Adenylyl cyclase as a signal integrator within
the cascades that link extracellular stimuli and the resulting cellular
responses
The early studies of hormone-stimulated AC signaling identified the

general G protein-mediated signal transduction mechanism by which
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extracellular ligands can modulate cellular responses via cAMP second
messenger signaling (i.e., receptor-binding of ligand stimulates G protein
activation, resulting in AC activation and cAMP formation). These studies
defined ACs as effectors of G protein-coupled receptor signaling. The decades
following these seminal studies have provided a great deal of research that has
built upon the backbone of G protein-mediated signal transduction to reveal a
high level of complexity and specificity. ACs serve as general signal integrators,
receiving input that is transduced from a variety of ligands that modulate diverse
types of G protein-coupled receptors, thus providing cAMP as an intermediate
signal between extracellular stimuli and cellular response.
The cellular levels of cAMP are directly modulated by two families of
enzymes: adenylyl cyclases, that synthesize cAMP from ATP as described above
(Hanoune and Defer, 2001), and phosphodiesterases (PDEs) that degrade cAMP
(Bender and Beavo, 2006). PDE activity was described soon after the discovery
of cAMP and AC activity (Butcher and Sutherland, 1962) and it is currently known
that PDEs are phosphohydrolase enzymes that regulate the cellular levels of
cyclic second messengers by catalyzing the hydrolysis of the 3’ cyclic phosphate
bonds of cyclic adenosine- and guanosine-3’,5’-monophosphate (cAMP and
cGMP) (Bender and Beavo, 2006). PDEs have been classified into 11 different
families based on amino acid sequence homology and can be further grouped
into three categories based on their substrate specificity (i.e., cAMP-specific,
cGMP-specific, or dual specificity for cAMP and cGMP). There are 21 different
gene products that have alternative transcriptional start sites and alternative
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splicing of mRNA, yielding the possibility of >100 PDE protein products (Bender
and Beavo, 2006). The many forms of PDE dynamically modulate the balance of
cellular cAMP and have been linked to specific physiological processes (Bender
and Beavo, 2006).
The ACs functionally integrate signals that are transduced from a variety
of diverse extracellular stimuli into a single second messenger molecule, cAMP.
Downstream of cAMP, the canonical signaling pathway proceeds by direct
activation of cAMP-dependent kinase, also known as protein kinase A (PKA). As
cAMP is the prototypical second messenger, PKA is the prototypical protein
kinase and was identified in 1968 (Walsh et al., 1968). The PKA holoenzyme is
formed by two regulatory subunits and two catalytic subunits from a selection of
four regulatory subunit isoforms (RIα, RIβ, RIIα, and RIIβ) that are functionally
non-redundant and three catalytic subunit isoforms (Cα, Cβ, and Cγ) (Taylor et
al., 2012). Upon binding of two cAMP molecules to each regulatory subunit
within a holoenzyme, the catalytic subunits dissociate and phosphorylate specific
targets on serine and threonine residues that are found within a (RRX-S/T-X)
PKA consensus motif (Kemp et al., 1977; Taylor et al., 2012; Ubersax and Ferrell,
2007). PKA signaling specificity is achieved by the complement of regulatory
and catalytic subunit isoforms and PKA substrates that are expressed within a
particular cell (Taylor et al., 2012). The signaling is further fine-tuned by the
directed subcellular localization of PKA by direct binding to A-kinase anchoring
proteins (AKAPs) (Welch et al., 2010). The AKAPs facilitate the formation of
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macromolecular complexes that form PKA signaling hubs within specific cellular
locations that contribute to diverse biological processes (Taylor et al., 2012).
PKA was initially thought to be the sole downstream effector of cAMP and
remains a prevalent effector signaling system, but it has also become apparent
that cAMP modulates additional downstream targets. For example, cyclic
nucleotides directly modulate channels that conduct cations into the cytoplasm.
Two structurally-related families of cyclic nucleotide modulated cation channels
have been identified that differ in their mode of activation (Craven and Zagotta,
2006). Specifically, the cyclic nucleotide gated (CNG) cation channels are
opened upon direct binding of cAMP or cGMP (Kaupp and Seifert, 2002). The
CNG channels have been detected in several tissue types and are highly
expressed in retinal photoreceptors and olfactory neurons, where they are known
to be key mediators of visual and olfactory signal transduction (Kaupp and Seifert,
2002). The other family of cyclic nucleotide-modulated cation channels are the
hyperpolarization-activated cyclic nucleotide-modulated (HCN) channels and are
mainly modulated by voltage (the channels open to cations upon
hyperpolarization, but close due to depolarization), but the probability of channel
opening is increased upon cyclic nucleotide binding (Craven and Zagotta, 2006).
HCN channels are expressed in brain and heart tissue and are thought to
underlie the cation current following hyperpolarization in excitable cells such as
neurons and cardiac pacemaker cells (Biel, 2009).
In 1998, it was discovered that cAMP activates a family of guanine
nucleotide exchange factors that were named exchange proteins activated by
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cAMP (Epacs) (de Rooij et al., 1998; Kawasaki et al., 1998). Two Epac isoforms
have been characterized, Epac1 and Epac2, and it is thought that Epacs catalyze
the exchange of GDP for GTP on the ras-like GTPases Rap1 and Rap2 upon
binding cAMP (Gloerich and Bos, 2010). Interestingly, Rap-independent Epac
signaling has more recently been observed through a variety of additional
signaling molecules including ras, phospholipase C, protein kinase D, and
ERK1/2 (Billington and Hall, 2012). The expanding signaling functions of Epac
proteins have gained attention for their contribution to cAMP signaling in the
heart, brain, pancreas, vasculature, and lungs (Schmidt et al., 2013).
In summary, ACs are central mediators of the signal relay that is initiated
by extracellular stimuli and results in a cellular response (Figure 1.3). Signaling
input from a large number of G protein-coupled receptors is integrated by ACs
and is further relayed in the form of cAMP. Cyclic AMP proceeds to modulate
downstream effector proteins that include PKA, Epacs, and CNG/HCN channels
that influence specific cellular responses that ultimately modulate diverse
physiological processes including metabolism (Robison et al., 1968), cell growth
and differentiation (Boynton and Whitfield, 1983; Friedman, 1976), learning and
memory (Kandel, 2001), cardiac contractility (Drummond and Severson, 1979;
Sobel and Mayer, 1973), and immune responses (Mosenden and Tasken, 2011;
Peters-Golden, 2009; Serezani et al., 2008). The complete molecular details that
contribute to the signaling specificity that allows for such diverse responses
remain unclear, but are thought to be dependent on the complement of signaling
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proteins that are expressed within a given cell and the molecular organization of
these associated signaling components.

14

Figure 1.3 Position of adenylyl cyclase within the cAMP signaling pathway.
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1.4

Adenylyl cyclase signaling properties: Contributions to cAMP signaling
specificity
The specificity of cAMP signaling is tightly regulated, in part, by the

repertoire and interplay of signaling molecules present within a given cell.
Though ACs are only one part of the cAMP signaling pathway, a major
contributing factor to this specificity is that nine membrane-bound mammalian AC
isoforms have been identified, each with distinct patterns of regulation by G
protein subunits, protein kinases, and Ca2+ (Hanoune and Defer, 2001; Patel et
al., 2001). The modulation of cAMP signaling at the level of AC is considered in
detail below.

1.4.1 G protein-coupled receptor signaling
1.4.1.1 G protein activation cycle
The G protein-coupled receptor family is a large (~1000 genes in the
human genome) (Fredriksson et al., 2003) and versatile receptor family whose
members contribute to nearly all physiological processes (Lefkowitz, 2004). G
protein-coupled receptors bind extracellular ligands that induce conformational
changes in the receptor that facilitate the activation of associated G protein
heterotrimers by exchange of GDP for GTP on the G protein α subunit (Gilman,
1987). Upon activation, the G protein heterotrimer undergoes a conformational
change that allows Gα and Gβγ subunits to dissociate/rearrange into an
orientation that permits these subunits to modulate effector proteins (Coleman et
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al., 1994; Lambright et al., 1994; Taussig et al., 1994). The G protein signaling
cycle terminates upon hydrolysis of GTP to GDP on the Gα subunit, resulting in
the inactivating reassociation/rearrangement of Gα and Gβγ (Figure 1.4)
(Coleman et al., 1994; Mixon et al., 1995).
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Figure 1.4 G protein activation cycle.
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1.4.1.2 Effector modulation
Four families of Gα, five Gβ subunit isoforms, and twelve Gγ subunit
isoforms have been identified (Hurowitz et al., 2000; Khan et al., 2013). Early
studies implicated Gα subunits in effector modulation and it is known that the
specific type of Gα subunit can contribute to the direct or indirect modulation of
AC (Figure 1.5). For example, members of the Gαs family (the GNAS gene is
thought to give rise to several gene products) (Bastepe, 2007) are thought to
directly bind to AC in the C2a region (Tesmer et al., 1997; Yan et al., 1997) and
stimulate AC activity (Iyengar, 1993). The inhibitory Gα subunits are comprised
of Gαi1, 2, and 3, Gαo, and Gαz and directly inhibit AC activity by interacting with the
C1a domain (Dessauer et al., 1998), presumably preventing the “closed state” of
the AC catalytic core (Tesmer and Sprang, 1998).
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Figure 1.5 Gα subunit signaling.
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The identification of Gα12 and Gα13 was first reported in 1991 (Strathmann and
Simon, 1991) and Gα12/13 modulation of Rho guanine nucleotide exchange
factor proteins (RhoGEFs) has been widely observed (Siehler, 2009). However,
Gα12/13 has also recently been implicated in the direct and selective modulation
of AC7 (Jiang et al., 2008; Jiang et al., 2013b). In contrast to Gαs, Gαi, and
Gα12/13 (that directly modulate AC activity), Gαq/11 is thought to indirectly
modulate AC activity. For example, Gαq/11 activates phospholipase C, which
catalyzes the conversion of PIP2 into IP3 (binds to IP3 receptors on the ER,
causing Ca2+ release) and diacylglycerol (stimulates protein kinase C) (Hepler et
al., 1993; Smrcka et al., 1991; Sternweis and Smrcka, 1992). Ca2+ and protein
kinase C (PKC) uniquely modulate ACs in isoform-dependent manners (see
regulatory properties).
Gβγ subunits were originally thought to be necessary for the inactivation of
Gα subunits (Northup et al., 1983) and reassociation/rearrangement of the G
protein heterotrimer, thus allowing receptor coupling and subsequent activation.
However, the Gβγ subunits have since gained appreciation for direct modulation
of a large number of effectors including ACs, phospholipase Cβ, Kir3 potassium
channels, and voltage-gated Ca2+ channels and are being increasingly
recognized for their contribution to diverse signaling pathways that are related to
the different effectors that they modulate (for reviews, see (Khan et al., 2013;
Smrcka, 2008)). Furthermore, genetic knockdown of individual Gβ and Gγ
subunits in animal models suggest that specific Gβγ subunit isoforms contribute
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to diverse biological functions including nociception, angiogenesis during
embryonic development, and seizure susceptibility (Khan et al., 2013).
1.4.1.3 Modulation of G protein cycle by accessory proteins
In addition to G protein-coupled receptor modulation, the G protein
activation cycle is sensitive to accessory proteins that include regulators of G
protein signaling (RGS) and activator of G protein signaling (AGS) proteins
(Blumer et al., 2007; Neubig and Siderovski, 2002). There are 20 distinct genes
that have been identified for RGS family members (some with splice variants)
that are categorized into four subfamilies (R4/B, RZ/A, R7/C, and R12/D)
(Abramow-Newerly et al., 2006). All members of the RGS protein family have a
conserved ~120 residue region that is known as the RGS domain and this region
binds directly to GTP-bound Gα subunits to accelerate the rate of GTP hydrolysis,
thereby terminating the G protein cycle (Abramow-Newerly et al., 2006; Neubig
and Siderovski, 2002). The AGS proteins are a diverse family of 10 proteins
(AGS1-10) that were identified in a functional yeast-based screen for receptorindependent signaling (Blumer et al., 2007). AGS proteins are divided into three
groups based on their activity in the yeast-based screen and biochemical studies
(Blumer et al., 2007). The Group I AGS protein (AGS1) displays guaninenucleotide exchange activity similar to that of a G protein-coupled receptor. The
remaining AGS proteins function independent of guanine-nucleotide exchange
and are subdivided based on their interaction partners. Specifically, Group II
AGS proteins (AGS3-AGS6) interact with Gα subunits and Group III AGS
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proteins (AGS2, 7, 8, and 10) interact with Gβγ subunits. The RGS and AGS
proteins influence G protein signaling and effector activation in diverse ways,
including modulation of the rate of GTP hydrolysis and the availability and/or
stability of Gα or Gβγ subunits (Blumer et al., 2007; Neubig and Siderovski, 2002;
Sato et al., 2006).

1.4.2 Regulatory properties of adenylyl cyclase isoforms
The common regulatory property of all AC isoforms is that they are
activated by the stimulatory G protein α subunit (Gαs), but otherwise display
unique regulatory profiles that are modulated by multiple arms of the G proteincoupled receptor pathways. The AC isoforms are categorized into four
subgroups based on their sequence similarities and specific regulatory properties
(Hanoune and Defer, 2001; Patel et al., 2001).

1.4.2.1 Group I ACs
Group I ACs (AC1, AC3, and AC8) are collectively considered the
Ca2+/calmodulin-stimulated ACs. Ca2+-bound calmodulin stimulates AC1 and
AC8 via direct interactions (Cali et al., 1996; Choi et al., 1992a) within the C1b
and C2 domains of AC1 and the N-terminus and C2 domains of AC8 (Gu et al.,
2000; Simpson et al., 2006). In contrast to AC1 and AC8, AC3 appears to be
conditionally activated by calmodulin, as it is dependent on activated Gαs or
forskolin treatment (Choi et al., 1992b). Extensive studies of AC1 and AC8
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suggest that these ACs are physiologically modulated by Ca2+ via a phenomenon
known as capacitative calcium entry (CCE) (Willoughby and Cooper, 2007).
CCE was first proposed in 1986 and is characterized by Ca2+ entering the cell
through store-operated calcium channels in the plasma membrane in response to
depletion of intracellular Ca2+ that is stored in the endoplasmic reticulum (Putney,
1986). It is thought that the proximity of ACs to the store-operated calcium
channels contributes to the modulation of these ACs by local pools of Ca2+
(Willoughby and Cooper, 2007). Interestingly, AC1 appears to be more sensitive
to Ca2+ stimulation than AC8, as Ca2+ more potently stimulates AC1 (Masada et
al., 2009). Furthermore , the modulation of AC1 and AC8 by Ca2+ appears to be
influenced by coincident signaling of Gαs because the convergent stimulation of
AC1 by Gαs and Ca2+ influx is synergestic, but merely additive for AC8 (Cumbay
and Watts, 2001; Nielsen et al., 1996). Though AC1 is relatively more sensitive
to Ca2+ and Gαs signaling than AC8, studies suggest that AC1 is also more
sensitive than AC8 to inhibition by Gαi in response to Gi-coupled receptor
activation (Cumbay and Watts, 2001; Nielsen et al., 1996; Taussig et al., 1993a).
Direct inhibition by Gβγ subunits is a common property of each of the group I
ACs (Diel et al., 2008; Diel et al., 2006; Steiner et al., 2006; Tang and Gilman,
1991). Specifically, Gβγ subunits modulate AC1 signaling with a pattern that
includes attenuation of AC stimulation in response to Gαs-mediated activation,
whereas the inhibition observed by Gαi is enhanced (Tang and Gilman, 1991;
Taussig et al., 1994).
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The group I ACs are also notably regulated by protein kinases. For
example, though Ca2+-bound calmodulin is known to stimulate group I ACs, AC1
and AC3 are inhibited directly by calmodulin-dependent kinase (CaMK)
phosphorylation. Specifically, AC1 is inhibited by CaMKIV (Wayman et al., 1996)
and AC3 is inhibited by CaMKII (Wei et al., 1996), offering distinct modes of
feedback inhibition through calmodulin, whereas AC8 does not appear to be
sensitive to either CaMKII or CaMKIV phosphorylation (Wayman et al., 1996). It
is also suggested that AC8 is insensitive to PKC modulation, whereas AC1 and
AC3 are stimulated by phorbol ester treatment (Jacobowitz et al., 1993).

1.4.2.2 Group II ACs
Group II ACs (AC2, AC4, and AC7) are collectively insensitive to Ca2+
(submicromolar concentrations) and widely believed to be insensitive to Gαi/o
modulation (Tang and Gilman, 1991; Taussig et al., 1993b; Taussig et al., 1994).
As with all AC isoforms, each of the group II ACs are activated by Gαs
stimulation. However, the group II ACs display unique profiles of modulation in
response to PKC activation. AC2 is stimulated by PKC activation and has been
the most extensively studied group II AC isoform with regard to PKC activation.
For example, PKC-mediated stimulation of AC2 has been demonstrated both in
vitro and in intact cell systems and has been observed in response to phorbol
ester treatment (Jacobowitz and Iyengar, 1994; Shen et al., 2012; Yoshimura
and Cooper, 1993; Zimmermann and Taussig, 1996) and via Gq-mediated PKC

25
activation (in response to Gq-coupled receptor activation and by constitutively
active Gq (Q209L)) (Cumbay and Watts, 2005). A comprehensive study of every
PKC isoform has not been reported, but PKCα and PKCδ have both been
implicated in the activation of AC2 (Nguyen and Watts, 2006; Zimmermann and
Taussig, 1996). Further solidifying the direct modulation of AC2 by PKC
phosphorylation, a recent study mapped the phorbol ester- and muscarinic
receptor-mediated PKC phosphorylation in HEK293 cells to S490 and S543 in
the C1b domain (Shen et al., 2012). Similar to AC2, AC7 is stimulated by PKC
activation in response to phorbol ester treatment (Hellevuo et al., 1995; Watson
et al., 1994). Phorbol ester treatment also potentiates Gs-coupled receptormediated AC7 activity (Haslauer et al., 1998) and PKCδ is thought to mediate
this potentiation response (Nelson et al., 2003). In contrast to AC2 and AC7,
AC4 does not appear to be activated by PKC as tested in response to phorbol
ester treatment and reconstituted PKCα (Jacobowitz et al., 1993; Zimmermann
and Taussig, 1996). Further, Gαs stimulation and Gβγ-mediated potentiation of
AC4 activity can be inhibited by PKCα activation (Zimmermann and Taussig,
1996).
In addition to PKC modulation of group II ACs, Gβγ subunits are thought
to modulate the AC activity of all members of group II (AC2, AC4, and AC7) (Gao
and Gilman, 1991; Tang and Gilman, 1991; Yoshimura et al., 1996).
Interestingly, the Gβγ-mediated stimulation of group II ACs is thought to be
conditional, as it is dependent on additional modes of AC stimulation (including
Gαs- and PKC-mediated activation) (Tang and Gilman, 1991; Taussig et al.,
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1993b; Taussig et al., 1994). These modulatory properties of group II ACs are
well-established and have been demonstrated in vitro and in intact cell assays in
response to Gi/o-coupled receptor activation. (Federman et al., 1992; Tang and
Gilman, 1991; Tsu and Wong, 1996; Zimmermann and Taussig, 1996). Studies
with AC2 are consistent with a direct modulation of AC2 activity, as multiple Gβγ
interaction sites have been characterized within the C1a, C1b, and C2 domains
of AC2 (See Figure 1.6) (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006;
Weitmann et al., 2001). Though Gβγ subunits in response to Gi-coupled
receptor activation provide enhancement of AC2 activity, recent evidence
suggests that Gβγ subunits from Gq-coupled receptor activation provide modest
inhibition of AC2 activity (Shen et al., 2012), suggesting bi-directional modulation
of AC2 by Gβγ subunits that is dependent on the Gα subunit that defines the
heterotrimer.
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Figure 1.6 Gβγ subunit interaction sites on adenylyl cyclase 2.
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Novel regulation of AC7 by Gα12/13 has also been reported. Initially, a
synergistic cAMP response to isoproterenol and sphingosine-1-phosphate in
RAW 264.7 macrophages was found to be mediated by the G13 pathway (Jiang
et al., 2007). Subsequent research identified AC7 as the specific AC mediator of
the synergistic response (i.e., AC2 did not mediate the synergistic response) and
it was also shown to be dependent on Gα12/13 subunits (Jiang et al., 2008).
Furthermore, the generation of a series of AC7/AC2 chimeras identified the C1a
and C1b domains of AC7 to be important for the synergistic response (Jiang et
al., 2013b).

1.4.2.3 Group III ACs
The group III ACs (AC5 and AC6) are known as the Ca2+-inhibited group
of ACs, as they are inhibited by submicromolar concentrations of free Ca2+.
Analogous to the modulation observed for group I ACs, it is hypothesized that
CCE is the mechanism by which AC5 and AC6 are physiologically modulated by
free Ca2+, including in response to Gq-mediated receptor activation (Fagan et al.,
2000; Willoughby and Cooper, 2007). In contrast to the inhibition of group III
ACs by Ca2+, Gq-coupled receptor activation in cardiac fibroblasts and gastric
smooth muscle (tissues that express both AC5 and AC6) provides enhanced
downstream AC signaling (Beazely and Watts, 2006; Meszaros et al., 2000;
Ostrom et al., 2003). However, Gq-mediated signaling observed in stably
transfected HEK293 cells indicates that Gq-mediated signaling enhances AC6,
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but not AC5, suggesting a possibility for selective modulation of AC6 (Beazely et
al., 2005).
AC5 and AC6 are robustly stimulated by Gαs subunits and inhibited by
Gαi subunits (Chen-Goodspeed et al., 2005). Though in vitro studies suggest
that group III ACs are insensitive to Gαo (Taussig et al., 1993a; Taussig et al.,
1994), a number of intact cell and studies of cAMP signaling in tissues that
express Group III ACs and Gαo suggest that receptor-mediated Gαo signaling
can modulate AC5 and AC6 activity (for review, see (Beazely and Watts, 2006)).
Some evidence exists for the modulation of group III ACs by Gβγ subunits. For
example, overexpression studies in cells suggest that Gβγ expression inhibits
AC5 and AC6 (Bayewitch et al., 1998). However, a more recent study suggests
that Gβγ subunits bind directly to the N-terminus of AC5 and AC6 as part of a
GαsGβγ heterotrimer and enhance Gαs-stimulated activity (Gao et al., 2007;
Sadana et al., 2009). The differences in the reports of Gβγ modulation of AC5
and AC6 may be attributed to differences in the experimental methodology.
Protein kinases are also thought to modulate AC5 and AC6 activity. For
example, PKA phosphorylation of AC5 and AC6 has been observed and provides
feedback inhibition for these isoforms (Bauman et al., 2006; Beazely et al., 2005;
Iwami et al., 1995). Furthermore, PKA-mediated inhibition of AC6 occurs via a
single phosphorylation site in the C1 domain (S674) (Chen et al., 1997), and the
corresponding residue in AC5 also mediates PKA-dependent inhibition (Bauman
et al., 2006).
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The effects of PKC activity on the modulation of group III ACs appear to
be complex. AC5 activity is thought to be enhanced by PKC activity, as both in
vitro and cell-based assays demonstrate stimulation of AC5 (Kawabe et al., 1996;
Kawabe et al., 1994). The effects of PKC activity on AC6, however, are difficult
to interpret because a range of modulation has been observed. For example,
early studies of phorbol ester treatment on recombinant AC6 transiently
expressed in HEK293 cells suggest only modest (Jacobowitz et al., 1993) or no
significant stimulation of cAMP accumulation (Yoshimura and Cooper, 1993).
However, PKC has been demonstrated to inhibit AC6 activity in in vitro
membrane experiments (Lai et al., 1999; Lin et al., 2002). In contrast, phorbol
ester treatment potentiated forskolin- and Gαs-mediated cAMP in HEK293 cells
stably expressing AC6 (Beazely et al., 2005). Furthermore, phorbol ester
treatment similarly potentiated drug-stimulated cAMP in two cell models thought
to abundantly express AC6 (Chinese hamster ovary cells and Cath.a
differentiated cells) (Beazely et al., 2005; Johnston et al., 2002; Varga et al.,
1998). The contrasting observations surrounding PKC modulation of AC6 may
reflect differential modulation by PKC isoforms and/or differences in the specific
experimental approaches that were utilized.

1.4.2.4 Group IV AC
AC9 is the lone member of group IV and is most recognized for its relative
insensitivity to stimulation by forskolin. The forskolin insensitivity is attributed to a
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single residue in the C2 domain (Y1021) because mutation of this residue to
leucine functionally restored sensitivity to forskolin (Yan et al., 1998). Early
studies suggest that AC9 is stimulated by Gαs (a property common to every AC
isoform) (Hacker et al., 1998), but distinctly inhibited by Ca2+/calcineurin
(Paterson et al., 1995). Gi/o-coupled receptor activation inhibits Gαs-stimulated
AC9 activity in a pertussis-toxin dependent manner, suggesting that AC9 is also
sensitive to inhibition by Gαi subunits (Cumbay and Watts, 2004). However, Gβγ
subunits may also contribute to AC9 inhibition because potentiation of Gαsstimulated cAMP activity in cells stably expressing AC9 was observed upon
sequestration of Gβγ subunits (via Gαt expression) (Cumbay and Watts, 2005).
In addition to G protein modulation, AC9 appears to be susceptible to modulation
by protein kinases. For example, phorbol ester treatment inhibits Gαs-stimulated
AC9 activity in a PKC isoform-dependent manner, as the PKC inhibitor
bisindolylmaleimide I was able to block phorbol ester-mediated inhibition, but
Gö6976 (a PKCα and –β selective inhibitor) had no effect (Cumbay and Watts,
2004). Interestingly, studies of Gq-mediated AC9 modulation identified a
Ca2+/calmodulin/CaMKII-mediated potentiation of Gαs-stimulated AC9 activity
that is PKC-independent (Cumbay and Watts, 2005). These studies suggest that
AC9 is complexly modulated by multiple arms of Ca2+ and kinase signaling
pathways.
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1.4.3 Adenylyl cyclase localization: Tissue distribution, compartmentalization,
and signalosomes
The specificity of AC signaling can be further attributed to the tissuespecificity and subcellular localization of AC isoforms and by their protein-protein
interactions within these locations. The AC isoforms are thought to display
unique tissue distribution profiles. It is notable that most AC expression studies
are inferred from mRNA measurements, as relatively low AC expression and the
lack of specific antibodies have hindered the study of AC isoform protein
expression (Hanoune and Defer, 2001). Table 1.1 summarizes the unique tissue
expression of AC isoforms. These expression patterns, together with the AC
isoform-dependent regulatory properties discussed above, suggest that the
concurrent expression of AC isoforms and other signaling molecules contribute to
distinct, tissue-specific AC-mediated signaling pathways.
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Table 1.1 Adenylyl cyclase tissue distribution

AC isoform
AC1
AC2
AC3
AC4
AC5
AC6
AC7
AC8
AC9

Tissue Distribution
Brain, adrenal gland
Brain, skeletal muscle, lung, heart
Brain, olfactory epithelium
Brain, heart, kidney, liver, lung
Brain, heart, kidney, liver, lung
Widespread
Brain, platelets, widespread
Brain, lung
Brain, skeletal muscle, widespread
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AC isoforms are also thought to selectively reside in specific membrane
microdomains (Ostrom et al., 2012; Ostrom and Insel, 2004). The segregation of
AC isoforms into membrane microdomains such as lipid rafts may contribute to
specificity observed for cAMP signaling. Lipid rafts are sphingolipid and
cholesterol rich portions of the plasma membrane (Simons and Ikonen, 1997)
and it is thought that AC isoforms differentially localize to either lipid raft or nonlipid raft domains of the membrane (Willoughby and Cooper, 2007). Specifically,
the Ca2+-modulated ACs (AC1, AC3, AC5, AC6, and AC8) are thought to reside
in lipid rafts, whereas the Ca2+-insensitive ACs (AC2, AC4, AC7, and AC9)
localize to non-lipid raft domains (Ostrom and Insel, 2004; Willoughby and
Cooper, 2007). Furthermore, many signaling molecules that are associated with
AC signaling including receptors, G proteins, and other effectors also reside with
ACs in specific membrane microdomains (Allen et al., 2007; Patel et al., 2008).
A relevant example of AC signaling specificity imparted by lipid raft organization
has been observed in human bronchial smooth muscle cells. It has been
demonstrated that β adrenergic receptor-mediated signaling specifically activates
AC6, whereas EP2 prostanoid receptor activation specifically modulates
AC2/AC4 signaling in this cell type (Bogard et al., 2012; Bogard et al., 2011).
Though all ACs are sensitive to stimulation by Gαs (Iyengar, 1993), and both β
adrenergic receptors and EP2 prostanoid receptors are Gs-coupled receptors,
AC-isoform-specific signaling was observed. It is particularly notable that the
selective signaling is consistent with the membrane microdomain organization of
receptors and AC isoforms in human bronchial smooth muscle cells (AC6 and β
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adrenergic receptors are in lipid rafts, whereas AC2/AC4 and EP2 prostanoid
receptors are in non-raft membrane domains) (Bogard et al., 2011). Similar
specific receptor-AC signaling has also been observed according to localization
in membrane microdomains of other tissues including aortic smooth muscle cells
and cardiac myocytes (Ostrom et al., 2001; Ostrom et al., 2002; Ostrom et al.,
2000). Thus, it is apparent that organization of signaling molecules into
membrane microdomains contributes to signaling efficiency and specificity by
concentrating specific receptor-AC groups in close proximity.
Lipid raft structures also appear to be important for CCE-modulation of
ACs (Willoughby and Cooper, 2007). Disruption of lipid rafts by sequestration of
cholesterol is known to disrupt the CCE modulation of AC6 (Fagan et al., 2000)
and AC8 (Smith et al., 2002). It is also thought that CCE machinery is localized
to lipid rafts, suggesting that CCE-modulated AC signaling is dependent on
membrane organization by lipid rafts (Martin et al., 2009; Pani et al., 2008). It is
clear that AC signaling modulation (and specificity) is influenced by the
localization of ACs and additional signaling molecules that modulate AC function
within specific membrane microdomains.
Cyclic AMP signaling specificity is also controlled by compartmentalization
of AC-containing multi-protein signalosomes (Dessauer, 2009). For example, the
AKAP family of proteins contributes to the signaling specificity that is observed
with cAMP signaling by enabling close proximity of signaling components via
signalosomes (Taylor et al., 2012; Welch et al., 2010). Over 50 AKAPs have
been identified and each AKAP has a common PKA regulatory subunit
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interaction motif, but are otherwise divergent (Welch et al., 2010). AKAPs are
localized to various subcellular areas and function to anchor PKA to specific
substrates (Dessauer, 2009). Interestingly, several of the AKAPs that localize to
the plasma membrane selectively associate with AC isoforms (Dessauer, 2009).
In some cases, AKAPs are thought to be components of a feedback loop for ACs
that are directly modulated by PKA. For example, AKAP79/150 directly interacts
with AC5/AC6 and also scaffolds PKA (Bauman et al., 2006). Expression of
AKAP79/150 functionally contributes to the modulation of AC5 by promoting
accelerated decay of Gs-coupled receptor-mediated cAMP responses via PKA
phosphorylation (Bauman et al., 2006). These observations suggest that
AKAP79/150 is part of a negative feedback loop to attenuate AC5/AC6 activation
(consistent with Group III ACs being inhibited by PKA phosphorylation). Similar
observations were also reported for PKA-dependent modulation of AC5 signaling
that is mediated by mAKAPβ in cardiac myocytes (Kapiloff et al., 2009).
In addition to PKA scaffolding, perhaps signaling efficiency is also attained
by additional scaffolding functions of AKAPs. It is known that AKAPs interact
with both upstream modulators and downstream effectors of AC (protein kinases,
G protein-coupled receptors, PDEs, and Epacs) (Bauman et al., 2007; DodgeKafka and Kapiloff, 2006; Dodge-Kafka et al., 2005). This is especially
interesting in light of AKAP-mediated AC modulation that is thought to be
independent of PKA function. For example, the AKAP Yotiao directly interacts
with AC2 and functionally inhibits AC2-mediated cAMP signaling (Piggott et al.,
2008), but AC2 is not thought to be modulated by PKA. The mechanism of
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Yotiao modulation of AC2 is unclear, but possibilities include anchoring of PDEs
in proximity of AC2 or by direct allosteric modulation (Dessauer, 2009). Together,
these studies suggest that AKAPs are diverse modulators of AC signaling, but an
appreciation of the underlying mechanisms of AKAP-mediated AC modulation
requires further study. A growing number of AC-interacting proteins that
modulate cAMP signaling (Sadana and Dessauer, 2009; Wang et al., 2009)
support the hypothesis that signalosome-mediated AC modulation is an
important contributor to cAMP signaling specificity and may even be crucial
components of the mechanisms that control cAMP-mediated signaling diversity.

1.5

Heterologous sensitization of adenylyl cyclase

Acute activation of Gi/o-coupled receptors generally leads to attenuation
of cAMP accumulation by inhibition of AC, but prolonged stimulation of Gi/ocoupled receptors results in heightened sensitivity to subsequent stimulatory
input to AC (Watts and Neve, 2005). This phenomenon, known as heterologous
sensitization of AC (also known as superactivation, cAMP overshoot, and
supersensitization), was first observed in Dr. Marshall Nirenberg’s laboratory in
1975 and was hypothesized to be a molecular form of adaptation that contributes
to opiate dependence and tolerance (Sharma et al., 1975). Since the
observation of δ opioid receptor-mediated AC sensitization in Nirenberg’s lab,
persistent activation of several additional types of Gi/o-coupled receptors
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including D2 dopamine, 5HT1A serotonin, µ opioid, and CB1 cannabinoid
receptors have also been found to mediate sensitization, suggestive of a
signaling adaptation that is common for nearly all Gi/o-coupled receptors (Watts
and Neve, 2005). Despite the prevalence of AC sensitization and the study of
this adaptive response since 1975, an understanding of the signaling steps that
link the initial Gi/o signaling event to the enhancement of AC responsiveness
remains elusive.
That sensitization occurs following prolonged Gi/o-coupled receptor
activation and is inhibited by pertussis toxin suggests that G protein subunits
from Gi/o heterotrimers are central to the development of sensitization (Watts,
2002). Subsequent studies utilized pertussis-toxin insensitive Gα subunits as
tools to investigate the specific roles of individual Gαi/o subunit isoforms in
heterologous sensitization of AC. Pertussis toxin-insensitive Gαo (but not
pertussis toxin-insensitive Gαi1, 2, or 3) was capable of supporting D2 dopamine
receptor-induced AC sensitization, but with a reduced response as compared to
that observed in the absence of pertussis toxin treatment in NS20Y cells stably
expressing the D2 dopamine receptor (Watts et al., 1998). Consistent with these
observations, pertussis toxin-insensitive Gαi1, 2, or 3 subunits are also unable to
support sensitization in response to μ or κ opioid receptor-activation (Tso and
Wong, 2000; Tso and Wong, 2001). In contrast, another study reported that
individual pertussis toxin-insensitive Gαi1,2,3, and Gαo subunits are able to
support μ opioid receptor-mediated sensitization of AC (but with a reduced level
of sensitization) in both C6 glioma and HEK293T cells and that the level of
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sensitization observed in these cell types is dependent on the expression levels
of the pertussis toxin-insensitive G protein subunits (Clark and Traynor, 2006).
Furthermore, pertussis toxin-insensitive Gαi1 partially recovers δ opioid receptorinduced sensitization (but pertussis toxin-insensitive Gαi3 and Gαi2/z have no
effect) (Tso and Wong, 2000; Tso and Wong, 2001). The attenuated
sensitization responses that are mediated by individual pertussis toxin-insensitive
Gαi/o subunits suggest the possibility that multiple Gαi/o subunit isoforms
simultaneously contribute to the development of the full sensitization response.
Pertussis toxin treatment also inhibits the rearrangement/release of Gβγ
subunits, thus implicating Gβγ subunit signaling in the development of
heterologous sensitization of AC. The most direct evidence for Gβγ subunits in
sensitization has been obtained with the Gβγ subunit-sequestering proteins Gαt
and the C-terminus of G protein-coupled receptor kinase 2 (GRK2-ct or βARK-ct).
Multiple studies demonstrate a consensus that expression of Gβγ subunit
sequestering tools provides inhibition of heterologous sensitization of AC in
response to persistent activation of several G protein-coupled receptors
(AvidorReiss et al., 1996; Nguyen and Watts, 2005; Rhee et al., 2000; Rubenzik
et al., 2001; Thomas and Hoffman, 1996). Given that Gβγ subunits differentially
influence the direction of AC modulation in an AC isoform-dependent manner
(see AC isoform regulatory properties), it is unlikely that the development of
heterologous sensitization is modulated by direct interactions of Gβγ with AC
isoforms. Thus, it is intriguing that Gβγ subunits are becoming more recognized
for modulation of diverse signaling pathways (Khan et al., 2013; Smrcka, 2008),

40
suggesting that Gβγ subunits are components of complex signaling pathways
that may lead to the development of AC sensitization.
Protein kinases modulate the activity of AC isoforms (see the regulatory
properties of AC section). It is therefore possible that prolonged Gi/o-coupled
receptor activation leads to the downstream modulation of protein kinases that
are able to enhance the activity of ACs, resulting in sensitization of AC.
Consistent with this hypothesis is that Gαi and Gβγ signaling are known to
modulate protein kinases that include PKC, PKA, and Raf-1 (Watts and Neve,
2005). For example, PKC enhances the activity of several AC isoforms (i.e., AC1,
AC2, AC5, AC6, and AC7) and heterologous sensitization has been observed in
cells that express AC2 and AC5, suggesting a role for PKC in the development of
AC sensitization. Furthermore, enhanced PKC-mediated phosphorylation of ACs
(group II ACs) was observed in ileum longitudinal muscle myenteric plexus
preparations obtained from chronic morphine-treated guinea pigs (Chakrabarti et
al., 1998).
Several studies also implicate Raf-1 kinase in heterologous sensitization.
For example, pharmacological inhibition of Raf-1 kinase in Chinese hamster
ovary (CHO) cells decreased cAMP signaling, suggesting that Raf-1 can
stimulate AC6 activity (endogenously expressed) (Tan et al., 2001; Varga et al.,
2003; Varga et al., 1998). Consistent with this observation, studies also suggest
that Raf-1 kinase inhibition attenuates sensitization of AC in CHO cells (Beazely
et al., 2005; Varga et al., 2002; Varga et al., 2003). Furthermore, studies
suggest that Raf-1 can enhance AC activity upon modulation by PKC and
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receptor tyrosine kinases (Beazely et al., 2005; Chen et al., 1995b; Tan et al.,
2001; Varga et al., 2003).
Protein kinase A may also have a role in heterologous sensitization of ACs.
For example, it is known that PKA phosphorylation inhibits AC5 and AC6 activity,
suggesting that inhibitory modulation of PKA may enhance the catalytic activity of
these isoforms. Consistent with this hypothesis, activators of PKA attenuated
sensitization, whereas inhibitors of PKA induced sensitization in a cell line that
endogenously expresses AC6 (Johnston et al., 2002). Additional studies also
support a role for PKA in sensitization via the use of a PKA-deficient cell line
(Thomas and Hoffman, 1989) and activators of PKA in DDT1-MF2 cells (Port et
al., 1992). Contrary to these studies, several approaches also suggest that PKA
is not essential for heterologous sensitization of AC (Avidorreiss et al., 1995;
Watts and Neve, 1996; Watts et al., 1999). These differences may be reflective
of the complement of ACs and other signaling molecules that are present in each
given system and demonstrate the complexity associated with differential
modulation of AC isoforms by protein kinases.

1.6

Adenylyl cyclase isoforms in physiology and disease

AC isoforms are implicated in a variety of physiological processes and
disease states in both the central nervous system and the periphery. Much of
our current understanding of the contribution of individual AC isoforms to
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biological processes is from knockout and transgenic animal studies and is
summarized below.

1.6.1 Adenylyl cyclase function in peripheral tissues
Knockout and transgenic overexpression models implicate both AC5 and
AC6 in cardiac function and heart failure. Specifically, AC5 deletion impairs
sympathetic, parasympathetic, and Ca2+-mediated regulation of left ventricular
function (Okumura et al., 2003a; Tang et al., 2006). However, cardiac-directed
overexpression of AC5 enhances heart rate and fractional shortening, but does
not differ from wild type mice in response to β adrenergic receptor stimulation
(Tepe et al., 1999). Interestingly, deletion of AC6 has no significant effect on the
basal left ventricular function, but disrupts cAMP signaling and Ca2+ handling and
reveals a role for AC6 in β adrenergic receptor-mediated left ventricular function
(Tang et al., 2008). Deletion of AC5 is protective against increased apoptosis
and reduces the left ventricular ejection fraction associated with heart failure in
response to pressure overload induced by thoracic aortic banding (Okumura et
al., 2003b). Targeted overexpression of either AC5 or AC6 displays protective
effects in cardiac function in response to Gq-expression induced cardiomyopathy
(Roth et al., 1999; Tepe and Liggett, 1999), but only AC6 overexpression
reduces hypertrophy and enhances survival (Roth et al., 2002). Interestingly,
subsequent studies further suggest beneficial effects of AC6 expression for
cardiac function (for review, see (Gao and Hammond, 2011)) and that many of
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these effects are independent of the cAMP-generating catalytic function of AC6
(Gao and Hammond, 2011; Gao et al., 2011). Further stratifying the biological
functions of AC5 and AC6, AC5-/- mice show protective effects against ageinduced cardiomyopathy and display increased life-span associated with
additional protective effects against age-related oxidative stress, apoptosis, and
loss of bone quality (Yan et al., 2007). In summary, AC5 and AC6 demonstrate
overlapping, but distinct functions in cardiac function and models of heart failure
and AC5 is implicated in pathophysiological processes associated with aging.
Immune responses also appear to be mediated by at least one AC isoform.
For example, AC7 has recently been implicated in distinct types of immune
responses. Specifically, mice with AC7-deficient immune systems are sensitive
to endotoxic shock (via lipopolysaccharide (LPS) injection) as measured by
survival following a semi-lethal dose of LPS (Duan et al., 2010). Biochemical
analysis revealed blunted cAMP responses and enhanced pro-inflammatory
cytokine production in macrophages from the AC7-deficient mice, suggesting that
AC7-mediated cAMP signaling may underlie immune responses to bacterial
infection (Duan et al., 2010). The AC7-deficient mice also display an overall
reduction of cAMP signaling in T and B cells, and altered antibody responses
(Duan et al., 2010). Interestingly, it has also been recently proposed that certain
pathogens may evade host immune responses by enhancing AC7-mediated
signaling in macrophages, thereby deceiving the system into reduced proinflammatory cytokine responses (Jiang et al., 2013a). These data suggest that
AC7-mediated cAMP signaling contributes to distinct types of immune responses
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and is potentially modulated by pathogens to evade host immune responses
(Duan et al., 2010; Jiang et al., 2013a).

1.6.2 Adenylyl cyclase function in the central nervous system
Several AC isoforms are implicated in distinct types of pain and analgesia.
AC5 is thought to mediate both acute and chronic pain responses. Specifically,
AC5-/- mice display reduced behavioral responses to acute pain elicited by
thermal and mechanical stimuli, inflammatory stimuli, and visceral nociceptive
stimuli (both inflammatory and non-inflammatory) (Kim et al., 2007). Furthermore,
AC5-/- mice show attenuated mechanical and thermal allodynia in two separate
neuropathic pain models (the L5 spinal nerve ligation model and a tail nerve
injury model) (Kim et al., 2007). Interestingly, the Ca2+/calmodulin-stimulated
ACs, AC1 and AC8 are also implicated in chronic pain, but not acute pain
responses. AC1-/-, AC8-/-, and AC1-/-/AC8-/- mice are not different than wild type
mice in acute pain response to noxious thermal, mechanical, and inflammatory
stimuli (Vadakkan et al., 2006; Wei et al., 2002). However, AC1-/- and AC1-//AC8-/- mice display reduced responses to chronic inflammatory stimuli (injection
of formalin and complete Freund’s adjuvant injection) (Vadakkan et al., 2006;
Wei et al., 2002). Furthermore, AC1-/-/AC8-/- mice show attenuated behavioral
responses to nerve injury (Wei et al., 2002).
Multiple AC isoforms have also been distinctly associated with morphine
action. AC5 is thought to mediate the behavioral effects of morphine because
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AC5-/- mice lost morphine-induced analgesia (latency for response to acute
thermal stimuli), locomotor activity, reward, dependence, and behavioral signs of
withdrawal (Kim et al., 2006). On the other hand, mice with genetic deletion of
Ca2+/calmodulin-stimulated ACs (AC1 and AC8) retain short-term morphineinduced analgesia, but display reduced tolerance and withdrawal-associated
behaviors (Li et al., 2006; Zachariou et al., 2008). Interestingly, transgenic mice
overexpressing AC7 in the CNS demonstrate enhanced sensitivity to the acute
analgesic effects of morphine (measured by paw-lick latency in the hot plate test)
and show more rapid tolerance to morphine treatment, but no difference in
withdrawal-associated behaviors as compared to wild type animals (Yoshimura
et al., 2000).
The Ca2+/calmodulin-stimulated ACs are implicated in important CNSrelated biological processes that are associated with aging. For example, the
Ca2+/calmodulin-stimulated ACs are thought to have redundant roles in long term
memory, as AC1-/-/AC8-/- mice are deficient in late phase long-term potentiation
and long term memory, but genetic deletion of AC1 or AC8 individually has no
effect on these measures (Wong et al., 1999). The Ca2+/calmodulin-stimulated
ACs are also implicated in neurodegenerative processes including excitotoxicity.
Excitotoxicity is neuronal damage/death that results from overstimulation of
NMDA receptors by glutamate. The excessive stimulation of NMDA receptors
results in a Ca2+ overload in neurons, resulting in cell death. It is thought that
excitotoxicity contributes to the acceleration of neurodegenerative processes.
AC1 is associated with excitotoxicity because primary cortical neurons from
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AC1-/- mice are resistant to glutamate- and NMDA-induced excitotoxicity and
AC1-/- mice have attenuated neuronal cell death in response to intracortical
injection of NMDA (Wang et al., 2007a). Ca2+-stimulated ACs are further
implicated in neurodegeneration in neonatal mice. Specifically, ethanol, the
GABAa receptor modulator phenobarbital, and the NMDA receptor antagonist
MK801 each enhance neurodegeneration in neonatal AC1-/-/AC8-/- mice.
Furthermore, AC1-/- or AC8-/- mice display similar neurodegenerative effects
(Maas et al., 2005). In summary, several AC isoforms contribute to biological
processes in the central nervous system including pain, analgesia, learning and
memory, and neurodegeneration.

1.7

Small molecule modulation of adenylyl cyclase

It is clear that AC isoforms are implicated in several disease states and it
is hypothesized that AC isoform-selective small molecules could be utilized
together with knockout and transgenic animal models to investigate the
physiological roles of AC isoforms and validate their therapeutic potential (Pavan
et al., 2009; Pierre et al., 2009). However, small molecule AC modulators are
generally non-selective and/or display low potency for AC modulation (Seifert et
al., 2012). The current collection of AC modulators is discussed below.
Forskolin (Figure 1.7) is a labdane diterpene that was isolated from the
roots of the Coleus forskohlii plant, and was found to be a reversible activator of
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adenylyl cyclase activity in several tissues including the cerebral cortex, striatum,
heart, and liver (Seamon et al., 1981). Subsequent studies with recombinant
adenylyl cyclases suggest that forskolin directly binds AC and is capable of
stimulating all AC isoforms with the exception of AC9 (Sadana and Dessauer,
2009; Tesmer et al., 1997). Though forskolin has been used extensively as a
research tool for the study of ACs and cAMP signaling (Insel and Ostrom, 2003),
several properties of forskolin are suboptimal. For example, forskolin is not
water-soluble, modulates AC isoforms in a non-selective fashion, and is known to
modulate other enzymes including glucose transporters (Laurenza et al., 1989).
To improve upon these shortcomings, much effort has been directed toward the
synthesis and pharmacological characterization of forskolin analogs. For
example, NKH477 was identified as a water-soluble forskolin analog that has
enhanced potency for AC5 as compared to AC3 and AC2 (Toya et al., 1998).
More recent studies identified forskolin derivatives that display a range of
modulatory properties, including inactivity, partial activation, enhanced efficacy
for AC isoforms, and inhibition of AC isoforms (Onda et al., 2001; Pinto et al.,
2008). Notably, BODIPY-conjugated forskolin displays potent inhibition of AC2,
while partially activating AC1 and AC5 (Pinto et al., 2008). Additional chemical
modification of forskolin may yield derivatives with novel modulatory properties or
more favorable AC isoform-selectivity profiles, but studies to date have only
provided marginal improvements.
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Figure 1.7 Chemical structures of small molecule adenylyl cyclase modulators.
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Early approaches to the development of adenylyl cyclase inhibitors
focused on compounds that are nucleotides that contain an adenine (or purine)
ring, known as the “p-site” inhibitors (Dessauer et al., 1999). The p-site inhibitors
are generally non-selective for inhibition of adenylyl cyclase isoforms (Johnson et
al., 1997) and bind to the active site in the presence of pyrophosphate (Tesmer
et al., 2000), but non-competitively with respect to ATP (Dessauer and Gilman,
1997; Tesmer et al., 2000). It is clear that the nucleotide phosphate groups
confer potency for inhibition of ACs, as adenine nucleoside 3’-polyphosphate
ligands are among the most potent p-site inhibitors (Johnson et al., 1997).
However, the polyphosphate groups are expected to be poorly membranepermeable. Though p-site ligands are generally non-selective, ribose-modified psite ligands such as SQ22,536 and 9-CP-Ade display some degree of AC isoform
selectivity in vitro (i.e., both compounds have similar potency values for inhibition
of AC1, AC6, and AC8, but little or no activity for inhibition of AC2), but are
relatively less potent than the adenine 3’-polyphosphate p-site ligands (Johnson
et al., 1997). The p-site inhibitors identified to date appear to have a trade-off
between potency and AC isoform selectivity. Furthermore, p-site inhibitors may
have off-target effects such as inhibition of DNA replication or purine metabolism
due to their adenine rings (Seifert et al., 2012).
Given concerns about an intact adenine ring facilitating off-target effects, a
virtual screen was conducted for compounds that retained the pharmacophore of
a ribose-substituted p-site inhibitor for AC, but without an adenine ring (Onda et
al., 2001). This screen yielded the second generation p-site inhibitor, NKY80
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(Onda et al., 2001). Though NKY80 displays selectivity for AC5 over AC2 and
AC3, and binds non-competitively with ATP and forskolin, the compound
generally lacks potency for inhibition of AC (Onda et al., 2001).
An additional strategy for the development of more potent and/or selective
inhibitors of AC involved the fusion of a metal-coordinating hydroxamic acid
moiety to an adenine ring to exploit the requirement of metal ions for AC catalytic
activity (Levy et al., 2003; Levy et al., 2002a; Levy et al., 2002b; Tesmer et al.,
1999). In in vitro Sf9 cell membrane assays, PMC-6 emerged as a selective AC5
inhibitor (over AC2 and AC3), and the most potent among the PMC class of
inhibitors (Iwatsubo et al., 2004). Furthermore, PMC-6 has activity for inhibition
of isoproterenol-stimulated cAMP in intact cardiac myocytes, where it also
displays efficacy for inhibition of apoptosis (Iwatsubo et al., 2004), suggesting
possible therapeutic utility.
More recent studies have identified NB001 as a potent inhibitor of AC type
1 in intact cell assays (Wang et al., 2011). Interestingly, in agreement with AC1
knockout mouse studies, inhibition of AC1 activity with NB001 has analgesic
effects in animal models of neuropathic and inflammatory pain (Vadakkan et al.,
2006; Wang et al., 2011). These studies suggest that targeting AC1 has
analgesic utility, but the activity of NB001 in in vitro AC assays and an
understanding of the structure-activity relationship surrounding NB001 remain to
be reported.
2’(3’)-O-N-Methylanthraniloyl (MANT)-substituted fluorescent nucleotides
were found to be a novel and potent class of competitive AC inhibitors (Gille and
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Seifert, 2003). Subsequent crystallography studies with MANT-GTP suggest that
the MANT moiety binds in a hydrophobic patch at the C1/C2 interface and
prevents a necessary rotation that is required for AC catalytic activity (Mou et al.,
2005; Wang et al., 2007b). Furthermore, a series AC isoform-selectivity and
structure-activity relationship studies on the MANT class of compounds revealed
a general preference for inhibition of AC5 and AC6 over other AC isoforms and
that the catalytic site can accommodate nucleotides including adenine, guanine,
hypoxanthine, and uracil (Gille et al., 2004; Goettle et al., 2009; Huebner et al.,
2011; Mou et al., 2006; Pinto et al., 2011; Suryanarayana et al., 2009).
Consistent with the latter observation, MANT-ITP was identified as the most
potent AC inhibitor from this class of compounds. Though the MANT nucleotides
are generally more potent than the p-site inhibitors for inhibition of AC in vitro,
these compounds are also limited by poor membrane-permeability (Seifert et al.,
2012). Thus, these studies are most useful for the structural information that
they provide surrounding the binding of ligands in the catalytic site of ACs.
Efforts to develop potent and AC isoform-selective small molecule
modulators have only modestly contributed to the current understanding of AC
targeting and several limitations surrounding specificity, AC isoform-selectivity,
and cell permeability remain. Furthermore, the current repertoire of AC
modulators has not been comprehensively studied with respect to each of the
nine membrane-bound AC isoforms in both in vitro and intact cell models, making
it difficult to fully assess the isoform-selectivity of these compounds (Seifert et al.,
2012). The discovery and development of novel small molecule modulators of
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AC that are potent and isoform-selective is expected to facilitate the in vivo study
of individual AC isoforms and allow for the full evaluation of AC isoforms as
potential therapeutic targets.

1.8

Scope of the work

The goal of the work reported here is to investigate the modulation of
adenylyl cyclase type 2 signaling within the context of the following three specific
aims:
1.) To test the hypothesis that AGS3 expression influences D2L dopamine
receptor-mediated cAMP signaling mediated via AC1 and AC2. This specific
aim was designed to investigate the effects of expression of the G protein
regulator, AGS3, on recombinant AC1 and AC2 in response to both acute and
persistent activation of the D2L dopamine receptor in HEK293 cells. The
differential modulation of AC1 and AC2 by G protein subunits offers unique
properties to study the effects of AGS3 expression on G protein-coupled receptor
signaling.
2.) To test the hypothesis that D2L dopamine receptor-mediated
heterologous sensitization of AC2 is Gβγ subunit-dependent. The
mechanism of D2L dopamine receptor-induced heterologous sensitization of AC2
is unclear. Specific aim 2 was designed to study the role of Gβγ subunit
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signaling to D2L dopamine receptor-mediated sensitization of AC2 in HEK293
cells.
3.) To develop and implement a high-throughput screening paradigm for
the discovery of small molecule modulators of AC2. Specific aim 3
encompassed the development of a cell-based high-throughput screening
paradigm for the measurement of cellular cAMP. The assay platform was then
utilized to conduct an intact-cell small molecule screen for direct AC2 inhibitors in
HEK293 cells. The work in this aim was designed as an intermediate step in the
overall goal to develop unbiased methods for the study of AC sensitization.
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CHAPTER 2. DIFFERENTIAL EFFECTS OF AGS3 EXPRESSION ON D2L
DOPAMINE RECEPTOR-MEDIATED ADENYLYL CYCLASE SIGNALING

2.1

Introduction

G protein-coupled receptors bind ligands that induce conformational
changes in the receptor and facilitate the activation of G protein heterotrimers by
exchange of GDP for GTP on the G protein α subunit (Gilman, 1987). Upon
activation, the G protein heterotrimer undergoes a conformational change that
allows Gα and Gβγ subunits to regulate effector proteins such as adenylyl
cyclases (ACs) (Coleman et al., 1994; Lambright et al., 1994; Taussig et al.,
1993a). The G protein signaling cycle ends by hydrolysis of GTP to GDP on the
Gα subunit (Coleman et al., 1994; Mixon et al., 1995). In addition to G proteincoupled receptor modulation, the G protein activation cycle is sensitive to
accessory proteins such as regulators of G protein signaling (RGS) or activator of
G protein signaling (AGS) proteins (Blumer et al., 2007; Neubig and Siderovski,
2002; Sato et al., 2004). These proteins influence G protein signaling and
effector activation by modulating the rate of GTP hydrolysis and the availability
and/or stability of Gα or Gβγ subunits (Blumer et al., 2007; Neubig and
Siderovski, 2002; Sato et al., 2004)
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The activator of G protein signaling 3 (AGS3) is a G protein regulator that
has been linked to adaptive behaviors involved with drugs of abuse (Bowers et
al., 2008; Bowers et al., 2004; Yao et al., 2005). AGS3 was identified as a
receptor-independent G protein activator and is thought to bind Gαi subunits in
the GDP-bound state, thereby preventing re-association of Gα and Gβγ subunits
(De Vries et al., 2000; Peterson et al., 2000; Takesono et al., 1999). The precise
molecular actions of AGS3 have yet to be fully described, however it is
hypothesized that AGS3 expression may specifically adjust the landscape of
effector activation by modulating Gα and Gβγ subunit signaling. Previous studies
examining the actions of AGS3 on G protein-coupled receptor signaling in cellbased assays suggest that the effects of AGS3-like molecules are dependent on
the duration of receptor activation. For example, an AGS3 consensus peptide
was shown to have no effect on the ability of D2DRs to modulate G proteinregulated inwardly rectifying potassium (GIRK) channels acutely, but promoted
functional desensitization of this response following repeated receptor activation
(Webb et al., 2005). Furthermore, the actions of AGS3 on α2 adrenergic
receptor regulation of cAMP signaling were explored in CHO cells, which
predominantly express AC6 (Varga et al., 1998). The acute effects on α2
adrenergic receptor-mediated AC signaling were not altered, but sensitization of
AC in response to persistent α2 receptor activation was attenuated by AGS3
expression (Sato et al., 2004). More recent studies in nucleus
accumbens/striatal neurons have suggested that opioid receptor-induced
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expression of AGS3 enhances the activity of AC5 and AC7 in a protein kinasedependent manner (Fan et al., 2009).
The observations described above suggest a complex mode of AGS3
modulation of receptor-mediated AC signaling. The complexity is further
exacerbated by the expression and signaling of multiple AC isoforms that display
unique patterns of Gα and Gβγ regulation (Sunahara et al., 1996; Watts and
Neve, 2005). The present study was designed to examine the effects of AGS3
on G protein-coupled receptor modulation of two recombinant ACs, AC1 and
AC2. AC1 is a member of the Ca2+-stimulated group of ACs and can be
activated by the Ca2+ ionophore, A23187, and inhibited by both Gαi and Gβγ
subunits (Choi et al., 1992a; Cumbay and Watts, 2001; Taussig et al., 1993b).
AC2 is a member of a group of ACs that are conditionally activated by Gβγ
subunits (Federman et al., 1992; Taussig et al., 1993b). AC2 is also robustly
activated by protein kinase C (PKC) phosphorylation in response to phorbol ester
stimulation (e.g. PMA) (Shen et al., 2012; Yoshimura and Cooper, 1993). The
distinct regulatory properties of AC1 and AC2 provide important tools to
selectively study the effects of AGS3 expression on G protein-coupled receptor
signaling.
It is widely accepted that alterations in cAMP signaling pathways and
enhanced activation of dopamine systems in the brain play central roles in the
molecular adaptations associated with drug addiction (Carlezon et al., 2005;
McClung and Nestler, 2003; Nestler, 2001). The dopaminergic signaling and
cAMP signaling pathways are linked by dopamine receptors that modulate
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adenylyl cyclases via G protein activation. There are two families of dopamine
receptors, D1-like (D1 and D5) that couple to Gαs, and D2-like (D2, D3, and D4)
that couple to Gαi/o (Missale et al., 1998). We chose to study D2LDR signaling
based on the overlapping tissue distribution of the D2LDR with AC1 and AC2 in
the brain, and its well-characterized roles in AC signaling and drug abuse, where
AGS3 has also been implicated (Maldonado et al., 1997; Phillips et al., 1998;
Ralph et al., 1999; Visel et al., 2006; Weiner et al., 1991). HEK293 cells
expressing the D2LDR together with either AC1 or AC2 were used to explore
cAMP signaling in the absence or presence of AGS3. Our studies revealed that
AGS3 expression had modest, but significant potentiating effects on acute D2LDR
modulation of AC1 or AC2 activity. In contrast, AGS3 displayed differential
effects on AC regulation following persistent D2LDR activation. These findings,
along with those reported in the literature, suggest that AGS3 modulates AC
signaling in a manner that is isoform-specific and dependent on the duration of
receptor activation.

2.2

Materials and methods
2.2.1 Materials

[3H]-cAMP (33 Ci/mmol) was purchased from PerkinElmer Life and
Analytical Sciences (Boston, MA). Spiperone, (±)-quinpirole, A23187, 3-isobutyl1-methylxanthine (IBMX), G418, Dulbecco’s modified Eagle’s medium (DMEM),
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and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO).
Phorbol 12-myristate 13-acetate (PMA) was purchased from Tocris Bioscience
(Ellisville, MO). Lipofectamine 2000 and Zeocin were purchased from Invitrogen
(Carlsbad, CA). FetalClone I (FCI) serum, bovine calf serum (BCS), and Earle’s
balanced salt solution (EBSS) were purchased from Hyclone (Logan, UT).
Hygromycin B was purchased from Calbiochem (La Jolla, CA).

2.2.2 Cell culture and stable cell line generation
HEK293 cells stably expressing AC1 or AC2 were grown in DMEM
supplemented with 5% FCI, 5% BCS, 1 unit/ml penicillin, 1 μg/ml streptomycin,
2.5 ng/ml amphotericin B, and either 100 μg/ml Hygromycin B (HEK-AC1) or 300
μg/ml G418 (HEK-AC2) and were maintained in a humidified incubator at 37°C
with 5% CO2. Cell lines were transfected with the dual expression vector
pBudCE4 with the gene for the human D2LDR driven by the CMV promoter and
either rat AGS3-Venus (long splice variant), AGS3-Q/A-Venus, or no gene
behind the EF-1α promoter. Several studies have utilized AGS3 fused with a
fluorescent protein at the c-terminus (An et al., 2008; Oner et al., 2010; Oner et
al., 2013; Vural et al., 2010) and these studies suggest that the AGS3-fluorescent
fusion proteins retain similar cellular localization (An et al., 2008; Blumer et al.,
2002; Pizzinat et al., 2001; Vural et al., 2010) and interaction with Gαi subunits
(De Vries et al., 2000; Oner et al., 2010; Oner et al., 2013; Peterson et al., 2000)
as compared to untagged AGS3. Stable transfections were carried out with
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Lipofectamine 2000 according to the manufacturer’s protocol. Clones were
isolated by selection with Zeocin (200 μg/ml) and characterized for specific AC
function by cAMP accumulation assays, D2LDR expression by radioligand binding,
and AGS3 expression by fluorescence microscopy.

2.2.3 Cyclic AMP accumulation assay
Cells were grown to confluency in 48-well plates and cAMP assays were
performed on ice in assay buffer (EBSS containing 15 mM Na+-HEPES, 2% BCS,
and 0.02% ascorbic acid). For acute cAMP accumulation experiments, cells
were stimulated at 37°C for 15 minutes in the presence of 500 μM IBMX. The
stimulation buffer was decanted and cells were lysed with ice-cold 3%
trichloroacetic acid. The plate was stored at 4°C for at least 1 h before cAMP
quantification. For persistent receptor activation experiments, cells were grown
to confluency in 48-well plates and pretreated in assay buffer with either vehicle
or 1 μM (±)-quinpirole for 2 h at 37°C and 5% CO2. Cells were washed with
assay buffer three times (3 minutes each), and subsequently stimulated as
described for acute cAMP accumulation assays. For desensitization assays,
pretreatments were carried out as described above, followed by re-activation of
the receptor as described for acute cAMP accumulation experiments. For
heterologous sensitization experiments, subsequent stimulation was achieved by
selective activation of AC isoforms (AC1, 10 μM A23187; AC2, 1 μM PMA) in the
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presence of 500 μM IBMX and 1 μM spiperone to block residual agonist binding
from the pretreatment.

2.2.4 Cyclic AMP quantification
Cyclic AMP was quantified using a competitive binding assay (Przybyla
and Watts, 2010). Duplicate samples of lysate from the cAMP accumulation
assay were added to reaction tubes, followed sequentially by [3H]-cAMP (~1 nM
final concentration), and cAMP-binding protein (~100 μg of crude bovine adrenal
extract) in 500 μL of cAMP binding buffer (100 mM Tris-HCl, 100 mM NaCl, 3
mM EDTA, pH 7.4). The assay was carried out at 4°C for 2 hr and harvested by
filtration through Millipore FB 96-well filter plates, and radioactivity was quantified
on a TopCount NXT scintillation counter (Perkin Elmer). Cyclic AMP
concentrations were estimated from a standard curve ranging from 300 pmol to 3
nmol cAMP.

2.2.5 Data analysis
GraphPad Prism software was used to generate all dose-response curves
(GraphPad Software, San Diego, CA). All logIC50/logEC50, and maximal
activation/inhibition values were calculated in GraphPad Prism using a non-linear
regression and sigmoidal dose-response equation and were analyzed by
unpaired t-tests.
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2.3

Results and discussion

AGS3 interacts with the GDP-bound state of Gαi subunits, and it has been
suggested that this interaction prevents the re-association of Gαi and Gβγ
subunits (De Vries et al., 2000; Peterson et al., 2000). The interaction between
AGS3 and Gαi-GDP may cause altered G protein signaling through effectors
regulated by Gαi and Gβγ subunits. AC isoforms display differential patterns of
regulation by G protein subunits (Sunahara et al., 1996; Watts and Neve, 2005).
Given that AGS3 may alter signaling by Gαi and/or Gβγ subunits, and AC
isoforms are differentially regulated by G protein subunits, we were interested in
studying the effects of AGS3 expression on the regulation of AC isoforms
following acute and persistent activation of D2LDRs.

2.3.1 Characterization of HEK293 stable cell lines
To study the effects of AGS3 on D2LDR-mediated signaling through AC
isoforms, several HEK293 cell lines were generated and characterized (HEKAC1-D2L, HEK-AC1-D2L-AGS3-Venus, HEK-AC2-D2L, HEK-AC2-D2L-AGS3Venus, and HEK-AC2-D2L-AGS3-Q/A-Venus). The function of the stably
expressed AC isoforms was characterized by the cAMP responses to
pharmacological conditions for the selective activation of either AC1 (10 μM
A23187) or AC2 (1 μM PMA) (Figure 2.1A and B).
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Figure 2.1 Selective activation of recombinant AC1 by the calcium ionophore,
A23187 and recombinant AC2 by the phorbol ester, PMA. A. Cell lines
expressing recombinant AC1 or B. recombinant AC2 were incubated under the
indicated conditions and cAMP accumulation was measured using a Cisbio
homogenous time-resolved fluorescent (HTRF) cAMP assay kit according to the
manufacturer’s protocol.
Data represent the mean ± S.E.M. of three
experiments. ** p < 0.01, compared to the basal condition within each cell line
(one way ANOVA, followed by Dunnett’s post hoc test).
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As expected, treatment with the Ca2+ ionophore, A23187 significantly stimulated
cAMP accumulation in cell lines expressing AC1, but had no effect in cell lines
expressing AC2. On the other hand, phorbol ester treatment selectively
enhanced the cAMP activity in cells expressing AC2, but had no effect in cells
expressing AC1. These results suggest that the stable cell lines expressing AC1
or AC2 can be selectively activated by A23187 or PMA, respectively. The cell
lines were further
characterized for the expression levels of the D2LDR, as quantified by [3H]methylspiperone saturation binding (Table 2.1). Each of the stable cell lines had
similar Bmax and Kd values, suggesting that the D2LDR expression levels were
similar. AGS3-Venus expression was confirmed by fluorescence microscopy
(Figure 2.2) and spectroscopy (Table 2.2). Together, these data suggest that cell
lines that were generated are suitable for studies of the effects of AGS3
expression on D2LDR mediated signaling mediated by either AC1 or AC2.
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Table 2.1 D2LDR expression levels in cellular models used for functional studies.
[3H]-Methylspiperone saturation binding assays and analysis was performed (as
described in Przybyla and Watts, 2010) to measure the D2LDR expression level
in each cell line. Data represent the mean ± S.E.M. of four independent
experiments.

Cell Line
HEK-AC1-D2L
HEK-AC1-D2L-AGS3-Venus
HEK-AC2-D2L
HEK-AC2-D2L-AGS3-Venus
HEK-AC2-D2L-AGS3-Q/A-Venus

Bmax
(pmol/mg
protein)
2.5±0.10
4.0±0.27
9.1±2.5
15±3.0
8.9±2.1

Kd
(nM)
0.10±0.02
0.11±0.02
0.11±0.01
0.17±0.04
0.10±0.01
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Figure 2.2 AGS3-Venus expression by confocal microscopy. Representative
fields were imaged for cell lines expressing AGS3 fused to the Venus fluorescent
protein at 20X magnification using a Nikon A1 confocal system when excited with
the 488 nm laser and filtered for detection of Venus fluorescence (Emission:
525/50).
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Table 2.2 The Venus fluorescence intensity (Ex: 485/20 nm and Em: 530/30) of
cell suspensions was measured in 384-well format using a Biotek Synergy 4
plate reader. The fluorescence intensity values of HEK-AC1-D2L and HEK-AC2D2L represent the background autofluorescence of the cells.

Cell Line
HEK-AC1-D2L
HEK-AC1-D2L-AGS3-Venus
HEK-AC2-D2L
HEK-AC2-D2L-AGS3-Venus
HEK-AC2-D2L-AGS3-Q/A-Venus

Fluorescence
Intensity
(RFU)
1530±110
18900±2110
1460±100
9400±2400
33700±3270

67
2.3.2 Modulation of acute D2LDR-mediated AC1 and AC2 signaling by AGS3
expression
Our initial studies used HEK293 cells stably expressing AC1 or AC2 and
the D2LDR. Recombinant AC1 can be selectively activated in HEK293 cells by
Ca2+ using the calcium ionophore, A23187 or by capacitative calcium entry (Choi
et al., 1992a; Cooper et al., 1994). To observe acute Gαi regulation, AC1 activity
was selectively increased using A23187, and inhibition by the D2DR agonist
quinpirole was examined. A23187-stimulated AC1 activity was inhibited by 54±2%
with a logIC50 of -8.08±0.13 (Figure 2.3A). In cells expressing AGS3, modest,
but significant increases in maximal inhibition (67±4%) and potency (logIC50 = 8.83±0.19) for D2LDR-mediated inhibition of AC1 activity by quinpirole were
observed. AC2 is conditionally stimulated (requiring co-activation of AC2 by Gαs
or PKC) by Gβγ subunits following the activation of Gi/o-coupled receptors (Tsu
and Wong, 1996; Yoshimura and Cooper, 1993; Zimmermann and Taussig,
1996). To study acute Gβγ subunit signaling, HEK293 cells stably expressing
AC2 and the D2LDR were incubated with PMA to stimulate AC2, and quinpirole to
activate the D2LDR (subsequently releasing Gβγ subunits). Maximal activation of
the D2LDR by quinpirole resulted in a robust increase in cAMP accumulation
through conditional activation of AC2 (240±18% of PMA response) with a
logEC50 of -7.05±0.06 (Figure 2.3B). AGS3 co-expression did not affect the
maximal activation of AC2 (250±20% of PMA response), but a significant shift in
the potency (logEC50 = -7.45±0.06) of quinpirole-potentiated cAMP accumulation
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was observed as compared to cells not expressing AGS3. Though modest, the
effects of AGS3 on D2LDR-mediated regulation of AC1 or AC2 are consistent with
enhanced Gβγ subunit modulation of each effector. Specifically, Gβγ subunits
inhibit signaling mediated by AC1, but increase AC2 activity, and AGS3
expression augments the potency of these effects, presumably by binding Gαi
subunits. The effects of AGS3 expression on acute D2LDR-mediated AC1 or
AC2 activity are contrary to other cell-based studies examining the effects of
AGS3 expression on acute G protein signaling. For example, AGS3 did not alter
α2-adrenergic receptor-inhibited AC activity in CHO cells (Sato et al., 2004).
Perhaps more relevant to our D2DR-AC2 studies is the observation that AGS3
failed to alter D2SDR-stimulated GIRK channel activity, a Gβγ mediated signaling
event (Webb et al., 2005). These findings suggest that AGS3 may display ACspecific or even effector-specific regulation of acute G protein signaling.
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Figure 2.3 Effect of AGS3 expression on acute regulation of AC isoforms. A.
Acute inhibition of A23187 (10 μM)-stimulated cAMP accumulation was
measured following incubation with quinpirole as indicated in HEK293 cells stably
expressing AC1 and the D2LDR, or AC1 and the D2LDR together with AGS3Venus. B. Cyclic AMP accumulation was quantified in HEK293 cells stably
expressing AC2 and the D2LDR with or without AGS3-Venus following acute
treatment with PMA (1 μM) and increasing concentrations of quinpirole as
indicated. Data points represent mean ± S.E.M. of at least three independent
experiments performed in duplicate.
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2.3.3 Desensitization of D2LDR-mediated AC1 and AC2 signaling
In addition to studying AC regulation by acute activation of the D2LDR, we
were also interested in studying desensitization of the D2LDR. Cells stably
expressing AC1 and the D2LDR were treated with quinpirole for 2 h in an effort to
promote functional receptor desensitization. Following washing, cells were reexposed to quinpirole and the subsequent cAMP accumulation was measured.
Persistent D2LDR activation by quinpirole failed to induce significant
desensitization of D2LDR modulation of AC1 activity. Specifically, quinpirole
treatment maximally inhibited A23187-stimulated AC1 activity by 56±9.1% with a
logIC50 of -8.0±0.20 following persistent D2LDR activation, as compared to
maximum inhibition of 59±1.8% and log IC50 of -8.5±0.20 after vehicle
pretreatment (n=2). We then examined the effects of AGS3 expression on
D2LDR-modulated AC1 activity following persistent D2LDR stimulation. These
experiments revealed that AGS3-expressing cells pretreated with quinpirole
displayed a desensitization of D2LDR-modulated AC1 inhibition that was
manifested as a significant loss of maximal inhibition (60±6%) compared to
vehicle pretreated cells (84±8%), but without a significant change in potency
(logIC50 = -8.03±0.39 and -8.64±0.17, respectively) (Figure 2.4). The AGS3promoted desensitization of AC1 inhibition may occur through interactions with
Gαi subunits that are involved in the inhibition AC1 activity. However, it has been
suggested that Gαi-AGS3 complexes can couple with, and be regulated by Gαicoupled receptors upon agonist activation, allowing for the possibility of indirect
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modulation of downstream Gβγ subunit signaling (Oner et al., 2010).
Furthermore, an AGS3 consensus peptide disrupted Gβγ subunit activation of
GIRK channels following repeated stimulation of D2SDRs (Webb et al., 2005).
Given that Gβγ subunits inhibit AC1 activity (Taussig et al., 1993b), these data
present the possibility that the desensitization of AC1 inhibition is also associated
with altered Gβγ subunit signaling.
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Figure 2.4 The effect of AGS3 expression on functional desensitization of D2LDRmodulated AC1 activity. HEK293 cells stably expressing AC1, the D2LDR, and
AGS3-Venus were treated with quinpirole (1 μM) or vehicle for 2 hrs, followed by
selective AC1 stimulation with A23187 (10 μM) and activation of the D2LDR with
quinpirole. Data represent the mean ± S.E.M. of three independent experiments.
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In contrast to AC1, a complete desensitization of D2LDR-mediated
potentiation of AC2 activation was observed following quinpirole pretreatment in
D2LDR-AC2 cells. Specifically, quinpirole pretreatment resulted in 103±11%
desensitization of D2LDR-mediated potentiation of AC2 activity as compared to
vehicle pretreatment (Figure 2.5). These observations suggest potential
differences in the general mechanisms for desensitization of D2LDR-modulated
AC1 and AC2 activity. Such mechanisms presumably reflect the differential
regulatory properties of AC1 and AC2 that involve G protein modulation
(Hanoune and Defer, 2001). Subsequent experiments examined the effects of
AGS3 on desensitization of D2LDR-potentiated AC2 activity. Surprisingly,
expression of AGS3 resulted in significantly less desensitization (46±7%) of
D2LDR-mediated potentiation of AC2 activity (Figure 2.5). The specificity of this
blockade was probed by expressing an AGS3 mutant that does not bind Gαi
subunits, AGS3-Q/A (Peterson et al., 2002). AGS3-Q/A failed to significantly
alter quinpirole-induced desensitization of D2LDR-AC2 signaling (78±3%),
suggesting that AGS3 expression inhibits desensitization of D2LDR signaling
through AC2 in a manner that is dependent on the interaction of AGS3 with Gαi.
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Figure 2.5 The effect of AGS3 expression on functional desensitization of D2LDRmodulated AC2 activity. HEK293 cells stably expressing AC2 and the D2LDR
alone, or together with AGS3-Venus or AGS3-Q/A-Venus were treated with
quinpirole (1 μM) or vehicle for 2 hrs, followed by stimulation with PMA (1 μM)
and quinpirole (1 μM). Data represent the mean ± S.E.M. of at least three
independent experiments. ** p < 0.01, compared with AC2+D2L condition, one
way analysis of variance followed by Dunnett’s post hoc test.
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2.3.4 Effects of AGS3 expression on heterologous sensitization of AC1 and AC2
In addition to desensitization, persistent activation of many Gi/o-coupled
receptors (e.g., D2 dopamine and μ-opioid) results in enhanced subsequent AC
activation. This heterologous sensitization (a.k.a. superactivation) of cAMP
signaling involves both Gαi/o and Gβγ subunits (Watts and Neve, 2005), but the
mechanisms of sensitization for AC1 and AC2 appear to differ (Cumbay and
Watts, 2001). The functional effects of AGS3 expression on AC sensitization
following persistent activation of the D2LDR were examined. For these
experiments, cells expressing AC1 and the D2LDR were stimulated with the D2DR
agonist quinpirole for 2 h, followed by selective activation of AC1 by A23187.
Quinpirole pretreatment resulted in a 235±4% enhancement of A23187stimulated AC1 activity compared to the vehicle pretreatment (Figure 2.6A).
Cells co-expressing AGS3 displayed a reduction in subsequent AC1 stimulation
(178±12% of vehicle condition) following quinpirole pretreatment, suggesting that
AGS3 expression attenuates AC1 sensitization by ~40%.
The effects of AGS3 expression on the regulation of AC2 following
persistent D2LDR activation were also explored. AC2 displayed an enhanced
responsiveness (182±9% of vehicle condition) to stimulation by PMA following
quinpirole pretreatment (Figure 2.6B). The D2LDR-mediated sensitization of AC2
was nearly eliminated (120±3% of vehicle condition) in AGS3-expressing cells.
In contrast, AGS3-Q/A did not alter D2LDR-mediated sensitization of AC2
(202±10% of vehicle response), suggesting that AGS3-Gαi subunit interactions
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are involved in the inhibition of AC2 sensitization. The ability of AGS3
expression to prevent heterologous sensitization of AC1 and AC2 is similar to
that observed by expressing the Gβγ subunit scavenger, βARK-CT ((Koch et al.,
1994; Nguyen and Watts, 2005) and see chapter 3 for AC2). These data add
support to the hypothesis that AGS3 potentially alters Gβγ subunit signaling
following persistent Gi-coupled receptor activation (Oner et al., 2010; Webb et al.,
2005).
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Figure 2.6 Effect of AGS3 expression on heterologous sensitization of AC
isoforms. A. HEK293 cells stably expressing AC1 and D2LDR were stimulated
with vehicle or quinpirole (1 μM) for 2 hr, washed, and subsequently stimulated
with A23187 (10 μM) as indicated. Data represent mean ± S.E.M. of three
independent experiments. * p < 0.05, unpaired t-test. B. HEK293 cells stably
expressing AC2 and D2LDR in the absence of, or coexpressed with AGS3-Venus
or AGS3-Q/A-Venus as indicated were pretreated with vehicle or quinpirole (1
μM) for 2 hr, washed, and subsequently stimulated with PMA (1 μM). Data
represent mean ± S.E.M. of at least three independent experiments. ** p < 0.01,
one way analysis of variance followed by Dunnett’s post hoc test.
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The inhibition of D2LDR-mediated sensitization of AC1 and AC2 by AGS3
expression is consistent with a report revealing that AGS3 inhibits α2-adrenergic
receptor-mediated sensitization of AC isoforms expressed in CHO cells
(predominantly expressing AC6) (Sato et al., 2004; Varga et al., 1998). In
contrast, evidence suggests that opioid receptor-induced up-regulation of AGS3
expression mediates sensitization of AC5 and AC7 in nucleus accumbens/striatal
neurons (Fan et al., 2009). These differential effects suggest an isoformdependence for sensitization that may reflect complex and unique isoformspecific mechanisms of AC sensitization involving Gαi, Gβγ, or a combination of
the two, and subsequently altered downstream signaling. Alternatively, the
isoform-specific effects on AC signaling may reflect differences in receptor types,
cell types, or experimental paradigms. The differential effects of AGS3 on AC
sensitization, desensitization, and acute D2LDR-mediated signaling are similar to
what has been observed for ligands that possess functional selectivity (or
promote agonist-directed trafficking) (Kenakin, 1995). Such an observation
posits that receptor- and effector-modulating signaling molecules introduce an
additional level of complexity for cell signaling studies. For example, AGS3
differentially alters desensitization of D2LDR-mediated modulation of AC1 and
AC2, while reducing sensitization of both AC isoforms. These complex
mechanisms for regulation by AGS3 in vitro suggest the opportunity for greater
signaling diversity in vivo.
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2.3.5 Significance of AGS3-regulated AC signaling to drugs of abuse
In vivo studies suggest that AGS3 has a “gatekeeper” role for drugseeking behavior in response to heroin, cocaine, or ethanol. For example,
knocking out AGS3 expression in specific brain regions resulted in a loss of drugseeking behavior or cocaine-induced locomotor sensitization (Bowers et al., 2008;
Bowers et al., 2004; Yao et al., 2005). Interestingly, AGS3 expression is upregulated in the nucleus accumbens core or prefrontal cortex during withdrawal
periods following prolonged ethanol or cocaine self-administration, respectively
(Bowers et al., 2008; Bowers et al., 2004). In conjunction with overwhelming
evidence that dopamine systems and cAMP signaling pathways are involved in
drug addiction (Carlezon et al., 2005; McClung and Nestler, 2003; Nestler, 2001),
our data suggest that AGS3 overexpression during periods of withdrawal may
change the profile of signaling through specific AC isoforms in response to
persistent Gi/o-coupled receptor activation. In addition, recent studies with AC
knockout mice suggest a role for Ca2+-stimulated ACs (AC1 and AC8) in the
regulation of cocaine behavioral sensitization (DiRocco et al., 2009). It will be
important to study the role of individual AC isoforms in specific brain regions in
the context of drug-seeking behavior, where AGS3 may be exerting its effects by
fine-tuning D2LDR-mediated signaling through distinct AC isoforms.
Taken as a whole, our data suggest that AGS3 expression alters D2LDRmediated regulation of effector proteins in a manner that is effector-specific and
dependent on the duration of Gi-coupled receptor activation. The expression of
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AGS3 has modest, but potency-enhancing effects on effector modulation in
response to acute Gi-coupled receptor stimulation. Expression of AGS3
promoted desensitization of prolonged D2LDR-mediated signaling through AC1,
but reduced desensitization of AC2 signaling. In addition, D2LDR-mediated
sensitization of AC1 and AC2 signaling was attenuated by AGS3 expression. It
is becoming apparent that AGS3 is involved in altering G protein signaling in a
complex fashion that is effector-specific
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CHAPTER 3. HETEROLOGOUS SENSITIZATION OF ADENYLYL CYCLASE 2
IS DEPENDENT ON G PROTEIN BETA-GAMMA SUBUNIT SIGNALING

3.1

Introduction

AC sensitization was first reported in 1975 in the lab of Marshall Nirenberg,
but an understanding of the mechanisms of AC sensitization remains elusive
(Watts and Neve, 2005). However, the signaling pathways underlying AC
sensitization appear to be overlapping, but distinct for each isoform (Watts and
Neve, 2005). The present study focuses on sensitization of adenylyl cyclase
type 2 (AC2), as AC2 is expressed in brain regions co-expressing D2DRs and
can be selectively activated in HEK293 cells (Cumbay and Watts, 2001; Visel et
al., 2006; Weiner et al., 1991). AC2 is activated by Gαs and protein kinase C
(PKC) phosphorylation in response to phorbol ester stimulation (e.g. PMA ) and
Gq-coupled receptor activation (Shen et al., 2012; Yoshimura and Cooper, 1993;
Zimmermann and Taussig, 1996). Furthermore, AC2 is also conditionally
activated by Gβγ subunits in response to Gi/o-coupled receptor signaling
(Federman et al., 1992; Taussig et al., 1993b). In response to persistent D2LDR
activation, AC2 is readily sensitized, but appears to have a unique mechanism of
sensitization. Specifically, AC2 enzymatic activity is enhanced in response to
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PKC-mediated activation, but not Gαs- or forskolin-mediated stimulation
(Cumbay and Watts, 2001). The mechanism of AC2 sensitization, however, has
been largely unexplored. An understanding of the molecular adaptations that
underlie D2 dopamine receptor-mediated sensitization of AC2 signaling would
provide insight into the diverse modulation of cAMP signaling through AC
isoforms and contribute to our understanding of the pathophysiology and
potential therapeutic targeting of neurological disorders including drug abuse.
Gβγ subunit signaling is necessary for sensitization of AC isoforms
including AC1 (Nguyen and Watts, 2005), AC5 (AvidorReiss et al., 1996), and
AC6 (Thomas and Hoffman, 1996), but has been unexplored for D2LDR-mediated
sensitization of AC2. We have demonstrated that D2LDR-mediated sensitization
of AC2 is inhibited by expression of AGS3 and it is hypothesized that AGS3
expression may lead to disrupted Gβγ signaling in response to persistent Gi/ocoupled receptor activation (Chapter 2). Thus, it is possible that sensitization of
AC2 in response to long-term D2LDR activation proceeds via Gβγ subunit
signaling. We directly examined the role of Gβγ subunits in the development of
D2LDR-mediated sensitization of AC2 with a Gβγ subunit sequestering protein,
two small molecule Gβγ signaling inhibitors, and a cell permeable peptide
inhibitor of Gβγ. We also pharmacologically investigated the roles of several
downstream Gβγ subunit effectors in the development of AC2 sensitization.
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3.2

Materials and Methods
3.2.1 Materials

[3H]-cAMP (33 Ci/mmol) was purchased from PerkinElmer Life and
Analytical Sciences (Boston, MA). Spiperone, (±)-quinpirole, 3-isobutyl-1methylxanthine (IBMX), G418, Dulbecco’s modified Eagle’s medium (DMEM),
and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO).
Phorbol 12-myristate 13-acetate (PMA) was purchased from Tocris Bioscience
(Ellisville, MO). Lipofectamine 2000, antibiotic-antimycotic solution, and Zeocin
were purchased from Invitrogen (Carlsbad, CA). FetalClone I (FCI) serum,
bovine calf serum (BCS), Hank’s balanced salt solution (HBSS), and Earle’s
balanced salt solution (EBSS) were purchased from Hyclone (Logan, UT).

3.2.2 Cell culture and transfection
HEK293 cells were grown in DMEM supplemented with 5% FCI, 5% BCS,
and 1% antibiotic-antimycotic solution and maintained in a humidified incubator
at 37°C and 5% CO2. For transient transfections, HEK293 cells were seeded
into 96-well plates and allowed to grow to 70% confluency. Transient
transfection was carried out for 48 h with Lipofectamine 2000 according to the
manufacturer’s protocol. The generation, characterization, and maintenance of
HEK293 cells stably expressing AC2 and the D2LDR was described in chapter 2.
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3.2.3 Cyclic AMP accumulation assay
Cells were grown to confluency in either 48-well or 96-well plates and
cAMP assays were performed on ice in assay buffer (EBSS containing 15 mM
Na+-HEPES, 2% BCS, and 0.02% ascorbic acid). For acute cAMP accumulation
experiments, cells were stimulated at 37°C for 15 minutes in the presence of 500
μM IBMX. The stimulation buffer was decanted and cells were lysed with icecold 3% trichloroacetic acid. The plate was stored at 4°C for at least 1 h before
cAMP quantification. For persistent receptor activation experiments, cells were
grown to confluency in 48-well plates and pretreated in assay buffer with either
vehicle or 1 μM (±)-quinpirole for 2 h at 37°C and 5% CO2. Cells were washed
with assay buffer three times (3 minutes each), and subsequent stimulation was
achieved by selective activation of AC2 (1 μM PMA) in the presence of 500 μM
IBMX and 1 μM spiperone to block residual agonist binding from the pretreatment.
Heterologous sensitization experiments with pharmacological inhibitors
were carried out in HEK293 cells stably expressing AC2 and the D2LDR. Cells
were seeded into 96-well plates and grown to confluency. Cell growth media
was decanted and cells were pretreated with pharmacological inhibitors in Hank’s
balanced salt solution (HBSS), 20 mM HEPES, and 0.1% fatty acid free bovine
serum albumin for 15 min at 37°C and 5% CO2. Cells with pharmacological
inhibitors were then pretreated for an additional 2 h with either vehicle or 100 nM
(±)-quinpirole. Subsequent AC2 activation was carried out by stimulating the
cells with 1 μM PMA in the presence of 500 μM IBMX and 1 μM spiperone at
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37°C and 5% CO2 for 15 min. The cells were lysed with 3% trichloroacetic acid
and stored at 4°C for at least 1 h before cAMP quantification.

3.2.4 Cyclic AMP quantification
Cyclic AMP was quantified using a competitive binding assay (Przybyla
and Watts, 2010). Duplicate samples of lysate from the cAMP accumulation
assay were added to reaction tubes, followed sequentially by [3H]-cAMP (~1 nM
final concentration), and cAMP-binding protein (~100 μg of crude bovine adrenal
extract) in 500 μL of cAMP binding buffer (100 mM Tris-HCl, 100 mM NaCl, 3
mM EDTA, pH 7.4). The assay was carried out at 4°C for 2 h and harvested by
filtration through Millipore FB 96-well filter plates, and radioactivity was quantified
on a TopCount NXT scintillation counter (Perkin Elmer). Cyclic AMP
concentrations were estimated from a standard curve ranging from 300 pmol to 3
nmol cAMP.

3.3

Results

Our initial sensitization experiments employed HEK293 cells that were
transiently transfected with AC2 and the D2LDR. Consistent with significant AC2
expression and function, HEK293 cells co-expressing AC2 and the D2LDR
displayed a robust increase in cAMP accumulation in response to PMA activation
of PKC (2.75±0.48 pmol/well, n = 3) as compared to cells transfected with empty
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vector (0.60±0.06 pmol/well, n = 3). To observe D2LDR-mediated sensitization of
AC2, cells were pretreated for 2 h with the D2LDR agonist quinpirole, and
subsequently stimulated with PMA to activate AC2. The quinpirole-pretreated
cells co-expressing AC2 and the D2LDR displayed PMA-stimulated cAMP
accumulation that was 251±34% of the vehicle pretreatment condition, whereas
the empty vector transfected cells provided a response that was similar to that of
vehicle-treated cells (Figure 3.1). These observations are consistent with our
previous studies using cells stably expressing AC2, where persistent D2LDR
activation resulted in a sensitized response to AC2 activation via PKC as
measured by the enhancement of cAMP accumulation over that of the vehicle
pretreatment condition (Chapter 2 and (Cumbay and Watts, 2001)). Studies
have suggested an important role for Gi/o protein subunits in the development of
AC sensitization (Watts and Neve, 2005). The regulatory properties of AC2 offer
a unique system to dissociate the functional roles of Gαi/o and Gβγ subunits in
AC sensitization. Specifically, AC2 is thought to be insensitive to functional
regulation by Gαi subunits (Tang and Gilman, 1991; Taussig et al., 1994),
thereby allowing the specific observation of Gβγ subunit-modulated AC2 activity.
To directly study the role of Gβγ subunits in AC2 sensitization, the membranelocalized Gβγ subunit-sequestering protein βARKct-CD8 was co-expressed with
AC2 and the D2LDR in HEK293 cells. Expression of βARKct-CD8 resulted in a
blockade of D2LDR-mediated sensitization of AC2 (124±13% of vehicle response),
suggesting a role for Gβγ subunits in sensitization of AC2 (Figure 3.1).
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Figure 3.1 Effect of the Gβγ subunit sequestering protein on heterologous
sensitization of AC2. HEK293 cells were transiently transfected with AC2, the
D2LDR, and either empty vector or βARKct-CD8. Cells were pretreated with
quinpirole or vehicle for 2 h and subsequently stimulated with 1 μM PMA. Data
are expressed as a percentage of the vehicle condition for each transfection and
are the mean ± S.E.M. of three independent experiments. The raw cAMP values
for each condition are as follows: AC2+D2L vehicle pretreatment condition = 2.75
± 0.48 pmol/well; AC2 + D2L quinpirole pretreatment condition = 6.97 ± 1.55
pmol/well; AC2 + D2L + βARKct-CD8 vehicle pretreatment condition = 2.73 ±
0.78 pmol/well; AC2 + D2L + βARKct-CD8 quinpirole pretreatment condition =
3.31 ± 0.89 pmol/well.
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The observation that βARKct-CD8 prevented heterologous sensitization
suggests that the role of Gβγ subunits in AC2 sensitization could be either direct
or indirect. In an effort to explore the direct pathway, we tested two small
molecule Gβγ signaling inhibitors for their ability to modulate sensitization of AC2.
HEK293 cells stably expressing AC2 and the D2LDR (HEK-AC2/D2L cells) were
pretreated with increasing concentrations of the agonist quinpirole, followed by
subsequent AC2 activation by PMA treatment. As expected, quinpirole
pretreatment resulted in a concentration-dependent enhanced responsiveness of
AC2 to activation by PMA (Figure 3.2A). Initial studies with the small molecule
inhibitors, M119 and gallein, revealed that the quinpirole-induced enhanced
response to PMA was not altered by the small molecule Gβγ signaling inhibitors.
The lack of efficacy of M119 and gallein may represent the reported specificity for
inhibition of specific Gβγ-effector interfaces (Bonacci et al., 2006). Thus, we
examined the ability of M119 and gallein to block conditional acute activation of
AC2 by Gβγ subunits (Federman et al., 1992; Taussig et al., 1993b). For these
studies HEK-AC2/D2L cells were treated with PMA (to activate AC2) in the
presence of quinpirole to activate the D2LDR (allowing for activation of Gαi and
release of Gβγ subunits) for Gβγ-dependent potentiation of AC2 activity. The
results of these studies revealed that the Gβγ signaling inhibitors, M119 and
gallein, had no effect on either PMA-stimulated or Gβγ-dependent potentiation of
AC2 (Figure 3.2B).
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Figure 3.2 The effect of Gβγ signaling inhibitors on D2LDR-mediated AC2
signaling. A. The effect of M119 and gallein (10 μM) on quinpirole-induced
sensitization was measured in HEK-AC2/D2L cells. Cells were pretreated with
increasing concentrations of quinpirole for 2 h in the presence of vehicle, M119,
or gallein and subsequently stimulated with 1 μM PMA. Data are representative
of two independent experiments. B. The effect of M119 and gallein (10 μM) on
acute quinpirole-induced potentiation of PMA-stimulated AC2 activity was
measured in HEK-AC2/D2L cells. Data are the mean ± S.E.M. of three
independent experiments.
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In an effort to rapidly assess the activity of several small molecules for
modulation of D2LDR-induced sensitization of AC2, we developed a 96 well
sensitization assay (with reduced wash and decant steps) for increased
throughput (Conley et al., in press). The higher throughput sensitization assay
provided the ability to efficiently investigate multiple pharmacological modulators
simultaneously. The observation that βARKct-CD8 expression inhibits D2LDRinduced sensitization of AC2 and lack of effect by M119 and gallein suggest the
hypothesis that AC2 sensitization is mediated by Gβγ subunits, in an indirect
fashion, by a downstream effector of Gβγ subunits. Furthermore, previous
sensitization studies with other adenylyl cyclases have provided evidence that a
number of kinases may also be involved in the development and expression of
sensitization of adenylyl cyclase (Chakrabarti et al., 1998; Johnston et al., 2002).
Thus, several ligands including a peptide Gβγ signaling inhibitor, small molecule
inhibitors of Gβγ effectors, and several additional kinase inhibitors were tested for
the ability to inhibit quinpirole-induced sensitization of AC2 in HEK-AC2/D2L cells.
Specifically, HEK-AC2/D2L cells were pretreated with inhibitors in the presence of
either vehicle or quinpirole, and subsequently stimulated with PMA to promote
PKC activation of AC2. The results of these studies are depicted as a
percentage of sensitization (i.e., quinpirole induced sensitization = 100%).
Consistent with the effects of βARKct-CD8, the cell-permeable Gβγ subunit
sequestering peptide, QEHA-TAT significantly inhibited sensitization in the HEKAC2/D2L cells, whereas the small molecule Gβγ subunit inhibitor, gallein, had no
effect (negative control) (Table 3.1). The next set of compounds included
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reported pharmacological kinase inhibitors that target Gβγ effectors that include
c-JNK, Raf-1, PI3K, or MEK. Much to our disappointment, there was no
significant difference observed in the D2LDR-mediated sensitization of AC2 in the
presence of the Gβγ-modulated kinase inhibitors (Table 3.1). Additional kinases,
including those that have been identified as being involved in sensitization of AC
isoforms (i.e., PKC and PKA) were also examined in the same manner
(Chakrabarti et al., 1998; Johnston et al., 2002). As expected, the PKC inhibitor
bisindolylmaleimide I (BisI) blocked sensitization of AC2 (3.0±1.7% sensitization).
Inhibitors of PKA (H89) and PI3K/PI4K (phenylarsine oxide, PAO) significantly
reduced the level of D2LDR-mediated sensitization of AC2 (29±12% and 29±5%
sensitization, respectively), suggesting roles for these kinases in sensitization of
AC2.
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Table 3.1 Effects of pharmacological inhibitors on D2LDR-mediated sensitization
of AC2. Data are expressed as a percent sensitization with the quinpiroleinduced sensitization = 100%. Data are the mean ± S.E.M. of five independent
experiments.

Compound
Control
10 μM Gallein
30 µM QEHA-TAT
10 μM SP600125
30 μM GW5074
300 nM Wortmannin
30 μM PD98059
10 μM H89
10 μM PAO
1 μM BisI

Target
Gβγ
Gβγ
c-JNK
Raf-1
PI3K
MEK
PKA
PI3K/PI4K
PKC

Mean±S.E.M.
100
110±24
62±8.2*
130±13
99±12
95±10
90±6.2
29±12 ***
29±5.5 ***
3.0±1.7 ***
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3.4

Discussion

G protein subunits are known to be important components of the signaling
pathways that contribute to the development of heterologous sensitization of
multiple isoforms of adenylyl cyclase (Watts and Neve, 2005). Studies with
pertussis toxin and pertussis-toxin insensitve Gαi/o subunits have indicated
essential roles for Gαi/o subunit activation in AC sensitization (Watts and Neve,
1996; Watts et al., 1998), but mounting evidence also suggests that Gβγ subunits
play an important part in the development of AC sensitization (AvidorReiss et al.,
1996; Nguyen and Watts, 2005; Rhee et al., 2000; Rubenzik et al., 2001). As
most ACs are differentially regulated by Gαi/o and Gβγ subunits, the precise
roles of these subunits in sensitization of cAMP signaling have been difficult to
examine (Hanoune and Defer, 2001; Patel et al., 2001). Nevertheless, AC2
shows only conditional activation by Gβγ subunits and is not directly regulated by
Gαi/o subunits (Tang and Gilman, 1991; Taussig et al., 1994). These unique
regulatory properties of AC2 allow for the selective study of Gβγ subunit signaling
in sensitization of PKC-stimulated AC2 activity. The present data suggest that
similar to other AC isoforms, Gβγ subunits are necessary for the sensitization of
AC2. Specifically, the membrane-localized Gβγ subunit sequestering protein
βARKct-CD8 attenuated D2LDR-mediated sensitization of AC2. Sensitization of
AC2 was also reduced using a cell-permeable peptide inhibitor of Gβγ signaling,
QEHA-TAT. The peptide sequence corresponds to a Gβγ subunit-binding
sequence derived from the C2 domain of AC2 and is known inhibit Gβγ subunit
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signaling (Chen et al., 1995a). Our data are in agreement with our previous
study, where AGS3 blocked D2LDR-mediated sensitization of AC2 (Chapter 2).
AGS3 is hypothesized to disrupt Gβγ subunit signaling in response to long-term
or repeated Gi-coupled receptor signaling. These findings, along with the unique
properties of AC2 suggest that D2LDR activation leads to a Gβγ-dependent event
that selectively enhances PKC-mediated activation of AC2.
Two small molecule Gβγ subunit signaling inhibitors, M119 and gallein
were also studied for their effects on D2LDR-mediated sensitization of AC2.
Surprisingly, neither small molecule (up to 10 μM) altered sensitization of AC2 or
D2LDR-potentiated AC2 activity (a Gβγ subunit-mediated effect). The lack of
activity of these compounds was discouraging, but may be explained by the
effector specificity profiles displayed by the small molecule inhibitors (Bonacci et
al., 2006). The small molecule inhibitors selectively bind to a common region of
Gβγ, known as the “Gβγ hot spot”, that interacts with Gα subunits and many Gβγ
effector proteins (Ford et al., 1998; Hamm, 1998; Li et al., 1998; Lin and Smrcka,
2011). It is thought that different residues or regions within the hot spot are
important for binding different effectors (Ford et al., 1998; Li et al., 1998). It is
possible that M119 and gallein do not interact with the region of Gβγ that
mediates acute potentiation of AC2 signaling.
Several studies have contributed evidence that suggests AC2 has multiple
Gβγ subunit binding sites (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006;
Weitmann et al., 2001). Specifically, at least five distinct sites have been
identified within C1a, C1b, and C2 regions of AC2 for their interaction with Gβγ
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subunits (see Figure 1.6) (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006;
Weitmann et al., 2001). It is therefore possible that persistent activation of the
D2LDR releases Gβγ subunits that directly interact with AC2, allowing a
conformation that provides an enhanced response to activation by PKC. The
identification of multiple Gβγ binding sites makes it tempting to speculate that the
Gβγ sites for sensitization of AC2 may be unique from those involved with
conditional activation.
Gβγ subunits regulate a multitude of downstream effectors (Khan et al.,
2013; Smrcka, 2008). Therefore, it is possible that Gβγ subunit signaling
indirectly leads to sensitization of AC2 via modulation of downstream Gβγ
effectors. We addressed this possibility by examining the ability of
pharmacological inhibitors of Gβγ subunit effectors to modulate D2LDR-mediated
sensitization of AC2 in HEK-AC2/D2L cells. The concentrations of
pharmacological inhibitors tested had no significant effect on D2LDR-mediated
AC2 sensitization. However, upon treatment of HEK-AC2/D2L cells with H89 or
PAO, significant inhibition of AC2 sensitization was observed, suggesting roles
for PKA and PI4K. Interestingly, subsequent studies with PAO revealed a
biphasic potentiation of acute AC2 stimulation in response to PMA treatment
(data not shown) and no effect of additional PI4K inhibitors (LY294002 and Pik93,
John Paul Spence and Val J. Watts, unpublished results). These results suggest
PAO modulation of D2LDR-mediated sensitization of AC2 is complex and perhaps
independent of its effects on PI4K. In summary, our data suggest that PKA and

96
PKC mediate sensitization of AC2 in response to persistent D2LDR activation by
quinpirole.
The present study leveraged the unique regulatory properties of AC2 (i.e.,
lack of direct modulation by Gαi/o subunits and selective sensitization to PKC
activation) to demonstrate that Gβγ subunits are required for AC sensitization.
However, the mechanism underlying the enhancement of PKC-stimulated AC2
remains unknown. Ongoing efforts to identify signaling components that mediate
AC sensitization include the development of higher throughput cell-based cAMP
detection methodology to facilitate unbiased approaches such as siRNA library
screening and small molecule screening (e.g., known kinase inhibitor sets).
These approaches are expected to expand the repertoire of signaling molecules
implicated in sensitization.
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CHAPTER 4. DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING
PARADIGM FOR THE DISCOVERY OF SMALL MOLECULE
MODULATORS OF ADENYLYL CYCLASE: IDENTIFICATION OF AN
ADENYLYL CYCLASE 2 INHIBITOR

4.1

Introduction

Cyclic AMP (cAMP) is a crucial component of signal transduction
cascades that modulates diverse fundamental biological processes (Hanoune
and Defer, 2001). The cellular levels of cAMP are dynamically modulated by two
families of enzymes. Specifically, adenylyl cyclases (ACs) synthesize cAMP
from ATP (Hanoune and Defer, 2001) and phosphodiesterase enzymes degrade
cAMP (Bender and Beavo, 2006). The specificity of cAMP signaling is influenced
by the interplay of signaling molecules that are expressed within a given cell. For
example, nine membrane-bound mammalian AC isoforms have been identified
that have unique profiles of regulation by G protein subunits, protein kinases, and
Ca2+ (Hanoune and Defer, 2001; Patel et al., 2001). Specifically, the AC
isoforms are commonly activated by the stimulatory G protein (Gs), but are
categorized into four subgroups based on their sequence similarities and
regulatory properties (Hanoune and Defer, 2001; Patel et al., 2001). The group I
ACs (AC1, AC3, and AC8) are stimulated by Ca2+/calmodulin. In contrast, group
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II ACs (AC2, AC4, and AC7) are insensitive to Ca2+, but conditionally activated
by G protein Gβγ subunits. The group III ACs (AC5 and AC6) are inhibited by
free Ca2+, Gαi/o subunits, and phosphorylation by protein kinase A. AC9, the
lone member of group IV is distinguished by its relative insensitivity to stimulation
by forskolin.
Insight from knockout and transgenic mouse studies suggest that
individual AC isoforms contribute to important physiological processes and
diseases (Sadana and Dessauer, 2009), suggesting that selective AC
modulators have therapeutic utility for the treatment of conditions involving
cardiac function, aging, and pain. As such, the AC5/AC6 inhibitors PMC-6 and
AraAde have shown efficacy in preventing cardiomyocyte apoptosis (Iwatsubo et
al., 2004) and a mouse model of heart failure, respectively (Iwatsubo et al., 2012).
Also, a small molecule AC1 inhibitor, NB001, has been reported to have
analgesic effects in animal models of neuropathic and inflammatory pain
(Vadakkan et al., 2006; Wang et al., 2011). However, a dearth of isoformselective small molecule AC modulators has limited the study of AC isoforms as
therapeutic targets (Pierre et al., 2009; Seifert et al., 2012). For example, AC2 is
potentially involved in skeletal muscle physiology, lung diseases, neuroendocrine
tumors (NETs), and colorectal cancer (Berdeaux and Stewart, 2012; Drozdov et
al., 2011; Duerr et al., 2008; Yu et al., 2011). Yet, the pharmacological study of
AC2 is difficult because most small molecule AC inhibitors preferentially inhibit
other AC isoforms (Pierre et al., 2009; Seifert et al., 2012). BODIPY-forskolin
appears to be the most potent AC2 inhibitor, but its use as a chemical probe for
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AC2 activity is hindered because it also partially activates AC1 and AC5 (Erdorf
et al., 2011; Pinto et al., 2008). Given the shortcomings of small molecule AC
modulators and the absence of published reports of AC2 knockout animals, the
identification of selective AC2 modulators is expected to provide useful chemical
probes to facilitate the study of AC2.
The present report describes the development and execution of a cellbased screening approach for the discovery of novel small molecule inhibitors of
AC2. We screened the NIH clinical collections I and II (727 compounds) for
small molecules that inhibit cAMP accumulation in response to selective
activation of AC2. Compounds identified as active were examined in a series of
confirmation assays to validate direct AC2 inhibition and define their AC isoformselectivity profiles. Our studies have resulted in the identification of SKF-83566
as a selective AC2 inhibitor that is expected to be a promising tool to investigate
the physiological roles of AC2.

4.2

Materials and methods
4.2.1 Materials

The NIH clinical collections I and II were purchased from Evotec, Inc
(South San Francisco, CA). Oxymetholone, tranilast, amlexanox, duloxetine, and
indatraline were purchased from Sequoia Research Products (Pangbourne,
United Kingdom). [3H]-cAMP was purchased from PerkinElmer Life and

100
Analytical Sciences (Boston, MA). A23187, 3-isobutyl-1-methylxanthine (IBMX),
loratadine, prochlorperazine, maprotiline, thioridazine, G418, Dulbecco’s
modified Eagle’s medium (DMEM), and trichloroacetic acid (TCA) were
purchased from Sigma-Aldrich (St. Louis, MO). Phorbol 12-myristate 13-acetate
(PMA), forskolin, MDL-12,330A HCl, prostaglandin E2 (PGE2), SQ22,536, and
(±)-SKF-83566 HBr were purchased from Tocris Bioscience (Ellisville, MO). 2’5’dideoxyadenosine was purchased from Santa Cruz Biotechnology (Dallas, TX).
Lipofectamine 2000, opti-MEM, and antibiotic-antimycotic 100x solution were
purchased from Life technologies (Grand Island, NY). FetalClone I serum,
bovine calf serum, HEPES, and Hank’s balanced salt solution (HBSS) were
purchased from Hyclone (Logan, UT). BisindoloylmaleimideI (BisI) was
purchased from Calbiochem (La Jolla, CA). The HTRF cAMP and Cellul’ERK
kits were purchased from Cisbio Bioassays (Bedford, MA).

4.2.2 Stable cell line generation and cell culture conditions
HEK293 cells were cultured in DMEM supplemented with 5% bovine calf
serum, 5% fetal clone I, and 1% antibiotic-antimycotic 100x solution and
maintained in a humidified incubator at 37°C and 5% CO2. For generation of a
clonal stable cell line, HEK293 cells were transfected with pcDNA3.1(+) encoding
human AC1, AC2, or AC5 using Lipofectamine 2000 according to the
manufacturer’s protocol. Stable clones were selected by growth in media
containing 600 μg/ml (AC2) or 800 μg/ml (AC1 and AC5) G418. Stable
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expression of AC isoforms was confirmed functionally by measuring cAMP
accumulation to selective pharmacological activation conditions. For example,
AC1 was stimulated with 3 µM A23187, AC2 was stimulated with the phorbol
ester, PMA, and AC5 was activated by 300 nM forskolin.
The C2C12 mouse skeletal muscle cell line was purchased from the
American Type Culture Collection. C2C12 myoblasts were maintained at a low
confluency in DMEM media containing 10% fetal bovine serum. Myoblasts
(passages 3-17) were plated in 96-well format at 5x104 cells per well.
Differentiation into myotubes was induced once the cells reached 90%
confluency by switching to medium supplemented with 2% horse serum. The
growth medium was changed every 24 hours. Myotubes were allowed to mature
for 5 days before being experiments were completed.

4.2.3 Cisbio HTRF cAMP assay
The cellular cAMP levels were measured using either the Cisbio HTRF
cAMP dynamic 2 assay kit or a dynamic 2/HiRange hybrid kit (consisting of
cAMP-d2 from the dynamic 2 kit and the anti-cAMP cryptate conjugate from the
HiRange kit). The cAMP assays were performed on cryopreserved cells that
were rapidly thawed at 37°C and resuspended in cell suspension buffer (HBSS,
20 mM HEPES, 0.1% fatty acid free BSA or opti-MEM for HEK-hAC1 cells).
Cells were centrifuged at 500×g and the supernatant was aspirated. Cells were
washed by resuspending in cell suspension buffer and centrifuged at 500×g. The
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supernatant was aspirated and cells were seeded into a 384-well plate and
allowed to incubate at 37°C and 5% CO2 for 2.5 h. Cells were then treated as
indicated with ligands diluted in stimulation buffer (HBSS, 20 mM HEPES, 500
µM IBMX or opti-MEM, 500 µM IBMX for HEK-hAC1 cells) and incubated for 1 h
at room temperature. The stimulation was terminated by sequential addition of
10 μl/well of cAMP-d2 and 10 µl/well of anti-cAMP cryptate conjugate, each
diluted (1:39) in lysis buffer. The experiments that used the dynamic 2 kit for
cAMP detection were performed without IBMX in the stimulation buffer (to
accommodate the sensitivity for cAMP detection), but with IBMX in the lysis
buffer (to prevent phosphodiesterase-mediated degradation of cAMP in the
lysate). Following a 1 h incubation at room temperature, the time-resolved
fluorescence energy transfer (TR-FRET) was measured with a lag time of 100 μs
and integration time of 300 μs using a Synergy4 (BioTek) fluorescence plate
reader (excitation filter: 330/80 nm and emission filters: 620/10 nm and 665/8
nm). The resulting cAMP concentrations were calculated in GraphPad Prism by
applying the 620/665 nm fluorescence ratio values to a standard curve of known
cAMP concentrations.

4.2.4 Screening conditions
Cryopreserved HEK-hAC2 cells were seeded into a 384-well plate at 15
μl/well using a MultiFlo (Biotek) bulk reagent dispenser. Following a 2.5 h
incubation at 37°C and 5% CO2, the cell plates were allowed to equilibrate to
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room temperature on the bench for 15 min. Test compounds (80 nl) were added
to the cells with a MultiPette-mounted 384-well pin tool and allowed to incubate
at room temperature for 30 min. AC2 activity was then stimulated by addition of
5 µl of PMA (50 nM final concentration) diluted in stimulation buffer with the
MultiFlo reagent dispenser, followed by incubation at room temperature for 1 h.
The Cisbio HTRF cAMP dynamic 2 kit was used to quantify the cellular cAMP as
described above. Briefly, the cAMP-d2 (containing 500 μM IBMX final volume)
and anti-cAMP cryptate conjugate working reagents were sequentially added (10
μl/well each) with a MultiFlo reagent dispenser and incubated at room
temperature for 1 h. Test compounds were initially screened in singlet or
duplicate and all cAMP concentrations were converted to percent inhibition of the
PMA-stimulated cAMP response.

4.2.5 3H-cAMP assay
Cryopreserved HEK-hAC2 cells were thawed and prepared as described
above. Cells were seeded at a density of 12,000 cells per well into a 384-well
plate in cell suspension buffer and incubated for 2.5 h at 37°C and 5% CO2.
Test compounds were added to the cells with a MultiPette-mounted 384-well pin
tool and allowed to incubate at room temperature for 30 min. The AC stimulation
was carried out at room temperature for 1 h and the reaction was stopped by the
addition of cold (4°C) TCA to provide a final TCA concentration of 3%. The
cAMP in the lysate was then quantified using a 3H-cAMP competition assay as
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previously described (Przybyla and Watts, 2010). C2C12 cell cAMP experiments
were performed similarly, with the exceptions that the assay was performed in
96-well format on continuously propagated cells before differentiation into
myotubes and compounds were delivered by multi-channel pipette for both
pretreatment and stimulation steps.

4.2.6 ERK1/2 phosphorylation assay
HEK-hAC2 cells were seeded into 96-well plates at a density of 25,000
cells per well in opti-MEM and incubated overnight at 37°C and 5% CO2. Drug
treatment was carried out in opti-MEM as follows. Cells were pretreated with test
compound (30 µM) at 37°C for 10 min and ERK1/2 phosphorylation was
stimulated by the addition of PMA (50 nM) and incubation for 10 min at 37°C.
The resulting ERK1/2 phosphorylation was measured using the Cisbio htrf
Cellul’ERK assay according to the manufacturer’s protocol (two-plate protocol).
Briefly, the stimulation buffer was decanted and supplemented lysis buffer was
added, followed by shaking at 500 rpm at room temperature for 30 min. The antiERK-Eu3+-cryptate and anti-phospho-ERK-d2 antibodies were combined and
added to a 384-well low-volume plate (PerkinElmer, white, Proxiplate 384 Plus).
Lysate from the stimulation or positive/negative control lysate was then added on
top of the HTRF reagents and incubated for 2 h at room temperature. The TRFRET was then measured on the Synergy4 (BioTek) plate reader.
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4.3

Results

4.3.1 Assay development and screening of the NIH clinical collections I and II
The lack of robust inhibitors of AC2 (Pavan et al., 2009; Pierre et al., 2009;
Seifert et al., 2012) and the absence of published reports on AC2-/- mice suggest
that the discovery of AC2 inhibitors will provide important research tools. Thus,
one initial goal of the present study was to develop an approach to identify and
validate novel inhibitors of AC2 activity in intact cells. To achieve this goal, we
developed and optimized assay parameters for the measurement of intracellular
cAMP in 384-well format in a semi-automated fashion, a tactic that may
ultimately allow for large-scale high-throughput screening to identify novel AC2
inhibitors.
HEK293 cells are known to endogenously express multiple AC isoforms
(Hellevuo et al., 1993; Ludwig and Seuwen, 2002). Therefore, to specifically
study AC2 modulation, it is important to identify pharmacological stimulation
conditions that selectively activate recombinant AC2 when expressed in HEK293
cells. We and others have previously reported that the protein kinase C (PKC)activating phorbol ester, PMA, selectively stimulates cAMP accumulation in
HEK293 cells stably expressing recombinant rat AC2 (Cumbay and Watts, 2001;
Yoshimura and Cooper, 1993). For this study, HEK293 cells stably expressing
human AC2 (hAC2) were constructed and screened for cAMP accumulation in
response to PMA. It is notable that the basal level of cAMP in the HEK-hAC2
cells was higher than the HEK-wt cells (data not shown) and is likely due to
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constitutive activity of AC2, a property that has been previously observed (Pieroni
et al., 1995; Pinto et al., 2008). As expected, PMA treatment had no effect on
cAMP in HEK-wt cells, but provided an ~8 fold enhancement of cAMP in HEKhAC2 cells (data not shown and Figure 4.1A). These results suggest that
recombinant hAC2 can be selectively activated by PMA in an HEK293 cell
background.
Following the verification of PMA treatment as a strategy for selective
activation of AC2, potential screening parameters were further explored by
performing a more in-depth evaluation of the effects of PMA in HEK-hAC2 cells.
PMA treatment provided a concentration-dependent increase in cAMP with an
EC50 value of 16±5.0 nM (n = 3) (Figure 4.1A). We chose to use 50 nM PMA
(~EC85 concentration) to stimulate AC2 for the study of AC2 inhibitors. As a
control for the inhibition of AC2 activity, the PKC inhibitor BisI was used to inhibit
the phorbol ester-mediated activation of AC2. Treatment with BisI provided full
inhibition of PMA-stimulated AC2 activity with an IC50 of 16±1.9 nM (n = 3),
suggesting that 1 μM BisI is sufficient to completely inhibit AC2 activity stimulated
by 50 nM PMA (Figure 4.1A, inset).
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Figure 4.1 Optimization of conditions for an intact-cell assay that is capable of
high-throughput screening for small molecule inhibitors of AC2.
A.
Concentration-response curve analysis of PMA for stimulation of an AC2mediated cAMP response in HEK-hAC2 cells. Data are the mean±S.E.M. of
three independent experiments. Inset: Inhibition of 50 nM PMA-stimulated AC2
activity with the PKC inhibitor BisI. Data are the mean±S.E.M. of three
independent experiments. B. Evaluation of assay robustness by Z’ analysis (Z’ =
((AVGmax – 3 * SDmax/√n) – (AVGmin + 3 * SDmin/√n)) / (SDmax/√n)). Data
are representative of three independent experiments.
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Ultimately, our approach for the identification of AC inhibitors relies on the
development of a cell-based assay that is capable of high-throughput screening
of small molecule libraries. Therefore, it was important to evaluate the
robustness of the HEK-hAC2 cell cAMP assay when converted to a semiautomated format that is amenable to high-throughput screening (see methods).
Specifically, assay robustness was examined by performing a Z’ analysis for the
assay parameters developed for screening (Zhang et al., 1999). The Z’ value
was calculated using 50 nM PMA as the maximum stimulation control and 1 μM
BisI as the minimum stimulation control. Our AC2 screening assay provided a Z’
= 0.44 ± 0.02 (n = 3), suggesting that the assay is appropriate for small molecule
library screening (Figure 4.1B) (NCGC Assay Guidance Manual,
www.ncbi.nlm.nih.gov/books/NBK53196/).
The NIH clinical collections I and II consist of 727 total test compounds
that have a history of use in human clinical trials (www.nihclinicalcollection.com).
The collections contain drug-like molecules with documented biological activity
and safety profile information. The modest size of the collections, paired with the
reasons stated above, make the NIH clinical collections a good starting collection
for early screening efforts in the search for AC2 inhibitors. The NIH clinical
collections were screened for the ability of test compounds (25 μM) to inhibit
PMA-stimulated AC2 activity in HEK-hAC2 cells. Of the 727 compounds
screened (the full screening results are reported in the appendix, Table A.1), 10
compounds identified as active for the inhibition of PMA-stimulated cAMP
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accumulation in HEK-hAC2 cells (displaying > 30% inhibition at 25 µM) were
chosen for additional confirmation and validation (Table 4.1).
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Table 4.1 Screening of NIH Clinical Collections I and II for inhibition of AC2
activity. The NIH Clinical Collections I and II (25 µM) were screened for inhibition
of PMA-stimulated (50 nM) cAMP accumulation in HEK-hAC2 cells using the
Cisbio HTRF cAMP dynamic 2 detection methodology. The data represent the
average percent inhibition of the PMA-stimulated cAMP response from duplicate
plates (see methods).

Compound
Name
SKF-83566
Tranilast
Loratadine
Thioridazine
Duloxetine
Amlexanox
Indatraline
Oxymetholone
Prochlorperazine
Maprotiline

Inhibition
(%)
85
69
64
58
51
41
39
37
35
33
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4.3.2 Confirmation and validation of activity
Confirmation studies were carried out using freshly prepared powders that
were purchased from commercial sources. The initial confirmation of active small
molecules used a single concentration (30 µM) of the test compounds for the
inhibition of AC2 activity. HEK-hAC2 cells were incubated with 50 nM PMA to
selectively activate AC2 in the presence of test compound and the resulting
cAMP accumulation was measured with the Cisbio HTRF cAMP dynamic 2 kit
(identical to the assay format used for small molecule library screen). All test
compounds provided inhibition of AC2 activity at 30 μM, confirming the activity
observed in the initial screen (Table 4.2).
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Table 4.2 Confirmation of the inhibitory activity of test compounds identified in the
screen of NIH Clinical Collections I and II. Active compounds (30 µM) were
tested for inhibition of PMA-stimulated cAMP in HEK-hAC2 cells using either the
Cisbio HTRF cAMP dynamic 2 technology or a [3H]-cAMP competition method
for detection of cAMP. Data are reported as the mean±S.E.M. of the percent
inhibition of the PMA response from three independent experiments. ND, not
determined.

Compound Name
SKF-83566
Tranilast
Loratadine
Thioridazine
Duloxetine
Amlexanox
Indatraline
Oxymetholone
Prochlorperazine
Maprotiline

Inhibition
(%)
TR-FRET
95±1.6
76±2.9
61±0.5
36±5.7
39±3.8
45±5.7
60±2.0
58±1.9
41±8.3
26±1.8

Inhibition (%)
3H-cAMP
94±2.8
79±5.3
71±8.1
ND
ND
ND
53±5.5
58±2.9
ND
ND
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The screening assay and initial confirmation of active compounds rely on
TR-FRET for the detection of cAMP (see materials and methods). It is possible
that the active compounds have inherent fluorescence that can be measured in
the same wavelengths as those utilized for cAMP detection, thereby skewing the
measured fluorescence and affecting the resulting estimation of the cAMP
concentration (Degorce et al., 2009). Thus, we assessed the ability of the best
compounds (i.e., those that provided at least 50% inhibition in the confirmation
assay) to inhibit AC2 activity in a non-fluorescence-based assay. The active
compounds SKF-83566, oxymetholone, tranilast, indatraline, and loratadine were
tested for their ability to inhibit PMA-stimulated cAMP accumulation in a 3HcAMP competitive binding assay. All of the compounds tested retained the ability
to inhibit PMA-stimulated cAMP accumulation in HEK-hAC2 cells, indicating bona
fide reduction of cAMP, rather than interference with the fluorescence detection
methodology (Table 4.2). Furthermore, the extent of inhibition of PMA-stimulated
AC2 activity by the test compounds in the 3H-cAMP assay was nearly identical to
that observed in the TR-FRET-based cAMP detection method.
Our screening strategy utilized PMA to selectively stimulate AC2 via
phosphorylation mediated by PKC (Jacobowitz and Iyengar, 1994). Thus, it is
possible that the compounds identified as active may exert their cAMPattenuating effects through inhibition of PKC rather than directly inhibiting AC2.
PMA-mediated PKC activation is known to stimulate ERK1/2 phosphorylation in
HEK293 cells (DellaRocca et al., 1997), allowing for a simple counter-screen to
eliminate false positives (Figure 4.2A). Specifically, we measured ERK1/2
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phosphorylation in response to PKC activation in HEK-hAC2 cells in the absence
and presence of the active compounds (Figure 4.2B). As expected, PMA
treatment resulted in a significant enhancement of ERK1/2 phosphorylation
(5.7±0.2 fold over basal) that was inhibited completely by the PKC inhibitor, BisI.
In contrast, SKF-83566, oxymetholone, tranilast, and loratadine did not
significantly alter the PMA-mediated ERK1/2 phosphorylation in HEK-hAC2 cells,
suggesting that these compounds do not inhibit PKC. Indatraline, however,
inhibited the PMA-mediated ERK1/2 phosphorylation by ~80%.
The lack of inhibition of PKC-dependent ERK1/2 phosphorylation by SKF83566, oxymetholone, tranilast, and loratadine is consistent with a direct
inhibition of AC2 activity by these drugs. To further test this supposition, we
examined the ability of SKF-83566, oxymetholone, tranilast, and loratadine to
inhibit AC2 activity stimulated via other mechanisms. AC2 is also stimulated in a
PKC-independent manner by Gαs in response to activation of Gs-coupled
receptors and directly via the small molecule AC activator, forskolin.
Prostaglandin E2 (PGE2) is known to bind and activate the Gs-coupled EP2/4
prostanoid receptors that are endogenously expressed in HEK293 cells (Bogard
et al., 2012; Willoughby et al., 2007). As expected, PGE2 treatment resulted in a
concentration-dependent increase in cAMP accumulation in HEK-hAC2 cells
(EC50: 160±78 nM, n = 3). To examine the effects of inhibitors on Gαs-stimulated
AC2 activity, the identified active compounds were then tested for the inhibition of
300 nM PGE2-stimulated cAMP in HEK-hAC2 cells (Figure 4.2C). Oxymetholone,
SKF-83566, tranilast, and loratadine significantly inhibited PGE2-stimulated
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cAMP in HEK-hAC2 cells. Next, they were similarly tested for their ability to
inhibit the cAMP generated in response to direct AC stimulation by forskolin
(Figure 4.2D). Oxymetholone, SKF-83566, tranilast, and loratadine significantly
inhibited forskolin-stimulated cAMP accumulation in HEK-hAC2 cells. These
data are in agreement with the effects of the test compounds on PKC-mediated
ERK1/2 phosphorylation. Specifically, indatraline and BisI inhibited PKCmediated ERK1/2 phosphorylation, but not Gαs- or forskolin-stimulated cAMP in
HEK-hAC2 cells. Taken together, these observations suggest that inhibition of
PMA-stimulated cAMP by indatraline in HEK-hAC2 cells is due to inhibition of
PKC. More importantly, our data indicate that SKF-83566, oxymetholone,
tranilast, and loratadine inhibit multiple modes of AC2 stimulation (i.e., PKC-,
Gαs-, and forskolin-mediated), but do not inhibit PKC activity.
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Figure 4.2 Counter-screening for validation of active compounds as AC2
inhibitors. A. Schematic for PKC-dependent and PKC-independent activation of
AC2. B. The effects of test compounds (30 µM) on PMA-stimulated ERK1/2
phosphorylation were measured in HEK-hAC2 cells. Data are mean±S.E.M. of
three independent experiments. ***, p < 0.001 (one sample t-test compared to
100). C. The effects of test compounds (30 µM) on 300 nM PGE2-stimulated
cAMP accumulation and D. 3µM forskolin-stimulated cAMP accumulation was
measured in HEK-hAC2 cells. Data are mean±S.E.M. of three independent
experiments. ** p < 0.01, compared to vehicle condtion, one-way analysis of
variance followed by Dunnett’s post hoc test.
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4.3.3 AC isoform selectivity profiles
The selectivity profiles of the active compounds for inhibition of AC
isoforms was explored using intact cell cAMP assays. The ability of compounds
to modulate cAMP levels in HEK-hAC2 cells was compared to that of HEK-hAC1
and HEK-hAC5 cells, as well as HEK-wt cells (Figure 4.3). AC1 and AC5 were
chosen as representative ACs from group I and group III ACs, respectively. AC1
activity was selectively activated by the calcium ionophore A23187 (3 µM) and
AC5 was stimulated by 300 nM forskolin in HEK293 cells stably expressing each
isoform (data not shown). Test compounds (30 µM) were evaluated for the ability
to modulate selective activation of AC1 and AC5 activity in HEK293 cells. None
of the test compounds inhibited AC1 activity, however, loratadine significantly
potentiated A23187-stimulated cAMP by ~150%. Studies with HEK-hAC5 cells
revealed that loratadine and tranilast strongly inhibited forskolin-stimulated cAMP
in HEK-hAC5 cells, while SKF-83566 had more modest activity (~35% inhibition).
Tranilast and loratadine also significantly inhibited forskolin-stimulated AC activity
in HEK-wt cells, whereas SKF-83566 had no significant effect. Oxymetholone
modestly, but significantly inhibited PMA-stimulated cAMP in HEK-hAC2 cells,
but had no effect on the AC responses in HEK-hAC1, -hAC5, or –wt cells. These
results suggest that the active compounds show distinct patterns of cAMP
modulation in HEK293 cells stably expressing recombinant AC1, AC2, or AC5.
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Figure 4.3 AC isoform-selectivity profile of test compounds in intact-cell studies.
AC isoform selectivity was assessed by testing the ability of test compounds (30
µM) to modulate A. 3µM A23187-stimulated cAMP in HEK-hAC1 cells, B. 50 nM
PMA-stimulated cAMP in HEK-hAC2 cells, C. 300 nM forskolin-stimulated cAMP
in HEK-hAC5 cells, and D. 3 µM forskolin-stimulated cAMP in HEK-wt cells. * p
< 0.05, ** p < 0.01, compared to vehicle condition, one-way analysis of variance
followed by Dunnett’s post hoc test.
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The direct modulation of AC isoforms was explored using a cell free,
reconstituted system to directly assess the effects of test compounds on AC
activity (Conley et al., under review). Specifically, the effects of the test
compounds have been studied in AC activity assays that were performed using
membranes from Sf9 insect cells expressing recombinant AC1, AC2, or AC5. As
expected, SKF-83566 significantly inhibited forskolin-stimulated AC2 activity (>
40%), suggesting a direct mode of inhibition (mechanistic studies suggest
noncompetitive inhibition with respect to ATP). SKF-83566 was inactive against
AC1 or AC5. A similar pattern of AC isoform selectivity was observed with
tranilast (See figure 4.4 for chemical structures of SKF-83566 and tranilast). In
contrast to SKF-83566 and tranilast, a commercially available AC inhibitor,
NKY80, showed marked inhibition of AC1 and AC5, but only modest inhibition of
AC2 activity. These studies identified SKF-83566 as the most favorable
compound to carry into further studies, as it provided the most robust AC2
inhibition, while having no effect on forskolin-stimulated cAMP levels in HEK-wt
cells and retention of AC2 inhibition in vitro.
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Figure 4.4 Chemical structures of SKF-83566 and tranilast.
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The AC isoform-selectivity of SKF-83566 was further characterized by
performing a concentration-response analysis for inhibition of cAMP in HEKhAC2 and HEK-hAC5 cells. SKF-83566 fully inhibited PMA-stimulated cAMP in
HEK-hAC2 cells with an IC50 value of 10±1.4 µM and maximum inhibition of
104±2% (Figure 4.5A). Additionally, the potency and efficacy values of SKF83566 for inhibition of 3 µM forskolin stimulation (IC50: 19±3.3 µM and maximum
inhibition: 113±2%, n = 3) and 300 nM PGE2 stimulation (IC50: 21±4.5 µM and
maximum inhibition: 117±2%, n = 3) in HEK-hAC2 cells were similar to those
observed for inhibition of the PMA response in HEK-hAC2 cells. The robust
inhibition below basal levels presumably reflects inhibition of the constitutive AC2
activity. As anticipated from the single point studies, SKF-83566 only partially
inhibited forskolin-stimulated cAMP in HEK-hAC5 cells (< 40%) at a
concentration of 130 µM. We consistently observed less inhibition of AC5 at 400
µM suggesting a biphasic response (Figure 4.5A). Nonetheless, these results
indicate marked selectivity of SKF-83566 for inhibition of AC2 over AC1 and AC5.
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Figure 4.5 Concentration-response analysis of SKF-83566 for inhibition of cAMP.
A. Dose-response curves of SKF-83566 for inhibition of PMA-stimulated (50 nM)
cAMP in HEK-hAC2 cells and forskolin-stimulated (300 nM) cAMP in HEK-hAC5
cells. B. Dose-response curves of SKF-83566, MDL-12,330A, SQ22,536, and
2’5’-dideoxyadenosine (2’5’ddAd) for inhibition of PMA-stimulated (50 nM) cAMP
in HEK-hAC2 cells. The SKF-83566 data in panels A and B are from the same
experiments, as these studies were performed simultaneously. Data are
expressed as a percentage of the stimulation response and are reported as the
mean±S.E.M. of three independent experiments.
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The ability of SKF-83566 to inhibit PMA-stimulated AC2 activity was
directly compared to several known AC inhibitors (i.e., SQ22,536, MDL-12,330A,
and 2’5’-dideoxyadenosine; Figure 4.5B). Efficacy comparisons revealed marked
differences between SKF-83566 (> 100% inhibition) and the known inhibitors (i.e.,
SQ22,536, 29±3%; MDL-12,330A, 33±4%; and 2’5’-dideoxyadenosine, 38±3%)
each at a concentration of 400 µM. These results demonstrate that SKF-83566
displays superior potency and efficacy for inhibition of AC2 activity when directly
compared to SQ22,536, MDL12,330A, and 2’5’-dideoxyadenosine in HEK-hAC2
cells.

4.3.4 SKF-83566 as a chemical probe for AC2 function
The most potent and selective AC2 inhibitor (SKF-83566) was examined
in cell models where AC2 is natively expressed (along with other AC isoforms),
allowing confirmation of its activity in a more physiological context and evaluation
of its use as a tool to probe AC2 function. AC2 is reported to be abundantly
expressed in skeletal muscle tissues (Ludwig and Seuwen, 2002; Suzuki et al.,
1998; Torgan and Kraus, 1996). Therefore, the ability of SKF-83566 to inhibit
forskolin-stimulated cAMP accumulation was studied in differentiated mouse
C2C12 skeletal muscle myotubes (Figure 4.6). As expected, SKF-83566
inhibited forskolin-stimulated cAMP with an IC50 value of 15±6.5 µM and
maximum inhibition of 69±8.8%, consistent with SKF-83566 inhibiting
endogenous AC2 activity (Figure 4.6).
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Figure 4.6 SKF-83566 as a chemical probe for native AC2 activity. The effect of
SKF-83566 on forskolin-stimulated (30 µM) cAMP was measured in mouse
C2C12 skeletal muscle cells that were differentiated into myotubes. Data are
mean±S.E.M. of three independent experiments.
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Human bronchial smooth muscle cells express AC2, AC4, and AC6
(Bogard et al., 2012) and recent studies suggest that forskolin-stimulated
interleukin-6 (IL-6) expression in hBSMCs is selectively mediated by AC2
(Bogard and Ostrom, 2013). Therefore, the effect of SKF-83566 on forskolinstimulated IL-6 mRNA expression was measured in hBMSCs using quantitative
RT-PCR (Conley et al., under review). SKF-83566 treatment reduced the
forskolin-stimulated IL-6 mRNA to 38±11% of the vehicle treated cells. These
results indicate that SKF-83566 inhibited the AC2-mediated upregulation of IL-6
mRNA expression in hBSMCs, suggesting that SKF-83566 may be a useful tool
to assess the function of AC2.

4.4

Discussion

Several studies have implicated AC isoforms in physiological functions
and disease states, leading to the hypothesis that ACs are potentially novel
therapeutic targets (Pierre et al., 2009; Sadana and Dessauer, 2009). However,
further research is required to validate AC isoforms as therapeutic targets and
advancements have been limited due to the current paucity of small molecule
modulators that are potent and AC-isoform selective. The need for additional
small molecule tools to assess the in vivo activity of AC isoforms is further
reinforced in the case of AC2, where there is both a lack of selective small
molecule modulators and an absence of published transgenic or knockout mouse
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studies for AC2. Therefore, we developed an HTS-compatible intact-cell small
molecule screening approach and subsequent validation paradigm for the
discovery of AC2 inhibitors.
The present study used the HTRF cAMP detection technology from Cisbio
to develop a robust and scalable HTS assay. The development of an intact-cell
assay for small molecule AC modulators was designed to reduce cellpermeability issues that have plagued the utility of several small molecule AC
modulators (Seifert et al., 2012). However, the intact-cell screening format
presents several challenges that are associated with apparent reductions in the
cAMP signal that are independent of direct AC inhibition, including fluorescence
detection artifacts, cell death/toxicity, and indirect modes of cAMP reduction that
require subsequent validation experiments. The effectiveness of the validation
experiments to identify PKC inhibitors was evident in the case of indatraline, as it
was found to inhibit PMA-stimulated ERK1/2 phosphorylation, but unable to
modulate PKC-independent stimulation of cAMP in HEK-hAC2 cells. The
complementary cAMP studies in wild type and stably transfected HEK293 cells
validated that the compounds selectively inhibit the exogenously expressed AC
isoform. For example, SKF-83566 appeared to have activity for inhibition of
cAMP in HEK-hAC2 and HEK-hAC5 cells, but no activity for the inhibition of
cAMP in the HEK293 cell background. Conversely, the inhibition observed by
tranilast and loratadine was more difficult to interpret because each of these
compounds strongly inhibited the forskolin-stimulated cAMP accumulation in the
HEK293 cell background, in addition to their apparent activity at the
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exogenously-expressed ACs. Therefore, tranilast and loratadine appeared to
have effects on multiple AC isoforms, including endogenous ACs expressed in
HEK293 cells. For example, our in vitro studies suggested direct modulation of
AC2 by tranilast, but indirect modulation of AC1 and AC5. The identification of
SKF-83566 as a selective and direct AC2 inhibitor demonstrated the utility of the
screening approach and the complementary validation experiments. The
success of this initial study combined with additional optimization for increased
assay robustness offers promise for future screening efforts of larger and more
diverse chemical libraries.
The identification of SKF-83566 as a selective AC2 inhibitor represents
another key contribution of the present report. SKF-83566 was originally
reported as an antagonist at D1 dopamine and 5HT2 receptors (Berkowitz et al.,
1984; Ohlstein and Berkowitz, 1985). Nevertheless, the differences in potency
between the receptor antagonism (Berkowitz et al., 1984; Ohlstein and Berkowitz,
1985) and AC2 inhibition by SKF-83566 (i.e., 0.5-30 nM for dopamine/serotonin
receptor antagonism versus ~10 µM for AC2 inhibition), together with our control
validation assays, suggested that we were observing AC2 inhibition in HEKhAC2 cells. Interestingly, a recent study suggests that D1/D5 dopamine
receptors are closely linked to AC by ligand similarity (Lin et al., 2013), perhaps
suggesting that receptor antagonism and AC2 inhibition may have overlapping
chemical requirements. Future studies with SKF-83566 should be focused on
enhancing its pharmacological properties including its specificity for AC and
selectivity for AC2. For example, we used a racemic mixture of SKF-83566,
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therefore, pharmacological studies of the resolved enantiomers is expected to
provide enhanced potency for inhibition of AC2. Additionally, classic structureactivity relationship studies would also be useful to identify chemical moieties and
functional groups that are important for AC2 inhibition and enhance the specificity
and isoform-selectivity for AC2.
Despite the potential drawbacks associated with its receptor antagonism,
SKF-83566 remains an important addition to the repertoire of AC modulators.
For example, SKF-83566 displayed unmatched potency and efficacy for inhibition
of AC2 when directly compared to several commonly used AC inhibitors (i.e.
NKY80, MDL-12,330A, SQ22,536, and 2’5’-dideoxyadenosine). SKF-83566 also
selectively inhibited AC2 (vs other AC isoforms), perhaps offering advantages
over the diterpene analog, BODIPY-forskolin, that non-selectively modulates AC
isoforms with a bidirectional modulation profile (i.e., inhibition of AC2 and partial
activation of AC1 and AC5) (Erdorf et al., 2011; Pinto et al., 2008). The
bidirectional modulation makes it difficult to use BODIPY-forskolin as a chemical
probe in systems where multiple AC isoforms are expressed. In contrast, our
studies with C2C12 mouse skeletal muscle cells and hBSMCs demonstrated the
applicability of SKF-83566 as a tool to assess native AC function in a
physiological context, suggesting the possibility for its use as an in vivo probe.
The identification of additional selective AC2 modulators is expected to
contribute to the understanding of the physiological roles of AC2. There is
currently little direct evidence that suggests AC2 as a therapeutic target, but this
may be due to the limited availability of research tools and strategies for studying
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AC2. Despite these limitations, AC2 has been associated with several diseases,
offering a wealth of opportunities for the use of SKF-83566 as a chemical probe
for AC2 function. For example, a potential role for AC2-mediated signaling in
skeletal muscle physiology is suggested by the abundant expression of AC2 in
adult skeletal muscle (Ludwig and Seuwen, 2002; Suzuki et al., 1998; Torgan
and Kraus, 1996) and that increased cAMP signaling is implicated in several
aspects of muscle physiology including hypertrophy, muscle repair, regeneration,
and functional adaptation (Berdeaux and Stewart, 2012). However, the
contribution of individual AC isoforms is not well-understood in these
physiological processes (Berdeaux and Stewart, 2012), suggesting that SKF83566 can be used as a chemical tool to study the contribution of AC2-mediated
cAMP signaling to muscle physiology and skeletal muscle pathologies including
Duchenne’s muscular dystrophy and muscle atrophy associated with cancer,
ageing, and AIDS.
Recent studies also suggest a role for AC2 in the airway, as AC2
mediates IL-6 expression in hBSMCs (Bogard and Ostrom, 2013). Consistent
with this observation, it observed that SKF-83566 was able to inhibit a forskolinstimulated IL-6 response in hBSMCs (Conley et al., under review). Interestingly,
increased IL-6 expression has been detected in asthma patients (Neveu et al.,
2010) and IL-6 is thought to play an active role in the pathogenesis of lung
diseases such as asthma and chronic obstructive pulmonary disease (Neveu et
al., 2010; Rincon and Irvin, 2012). Taken together, it’s possible that AC2 is
contributing to lung disease pathology by mediating elevated IL-6 in hBSMCs.
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Thus, SKF-83566 can be utilized to determine if AC2 mediates the increased IL-6
levels in lung diseases, and if this event contributes to pathogenesis.
AC2 also appears to be involved in neuroendocrine tumors (NETs), as
ADCY2 expression is upregulated in a “malignant cluster” of pancreatic NETs
(Duerr et al., 2008) and identified as a component of an upregulated
cAMP/protein kinase A/CREB pathway in small intestinal NETs (Drozdov et al.,
2011). Further in vitro expression and pharmacological analysis suggested that
AC2 may be a functional mediator for upregulation of CREB-regulated transcripts
that are associated with proliferation in small intestinal NETs (Drozdov et al.,
2011). It is also noteworthy that ADCY2 expression is inversely correlated with
survival in colorectal cancer patients (Yu et al., 2011). The studies described
above suggest that AC2 has a potential role in the progression of NETs and
colorectal cancer, but it is unclear if the enhanced AC2 expression is pathological,
protective, or merely a marker of these disease states. SKF-83566 could be
used as a chemical probe to test the functional role of AC2 catalytic activity in
these pathophysiological states, and in the case of a causal relationship, suggest
therapeutic utility for targeting AC2.
In conclusion, the present report describes the development and
implementation of an HTS-capable intact-cell screening assay and subsequent
validation strategy to identify small molecule inhibitors of AC2. This initial
screening effort identified SKF-83566 as a selective AC2 inhibitor with superior
pharmacological properties for selective modulation of AC2 when directly
compared to the currently available AC inhibitor
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS

This work addressed various aspects of AC2 modulation within the
framework of three main research aims: 1.) To test the hypothesis that AGS3
expression influences D2LDR-mediated cAMP signaling mediated via AC1 and
AC2. 2.) To test the hypothesis that D2LDR-mediated heterologous sensitization
of AC2 is Gβγ subunit-dependent. 3.) To develop and implement a highthroughput screening paradigm for the discovery of small molecule modulators of
AC2. The conclusions of this work and its implications for future research are
discussed below.
Activator of G protein signaling 3 was first identified in a yeast-based
screen for receptor-independent activation of G protein signaling and in vitro
biochemical studies revealed that AGS3 binds Gαi subunits in the GDP-bound
state and serves as a guanine nucleotide dissociation inhibitor (De Vries et al.,
2000; Takesono et al., 1999). Such biochemical studies suggested the
hypothesis that stabilization of Gαi-GDP by AGS3 prevents the inactivating reassociation/rearrangement of the G protein heterotrimer, thus resulting in
sustained Gβγ subunit signaling. In addition to the biochemical function of AGS3,
several studies have implicated AGS3 as in important mediator of behavioral
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responses associated with drugs of abuse and have demonstrated that AGS3
expression is up-regulated in the nucleus accumbens core or prefrontal cortex
during withdrawal periods following prolonged ethanol or cocaine selfadministration, respectively (Bowers et al., 2008; Bowers et al., 2004). Taken
together, the biochemical and in vivo studies suggest that AGS3 may contribute
to molecular changes associated with drugs of abuse by affecting G proteinmediated AC/cAMP signaling. Consistent with this hypothesis, others have
demonstrated that AGS3 expression results in attenuated α2-adrenergic
receptor-induced heterologous sensitization of AC in CHO cells (Sato et al.,
2004). However, AC isoforms display distinct patterns modulation by G protein
subunits, suggesting that AGS3 may differentially modulate G protein signaling
through AC isoforms. Given the evidence that AGS3, cAMP signaling pathways,
and dopamine systems are each involved in drug addiction (Carlezon et al., 2005;
McClung and Nestler, 2003; Nestler, 2001), we studied the effects of AGS3
expression on D2LDR-mediated signaling mediated by individual AC isoforms in
HEK293 cells.
We examined the ability of AGS3 to modulate recombinant AC1 or AC2
signaling in HEK293 cells following both acute and prolonged activation of the
D2LDR. AGS3 expression modestly enhanced the potency of acute quinpiroleinduced D2LDR modulation of AC1 or AC2 activity. Prolonged quinpirole
activation of the D2LDR was altered by AGS3 in a manner that promoted
desensitization of D2LDR-mediated inhibition of AC1, whereas desensitization of
D2LDR-mediated AC2 activation was significantly attenuated. Additionally, AGS3
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reduced D2LDR-mediated sensitization of AC1 and AC2 in HEK293 cells. These
data suggest that AGS3 is involved in altering G protein-mediated cAMP
signaling in a complex fashion that is both effector-specific and dependent on the
duration of receptor activation.
The effects of AGS3 on D2LDR-mediated sensitization of AC1 and AC2
are consistent with a mechanism where AGS3 disrupts Gβγ subunit signaling
associated with persistent Gi-coupled receptor modulation. Several lines of
evidence converge to suggest that AGS3 influences Gβγ-mediated effector
signaling. For example, our results are consistent with a previous study that
demonstrated the ability of an AGS3 consensus peptide to disrupt signaling
mediated by a different Gβγ subunit effector (G protein inwardly rectifying
potassium channels) following repeated activation of the D2SDR (Webb et al.,
2005). Furthermore, Gβγ subunit sequestering by expression of βARKct
inhibited D2LDR-mediated sensitization of both AC1 (Nguyen and Watts, 2005)
and AC2 (Chapter 3), suggesting that Gβγ subunit signaling is necessary for
D2LDR-mediated sensitization of these isoforms. Interestingly, a recent study
that utilized bioluminescence resonance energy transfer demonstrated that
AGS3 is able to functionally couple with and dissociate from Gi-coupled
receptors in an agonist-dependent manner (Oner et al., 2010). Taken together,
these studies suggest the possibility that AGS3 competes with Gβγ subunits for
binding with Gαi-GDP, thus selectively blocking Gβγ subunit signaling in an
indirect manner via Gαi-AGS3 coupling to receptor. Adding further complexity,
the effects of AGS3 on G protein signaling appear to be dependent on the
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duration of receptor activation because AGS3 alters persistent receptor activation,
but only displays modest or no significant effects for signaling in response to
acute receptor activation.
Our subsequent studies from chapter 3 directly examined the Gβγ subunitdependence of D2LDR-mediated sensitization of AC2 and are therefore relevant
to the observed effects of AGS3. The regulatory properties of AC2 provide a
means to differentiate the contribution of Gα and Gβγ subunits to sensitization.
Specifically, AC2 is conditionally activated by Gβγ subunits and is not directly
regulated by Gαi/o subunits (Tang and Gilman, 1991; Taussig et al., 1993b;
Taussig et al., 1994). These unique regulatory properties of AC2 allowed for the
selective study of Gβγ subunit signaling in sensitization of PKC-stimulated AC2
activity. The observations from chapter 3 suggest that similar to other AC
isoforms, Gβγ subunits are necessary for the sensitization of AC2. Specifically,
the membrane-localized Gβγ subunit sequestering protein βARKct-CD8 and the
cell-permeable peptide inhibitor of Gβγ signaling, QEHA-TAT both attenuated
D2LDR-mediated sensitization of AC2. The Gβγ subunit-dependence of D2LDRmediated sensitization of AC2 is in agreement with our observations from chapter
2, where AGS3 blocked D2LDR-mediated sensitization of AC2, further
contributing to the emerging hypothesis that AGS3 alters Gβγ subunit signaling
following persistent Gi-coupled receptor activation.
Future studies of the molecular effects of AGS3 expression on receptormediated Gβγ subunit expression and translocation/localization may shed light
on the mechanisms underlying the influence of AGS3 on cAMP signaling
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mediated by AC1 and AC2. The localization and translocation of Gβγ subunits
have been studied by fluorescence microscopy upon expression of recombinant
fluorescently-labeled G protein subunits (Digby et al., 2008), suggesting that the
influence of AGS3 on D2LDR-mediated Gβγ subunit localization can be explicitly
studied and in a temporal fashion. The effects of AGS3 on the localization of
specific Gβ and Gγ subunit dimer combinations can be similarly studied by
bimolecular fluorescence complementation (Digby et al., 2006; Digby et al., 2008;
Mervine et al., 2006; Yost et al., 2007). This technology relies on the use of a
fluorescent protein that is split into two non-fluorescent fragments. One of the
fragments can be fused to Gβ and the complementary fragment can be fused to
Gγ, and upon interaction of the tagged Gβ and Gγ subunits, the full fluorescent
protein reconstitutes, providing fluorescence. In summary, our data and the
observations of others suggest that AGS3 may alter Gβγ subunit signaling in
response to persistent Gi-coupled receptor activation. Future studies that utilize
fluorescently labeled Gβγ subunits may facilitate the direct examination of the
effects of AGS3 on the temporal and spatial localization of Gβγ subunits, perhaps
providing insight into the mechanistic details of their effects on AC isoform
signaling.
It is clear that Gβγ subunit signaling is necessary for D2LDR-mediated
sensitization of AC2 in HEK293 cells. Gβγ subunits directly interact with AC2 in
several areas and modulate its catalytic activity in a conditional fashion (Boran et
al., 2011; Diel et al., 2008; Diel et al., 2006; Tang and Gilman, 1991; Taussig et
al., 1993b; Taussig et al., 1994; Weitmann et al., 2001). However, Gβγ subunits
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also directly modulate several downstream effectors including PLCβ2, KIR3.1
potassium channels, and voltage-gated Ca2+ channels (Khan et al., 2013;
Smrcka, 2008), suggesting that development of sensitization may occur by either
direct Gβγ modulation of AC2 or via an indirect Gβγ signaling pathway. Though
the pharmacological investigation of downstream Gβγ subunit effectors in
chapter 3 did not identify effectors involved in sensitization, several observations
support the hypothesis that the development of D2LDR-mediated sensitization of
AC2 occurs through indirect Gβγ signaling pathways, rather than Gβγ directly
modulating AC2. Specifically, D2LDR-mediated sensitization of AC1 is Gβγ
subunit-dependent (Nguyen and Watts, 2005), but is inhibited by Gβγ subunits
(Taussig et al., 1993b; Taussig et al., 1994). Furthermore, several intermediate
signaling components have been implicated in the development of AC
sensitization (Johnston et al., 2002; Varga et al., 2002; Varga et al., 2003; Watts
and Neve, 2005). We also observed a complete loss of subsequent D2LDRmediated potentiation of PKC activation of AC2 following long-term D2LDR
activation (Chapter 2). Though D2LDR activation acutely stimulates AC2
conditionally via Gβγ subunits, this observation suggests a loss of Gβγ subunit
activation of AC2 following long term D2LDR stimulation. Nonetheless, the
hypothesis that AC2 sensitization is facilitated by direct Gβγ subunit binding to
AC2 can be directly tested. Similar to the Gβγ localization studies proposed
above, fluorescently labeled Gβγ subunits can be monitored by fluorescence
microscopy following prolonged D2LDR activation. Furthermore, Rluc-tagged
AC2 has been utilized in BRET studies to examine the direct interaction of
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fluorescently-tagged proteins with Rluc-AC2 (Baragli et al., 2008; Dupre et al.,
2007; Petrin et al., 2011; Rebois et al., 2012). These available research tools
suggest that BRET studies of fluorescently-tagged Gβγ subunits and Rluc-AC2
following prolonged D2LDR activation can be used to test the hypothesis that
D2LDR-mediated sensitization of AC2 occurs by direct modulation of AC2 by Gβγ
subunits.
The observations in chapter 3 provided evidence for Gβγ subunits as
mediators of AC2 sensitization, but a comprehensive mechanism remains
unsolved. However, several possible mechanisms can be proposed for the
development of the enhanced PKC-mediated stimulation of AC2 following longterm D2LDR activation. Previous studies suggest that AC2 shows an activatorselective pattern of heterologous sensitization (Cumbay and Watts, 2001).
Specifically, persistent D2LDR activation enhances AC2 cAMP responses to
phorbol ester activation of PKC, but not in response to forskolin or the Gscoupled β-adrenergic receptor agonist, isoproterenol (Cumbay and Watts, 2001).
These data clearly implicate PKC in AC2 sensitization. It is possible that longterm D2LDR activation results in enhanced PKC expression in HEK293 cells,
leading to enhanced responses to phorbol ester-mediated AC2 activation. PKC
expression profiling by western blotting for PKC isoforms in HEK293 cells can be
performed following prolonged quinpirole treatment and compared to the
expression levels of a vehicle treatment. PKCα (Zimmermann and Taussig, 1996)
and PKCδ (Nguyen and Watts, 2006) are implicated in the acute activation of
AC2, but a comprehensive assessment of the effects of PKC isoforms on AC2
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remains to be reported. A combination of approaches that include siRNA, PKC
isoform overexpression, and isoform-selective PKC peptide inhibitors can be
used to determine the specific PKC isoforms that are involved in both acute and
subsequent activation of AC2 following persistent D2LDR activation. It is also
possible that long-term D2LDR activation altered the levels of PKC that are in
close proximity to AC2. The latter possibility could be mediated by two anchoring
proteins (i.e., RACK1 and AKAP79) that are endogenously expressed in HEK293
cells (Bauman et al., 2006; Liu et al., 2007). For example, the PKC anchoring
protein RACK1 functions to target PKC to its substrates (Schechtman and
Mochly-Rosen, 2001). Furthermore, RACK1 is known to directly bind Gβγ
subunits and influence Gβγ-mediated signaling (Chen et al., 2008; Chen et al.,
2005; Chen et al., 2004). Alternatively, AKAP79 directly interacts with AC2
(Efendiev et al., 2010) and is also known to scaffold PKA and PKC (Welch et al.,
2010), but Gβγ subunit-modulation of this protein has not been reported (based
on my knowledge). Future research should be focused on the potential role of
these proteins in the development of D2LDR-mediated sensitization of AC2.
Molecular studies of heterologous sensitization have largely focused on
the roles G proteins (e.g., Gαi/o, Gβγ, and Gαs subunits), proteins that modulate
G protein signaling (e.g., RGS and AGS proteins), and protein kinases that are
well-known to be downstream of G proteins. The precise mechanisms of AC
sensitization are not well understood, even after nearly four decades of research.
We propose that unbiased approaches can be utilized to identify novel
components of the signaling pathways that are involved in the mechanisms of AC
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sensitization. Such unbiased approaches include siRNA library screening or
small molecule screening of known pharmacological modulators (e.g., kinase
inhibitor collections). The cell-based cAMP detection methodology that our
laboratory has utilized to study sensitization, however, was generally unsuitable
for siRNA library or small molecule screening endeavors. Therefore, steps were
taken to reduce the number of wash and decant steps, miniaturize the cAMP
quantification assay, and identify an assay workflow that is amenable to
automation to facilitate the development an assay format that is amenable to the
unbiased strategies for the study of sensitization (Conley et al., in press). As part
of the initial validation of the high-throughput screening capable cAMP assay and
workflow, the implementation of this technology to screen for small molecule
inhibitors of AC2 was reported in chapter 4. The cell-based high-throughput
screening paradigm that we developed can likely be readily adjusted to measure
small molecule modulation of heterologous sensitization. Furthermore, the assay
format has since been modified to accommodate screening of an siRNA library
against the kinome for inhibition of Gi-coupled receptor-mediated sensitization of
AC isoforms (Conley et al., in press). It is expected that these unbiased
approaches will provide new mechanistic information regarding the adaptive
heterologous sensitization response.
The development of an HTS-capable cell-based assay to measure the
modulation of AC activity was initially designed to address assay format
requirements for the unbiased approaches to study heterologous sensitization as
described above. However, as a strategic intermediate step to the development
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of an assay format for an siRNA library screen for the modulation of heterologous
sensitization of AC, we first developed and implemented a screening assay for
small molecule modulators of acute AC activity. This strategy allowed for the
initial development of a relatively simpler assay, while providing the opportunity
to assess the robustness of the cAMP detection technology and the miniaturized
assay platform for its HTS-amenable attributes. Furthermore, the lack of potent
and selective small molecule AC modulators presented an opportunity to address
a well-known research need in the AC field, while providing proof-of-concept for
the HTS-amenable cAMP assay. Specifically, AC isoforms are implicated in
several physiological processes and disease states (Pierre et al., 2009; Sadana
and Dessauer, 2009), but advancements in the therapeutic targeting of AC
isoforms have been limited by the lack of potent and isoform-selective small
molecule modulators (Pavan et al., 2009; Pierre et al., 2009; Seifert et al., 2012).
The discovery of AC isoform-selective small molecules is expected to facilitate
the validation of AC isoforms as therapeutic targets and augment the study of AC
isoform function in vivo. Identification of chemical probes for AC2 is particularly
important because there are no published genetic deletion studies and few small
molecule modulators. Chapter 4 demonstrates the development and
implementation of an intact-cell small molecule screening approach and
subsequent validation paradigm for the discovery of AC2 inhibitors. The NIH
clinical collections I and II were screened for inhibitors of AC2 activity, using
PMA-stimulated cAMP accumulation as a functional readout. Active compounds
were subsequently confirmed and validated as direct AC2 inhibitors using
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orthogonal and counter screening assays. The screening effort identified SKF83566 as a selective AC2 inhibitor with superior pharmacological properties for
selective modulation of AC2 when compared to currently available AC inhibitors.
Furthermore, the utility of SKF-83566 as a small molecule probe to study the
function of endogenous ACs was demonstrated in C2C12 mouse skeletal muscle
cells.
Future studies should be aimed at understanding the molecular basis of
AC2 inhibition by SKF-83566. A combination of biochemical, molecular modeling,
and mutagenesis studies have typically been employed to understand the
mechanisms of small molecule modulation of AC. Biochemical studies of
enzyme kinetics using cell membranes that overexpress AC2 suggest that SKF83566 is noncompetitive with respect to ATP (Conley et al., under review), but its
relationship to other activators, such as forskolin, or Gαs (Dessauer, 2002;
Dessauer and Gilman, 1997; Dessauer et al., 1999; Iwatsubo et al., 2004; Onda
et al., 2001) can also be studied. There is also a precedent for molecular
modeling based on the crystal structures of the catalytic C1 and C2 domains
(Pinto et al., 2008; Tesmer et al., 1997; Zhang et al., 1997). Similar molecular
modeling analyses are underway for SKF-83566 docking to AC to predict the
specific site of interaction. Subsequent to molecular modeling studies, mutation
of residues that are predicted to be crucial for binding can be performed to
experimentally validate the model. The complementary approaches described
above may provide useful insight into the mechanism of AC2 modulation by SKF83566.
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SKF-83566 is an important new chemical probe for AC2, but it also
displays antagonist activity against D1 dopamine and 5HT2 serotonin receptors
(Berkowitz et al., 1984; Ohlstein and Berkowitz, 1985). Future efforts should be
focused toward strategies to enhance the pharmacological properties of SKF83566 to increase the specificity for AC and enhance the potency and selectivity
for inhibition of AC2. First, our study utilized SKF-83566 as a racemic mixture,
warranting additional pharmacological studies to determine which enantiomer is
more active for inhibition of AC2. Interestingly, a recent study suggests that
D1/D5 dopamine receptors are closely linked to AC by ligand similarity (Lin et al.,
2013), perhaps suggesting that receptor antagonism and AC2 inhibition will
share the same active enantiomer (i.e, (+)-SKF-83566) (Berkowitz et al., 1984;
Ohlstein and Berkowitz, 1985). Furthermore, (+)-SCH-23390 (a structural
analogue of SKF-83566) significantly inhibited PMA-stimulated AC2 activity in
HEK-hAC2 cells, suggesting that (+)-SKF-83566 is the active enantiomer for
inhibition of AC2 (Table A.2 and Figure A.1). The enantiomer studies are
expected to at least provide enhanced potency for inhibition of AC2. Additionally,
classic structure-activity relationship studies would also be useful to identify
chemical moieties and functional groups that are important for AC2 inhibition and
enhance the specificity and isoform-selectivity for AC2. A modest structureactivity study is reported in Table A.2 and Figure A.1 of the appendix.
Our results from chapter 4 demonstrate the utility of the screening
approach and suggest that the series of complementary post-screening
experiments are able to validate direct and selective AC2 inhibitors. Importantly,
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the success of the initial pilot screen of a 727 compound collection (NIH clinical
collections I and II) suggests that the screening and validation paradigm is
sufficiently robust to accommodate future screening of larger and more diverse
chemical libraries to identify additional novel small molecule AC2 inhibitors.
Consistent with this prediction, a screen of the Spectrum Collection (2,320
compounds) for inhibitors of AC2 activity has been performed and the results and
initial confirmation of activity is reported in the appendix (Table A.3 and Table
A.4). Furthermore, the assay format that was developed to study cAMP levels in
HEK-hAC2 cells is expected to be readily adapted for other AC isoforms,
including AC1 and AC5. Specifically, parameters such as pharmacological
stimulation conditions and cell number should be optimized for each specific
target, but the overall semi-automated workflow and cAMP detection technology
is expected to support these studies without modification. Identification of new
small molecule modulators of AC1 and AC5 are expected to contribute to our
understanding of these isoforms in physiological processes including pain
perception, learning and memory, and cardiac function.
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A high-throughput screening approach for the discovery of small molecule
inhibitors of AC2 was described in chapter 4. Specifically, the NIH clinical
collections I and II were screened for the ability of compounds (25 μM) to inhibit
50 nM PMA-stimulated AC2 activity in HEK-hAC2 cells. The complete screening
results are reported in Table A.1.
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Table A.1 Screening of NIH Clinical Collections I and II for inhibition of AC2
activity. The NIH Clinical Collections I and II (25 µM) were screened for inhibition
of PMA-stimulated (50 nM) cAMP accumulation in HEK-hAC2 cells using the
Cisbio HTRF cAMP dynamic 2 detection methodology. The data represent the
average percent inhibition of the PMA-stimulated cAMP response from duplicate
plates.
Compound Name
(-)-Cotinine
(+)-3-HYDROXY-N-METHYLMORPHINAN D-TARTRATE
(+)-CIS-DILTIAZEM HYDROCHLORIDE
(+/-)-Epinephrine hydrochloride
(+/-)-NOREPINEPHRINE HYDROCHLORIDE
(Â±)-Vesamicol hydrochloride
1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol
1,1-DIMETHYL-4-PHENYLPIPERAZINIUM IODIDE
1,3,5(10)-ESTRATRIEN-3-OL-17-ONE SULPHATE, SODIUM SALT
10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl- [CAS]
17-BETA-ESTRADIOL 17-VALERATE
19-Norethindrone
19-NORETHINDRONE ACETATE
1-BENZYLIMIDAZOLE
1H-Cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro-,
monohydrochloride- [CAS]
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS]
1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)[CAS]
1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]
2(1H)-Pyrimidinone, 4-amino-1-ÃƒÂ¿-D-arabinofuranosyl- [CAS]
2-(2-AMINOETHYL)PYRIDINE
2',3'-DIDEOXYCYTIDINE
2',3'-DIDEOXYINOSINE
2-CHLORO-2'-DEOXYADENOSINE
2-CHLOROADENOSINE
2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)- [CAS]
3(2H)-Pyridazinone, 6-[4-(difluoromethoxy)-3-methoxyphenyl]- [CAS]
3,5,3'-TRIIODOTHYRONINE
3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
3'-deoxydenosine
3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE
3-Hydroxy-2-methyl-4-pyrone
3-PYRIDINEMETHANOL
4-(AMINOMETHYL)BENZENESULFONAMIDE ACETATE
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide

% Inhibition
-14.29
23.30
-60.31
-123.98
-71.99
-5.49
-41.71
-12.35
-34.06
35.21
-427.70
-79.01
-162.15
23.73
-1.71
-14.30
-43.54
-866.27
11.06
2.82
-16.86
-21.84
-129.30
-213.14
-95.83
-210.56
-11.34
-147.33
-10.67
-0.82
-61.63
36.49
-57.21
-20.07
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Table A.1 Continued.
4-Thiazolidinecarboxylic acid, 2-oxo-, (R)- [CAS]
5-Amino-2-hydroxy-benzoic acid
5-Azacytidine
5-fluoro-2-pyrimidone
5-FLUOROCYTOSINE
5-FLUOROURACIL
5-Methoxytryptamine
5-Nonyloxytryptamine
6-[2-ETHOXY-1-NAPHTHAMIDO]-PENICILLIN SODIUM SALT
6ALPHA-METHYL-11BETA-HYDROXYPROGESTERONE
6-AMINOINDAZOLE
6-AZAURIDINE
6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[[2-[(diethylamino)methyl]1-piperidinyl]acetyl]-5,11-dihydro- [CAS]
7-NITROINDAZOLE
8-Azaspiro[4.5]decane-7,9-dione, 8-[2-[[(2,3-dihydro-1,4-benzodioxin-2yl)methyl]amino]ethyl]-, monomethanesulfonate [CAS]
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine
9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE
ACARBOSE
ACEBUTOLOL HYDROCHLORIDE
Acetamide, 2-amino-N-(1-methyl-1,2-diphenylethyl)-, (+/-)- [CAS]
Acetazolamide
Acitretin
ACTARIT
Acyclovir
Adenine 9-beta;-D-arabinofuranoside
Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)- [CAS]
Albalon
Albendazole
ALFUZOSIN
Allegra
Allopurinol
ALOSETRON HCl
Alprazolam
Altanserin
Altretamine
AM 404
AM-251
AMCINONIDE
AMFEBUTAMONE HCl
Aminoglutethimide
Aminolevulinic Acid

-28.68
11.79
-26.30
-1.08
13.73
-4.98
-35.57
-39.73
-65.07
-102.01
-10.70
-3.55
6.14
-49.80
-28.35
13.56
11.92
-10.38
-25.27
-36.70
-48.41
-23.36
-7.99
-30.21
-9.90
-36.70
-71.39
-62.52
-1.64
-10.48
-43.46
-42.93
-46.53
-611.22
-12.49
-283.12
5.15
-1.11
-12.60
-38.97
-80.40
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AMIODARONE HYDROCHLORIDE
Amisulpride
AMLEXANOX
AMLODIPINE BASE
AMOXAPINE
AMOXICILLIN CRYSTALLINE
Ampicillin Sodium
AMPIROXICAM
Anafranil
ANAGRELIDE HCl
ANASTROZOLE
Annoyltin
ARGATROBAN
ARIPIPRAZOLE
Artane
ARTEMETHER
ARTESUNATE
ATENOLOL
ATOMOXETINE HCl
ATRACURIUM BESYLATE
ATROPINE
Azasetron
Azathioprine
AZELASTINE HCl
Azithromycin
BALSALAZIDE
Beclomethasone
Beclomethasone dipropionate
BENACTYZINE HYDROCHLORIDE
BENAZEPRIL HCl
Bendrofluazide
BENIDIPINE HCl
BENPROPERINE PHOSPHATE
Bentyl
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt
[CAS]
Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9azatricyclo[3.3.1.02,4]non-7-yl ester, [7(S)(1Alpha,2ÃƒÂ¿,4ÃƒÂ¿,5Alpha,7ÃƒÂ¿)]- [CAS]
Benzeneacetonitrile, Alpha-[3-[[2-(3,4dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1methylethyl)-, (R)- [CAS]
Benzenebutanoic Acid

-370.47
-19.13
41.47
24.13
-16.78
-60.10
-64.53
-39.71
-68.51
-115.28
-9.63
-15.14
-1.41
-54.30
1.60
-53.69
-12.63
14.86
1.54
-64.73
-60.91
-2.06
-29.00
1.65
-44.56
-16.93
-66.70
-20.74
-48.45
-4.13
-24.41
-194.19
-8.36
-89.31
-2.76
-14.01

-19.11
-5.73
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Benzo[a]phenanthridine-10,11-diol, 5,6,6a,7,8,12b-hexahydro-, trans[CAS]
BESTATIN
BETA-ESTRADIOL
Betamethasone
Betaxolol hydrochloride
BICALUTAMIDE
Bifemelane
BIFONAZOLE
BISOPROLOL FUMARATE
Brimonidine
Brucine
BUDESONIDE
Buflomedil HCl
BUMETANIDE
BUPROPION HYDROCHLORIDE
Buspar
Busulfan
CALCIPOTRIOL
CALCITRIOL
Cantil
Capsaicin
CAPTOPRIL
Carbamazepine
CARBIDOPA
Carbinoxamine Maleate
Cardene
Carisoprodol
CARMOFUR
Carvedilol
CCPA
CEFACLOR
CEFATRIZINE PROPYLENE GLYCOL
CEFAZOLIN SODIUM SALT
CEFDINIR
CEFIXIME TRIHYDRATE
CEFOTAXIME SODIUM SALT
CEFOXITIN SODIUM SALT
CEFPODOXIME PROXETIL
Cefuroxime
Celecoxib
Cephalexin monohydrate
CERIVASTATIN Na
Cetirizine

-0.81
-23.10
-61.63
-16.61
9.57
-55.60
-15.19
-269.21
-25.29
-86.58
9.29
-26.53
-6.25
-1.04
-14.45
-25.47
-12.09
-78.88
-79.52
4.85
-58.39
-35.91
-47.13
-14.95
-52.66
-391.56
-16.15
-5.31
-85.91
-32.69
-6.56
-28.72
-44.82
10.10
-6.49
-28.23
-58.42
-42.62
9.32
16.11
-47.87
-49.49
-59.23
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CETRAXATE HCl
CGS 12066B
CGS 15943
CHLORAMBUCIL
Chloramphenicol
CHLORDIAZEPOXIDE
Chlorothiazide
Chloroxine
Chlorpheniramine
Chlorpropamide
Chlorthalidone
Chlorzoxazone
CILASTATIN Na
Cimetidine
Cinanserin
Cisapride
Citalopram
citalopram hydrobromide
CLARITHROMYCIN
Clobenpropit
CLOBETASOL PROPIONATE
CLOFAZIMINE
Clomid
clopidogrel
CLOTRIMAZOLE
Clozapine
Cogentin Mesylate
Cortell
CORTICOSTERONE
CORTISONE
CORTISONE ACETATE
Cromolyn Sodium
CYPROHEPTADINE
Cytoxan
d-3-Methoxy-N-methylmorphinan hydrobromide
DACTINOMYCIN
DANAZOL
Dantrolene sodium salt
Dapsone
DAUNORUBICIN HYDROCHLORIDE
D-CYCLOSERINE
D-CYCLOSERINE
DEHYDROCHOLIC ACID
DEHYDROEPIANDROSTERONE

-19.18
-235.66
-118.86
-54.68
-31.91
-109.83
8.06
-302.28
-4.76
-74.63
-2.90
-31.15
11.23
-17.64
-28.54
-45.26
-86.53
-51.02
0.08
-37.96
-82.01
-76.90
-266.53
-69.38
-136.54
-22.10
-36.32
-62.85
-74.11
-78.06
-39.61
0.10
-26.41
-21.75
-21.95
-28.81
-351.79
-16.00
-5.46
-18.55
-10.81
-42.47
21.82
-50.60
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DELTA1-HYDROCORTISONE 21-HEMISUCCINATE SODIUM SALT
Demeclocycline
DEPO-MEDROL
DEPRENALIN
DEPRENALIN
DESOXIMETASONE
Dexamethasone
DEXBROMPHENIRAMINE MALEATE
DEXCHLORPHENIRAMINE MALEATE
Diazepam
DIAZOXIDE
Dibenzyline
DICHLOROACETIC ACID
DICLOXACILLIN SODIUM
Diflunisal
DIGOXIN
Dilantin
Diphenhydramine hydrochloride
DIPHENOXYLATE
diphenylcyclopropenone
DIPYRIDAMOLE
Disipal
DL-PENICILLAMINE
DOCETAXEL
DOFETILIDE
DOLASETRON MESYLATE
Donepezil
DOXAPRAM HYDROCHLORIDE
Doxazosin
Doxepin
DOXEPIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE
Doxylamine succinate salt
DROPERIDOL
Duloxetine
DULOXETINE HCl
Duremesin
Duvadilan
EBSELEN
Econazole Nitrate
EDROPHONIUM CHLORIDE
EFAVIRENZ
ENALAPRIL MALEATE

-5.61
-45.09
-48.24
-45.50
-74.72
-16.70
-13.53
-27.93
27.54
-43.54
-9.39
-459.58
-55.71
-52.25
-144.95
35.26
-12.65
4.15
-65.13
-424.00
15.69
0.76
-50.23
-34.98
-13.63
-29.16
-26.59
-14.91
-92.28
-51.07
-26.94
33.53
37.36
-27.08
-39.13
16.04
50.54
-458.71
-18.67
-166.51
-301.82
46.54
-44.75
-2.74

194
Table A.1 Continued.
ENALAPRILAT
ENROFLOXACIN
Epigallocatechin gallate
EPIRUBICIN HYDROCHLORIDE
Eryped
ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE Mg
Eszopiclone
ETHACRYNIC ACID
Ethambutol
Ethionamide
Ethylestrenol
ETHYNYLESTRADIOL
Etodolac
Etomidate
etoposide
Evista
EXEMESTANE
EZETIMIBE
FAMCICLOVIR
FAMOTIDINE
Felbamate
Felodipine
FENOFIBRATE
FENOLDOPAM MESYLATE
FENPIVERINIUM BROMIDE
FINASTERIDE
Flecainide Acetate
Floxuridine
FLUBENDAZOLE
Fluconazole
FLUDARABINE
Flumadine
FLUMAZENIL
FluniSOLIDe
FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE 21-ACETATE
Fluorometholone
Fluperlapine
Fluphenazine Dihydrochloride
Flurbiprofen
Flurbiprofen
FLUTAMIDE

22.39
-26.16
-13.06
18.31
4.37
-33.09
-9.35
-70.39
-48.05
-34.64
-56.84
-55.49
-81.07
-91.02
-46.54
9.69
-16.54
-100.36
-115.77
-46.48
-28.61
-5.01
-41.46
-95.05
-228.94
-22.47
5.18
-22.29
-17.60
-13.78
-53.87
-39.05
22.76
-12.51
-29.89
-198.75
12.99
-35.57
-76.25
-9.92
14.21
-44.40
-78.82
-56.61
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FLUTICASONE PROPIONATE
fluvastatin
Fluvoxamine
Folic acid
FORMOTEROL FUMARATE DIHYDRATE
FTORAFUR
FUROSEMIDE
Gabexate mesylate
Galanthamine
Ganciclovir
Gatifloxacin
GEMFIBROZIL
GLIMEPIRIDE
GLIPIZIDE
Glyburide
Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-,phenylmethyl
ester [CAS]
Glycopyrrolate
Glycopyrrolate
GOSERELIN ACETATE
GR 89696
GRANISETRON HCl
Griseofulvin
Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl- [CAS]
HALOMETASONE MONOHYDRATE
Haloperidol
Hexachlorophene
HOMOHARRINGTONINE
Homoveratrylamine
HONOKIOL
HTMT
HUPERZINE A
Hydrochlorothiazide
HYDROCORTISONE
HYDROCORTISONE HEMISUCCINATE
HYDROFLUMETHIAZIDE
HYPEROSIDE
IBUPROFEN
ICARIIN
IDARUBICIN HCl
IDEBENONE
Ifenprodil
IMATINIB MESYLATE
Imodium

29.83
-44.95
16.65
-22.44
-88.12
-27.87
-11.34
-91.14
-41.37
-41.16
-0.22
-44.81
-40.10
11.22
-5.62
-7.71
8.42
-29.69
2.29
17.49
-16.86
-83.55
9.58
-6.37
15.22
-257.07
-37.36
-36.42
-137.50
0.82
17.45
-54.49
-39.84
-65.75
10.38
-68.78
-35.67
-43.84
-58.20
-328.07
16.10
-123.01
-8.23
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INDAPAMIDE
Indatraline
Inderal
INDINAVIR SULPHATE
Indirubin
Indomethacin
Intropin
IPRATROPIUM BROMIDE MONOHYDRATE
IPRIFLAVONE
IRBESARTAN
IRINOTECAN HCl )trihydrate)
IRSOGLADINE MALEATE
Isoniazid
Isoquercitrin
Isotretinoin
ISRADIPINE
Isuprel
ITAVASTATIN Ca
ITOPRIDE HCl
ITRACONAZOLE
Kemadrin
ketoconazole
KETOPROFEN
Ketorolac tromethamine
KETOTIFEN FUMARATE
KITASAMYCIN
L-694,247
LABETALOL HYDROCHLORIDE
LACIDIPINE
LAMIVUDINE
LAMIVUDINE
LAMOTRIGINE
LANSOPRAZOLE
LATANOPROST
LETROZOLE
LEVETIRACETAM
LEVOCETIRIZINE
LEVOFLOXACIN
LEVONORGESTREL
LEVOSULPIRIDE
L-Glutamic acid, N-[4-[[(2,4-diamino-6pteridinyl)methyl]methylamino]benzoyl]- [CAS]
LIDOCAINE
Lincomycin hydrochloride

-57.29
38.92
-14.01
1.17
26.64
-26.12
41.82
-53.51
-31.76
-25.62
-32.70
-30.34
-6.49
-17.85
-150.35
-99.96
-99.87
-53.39
-35.59
-90.04
-56.49
-170.07
-81.27
-73.56
-15.38
-38.50
-3.82
-19.73
-881.61
-11.89
-29.52
-12.56
-228.54
-364.86
-57.57
-17.12
-17.88
23.25
-46.15
-37.31
10.82
-21.96
-66.35
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LINEZOLID
LOBELINE HYDROCHLORIDE
LOFEPRAMINE
LOFEXIDINE HCl
LOMERIZINE DiHCl
LOMIFYLLINE
LORATADINE
Lorazepam
L-Ornithine, N5-[imino(methylamino)methyl]-[CAS]
LOSARTAN Potassium
LOTEPREDNOL ETABONATE
Lovastatin
Loxapine succinate
LOXOPROFEN SODIUM
L-THYROXINE
LY 171883
Maprotilline HCl
Maxolon
Mebendazole
MECILLINAM
Meclomen
MEDROXYPROGESTERONE
Medroxyprogesterone 17-acetate
Mefenamic Acid
Mefloquine hydrochloride
MEGESTROL ACETATE
Meloxicam
MEMANTINE HYDROCHLORIDE
Memantine hydrochloride
MEPIRIZOLE
MEPIVACAINE HYDROCHLORIDE
Mercaptopurine
MEROPENEM
Mesna
Mesoridazine
Mestanolone
Mestinon
MESTRANOL
Metaproterenol
Methanesulfonamide, N-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4piperidinyl]carbonyl]phenyl]-, dihydrochloride [CAS]
Methazolamide
Methimazole
Methocarbamol

-10.12
-13.53
-179.59
0.30
-512.44
-0.91
64.39
-221.43
15.83
-9.59
-6.30
-153.47
-21.33
1.74
-9.99
13.22
33.13
-47.34
-62.43
-28.98
-129.92
-58.63
-58.25
-141.11
31.17
-52.62
-22.67
3.22
-62.34
-33.25
-32.43
-6.31
6.18
-42.14
27.11
-49.42
15.65
-65.51
-178.71
-61.27
-55.00
-56.87
-78.32
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Methoxsalen
METHYLANDROSTENEDIOL
Methyldopa
METHYLPREDNISOLONE
Methyltestosterone
METRONIDAZOLE
Metylperon
METYRAPONE
mevastatin
Mexitil
MICONAZOLE NITRATE
Micropenin
MIDAZOLAM HCl
MIFEPRISTONE
MIGLITOL
Milnacipran
MILRINONE
MINOCYCLINE HYDROCHLORIDE
Minoxidil
Miochol
MIRTAZAPINE
mirtazapine
MITOXANTRONE
Moban
Modafinil
MONTELUKAST Na
MOSAPRIDE CITRATE
MOXIFLOXACIN HCl
MOXONIDINE HCl
Mupirocin
N,N'-DIACETYL-1,6-DIAMINOHEXANE
NABUMETONE
NADOLOL
Nafadotride
NAFTOPIDIL
Nalbuphine
Nalidixic Acid
NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE
Naltrindole
nandrolone
NAPROXEN SODIUM
NATEGLINIDE
Nefazodone

-250.02
-25.46
-49.37
-5.71
-49.64
15.03
-41.07
-43.67
-44.00
-26.24
-1049.78
1.62
-23.02
-47.38
-31.50
1.31
-2.02
-48.09
-42.84
-19.44
-63.94
-21.76
85.56
-6.90
-28.40
-35.55
-35.42
22.06
-2.44
-79.38
-19.56
-16.27
-6.63
8.12
-115.20
-38.64
-16.93
-48.66
-7.68
-16.75
-1195.60
-101.28
-2.38
-131.94
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NELFINAVIR MESYLATE
N-Ethyl-o-crotonotoluidide
NIALAMIDE
NICORANDIL
NICOTINAMIDE
NICOTINE
Nicotinic Acid
NIFEDIPINE
NIFEKALANT HCl
Nimetazepam
NIMODIPINE
NISOLDIPINE
NITAZOXANIDE
Nitrazepam
NITRENDIPINE
NITROFURANTOIN
NIZATIDINE
Nobiletin
Norflex
NORFLOXACIN
Nornicotine
Norpace
Norpramin
Novocain
OFLOXACIN
OLANZAPINE
OLIGOMYCIN C
OLMESARTAN MEDOXOMIL
OLOPATADINE HCl
OMEPRAZOLE
Ondansetron
ONDANSETRON HYDROCHLORIDE
ORLISTAT
ORMETOPRIM
ORNIDAZOLE
OXAPROZIN
OXICONAZOLE NITRATE
Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS]
OXYBUTYNIN CHLORIDE
Oxymetholone
OXYPHENONIUM BROMIDE
Oxytetracycline hydrochloride
ozagrel, monohydrochloride
PALONOSETRON HCl

-28.63
-39.81
-63.84
-14.00
-20.26
2.90
-68.84
-241.22
-26.49
-18.85
-150.38
-67.12
-38.92
-43.67
-129.66
-0.81
-9.63
-217.65
-41.19
-30.60
-5.64
-58.43
-14.30
-10.70
37.67
-39.83
-25.65
17.80
-4.64
-74.37
-44.81
-1.88
-26.07
-3.87
-20.09
-1.88
-471.14
-119.90
7.90
37.00
-0.88
-32.15
-12.71
-50.02
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Pamelor
Pancuronium
PANTOPRAZOLE SODIUM SALT
PARECOXIB Na
Paroxetine
PAROXETINE
Paroxetine
PAZUFLOXACIN
PD 81723
PEFLOXACIN MESYLATE
Pemoline
PENCICLOVIR
Penicillin V
Pentoxifylline
PERGOLIDE MESYLATE
PEROSPIRONE HCl
PERPHENAZINE
Pfizerpen
Phenelzine
PHENELZINE SULFATE SALT
Phenergan
PHENOTHIAZINE
PHENPROBAMATE
PHENTOLAMINE HCL
Phylloquinone
Physostigmine
PICEID
Picrotin - Picrotoxinin
PIDOTIMOD
PILOCARPINE HYDROCHLORIDE
Pinacidil monohydrate
PINDOLOL
PIOGLITAZONE HCl
PIPERACILLIN SODIUM SALT
PIRENPERONE
Piribedil
Piroxicam
Pizotyline
Podofilox
Pramipexole
PRAMIPEXOLE HCl
PRAVASTATIN Sodium
PRAZIQUANTEL

10.67
-2.82
4.43
-41.08
28.75
13.20
29.11
-17.74
-101.66
2.49
-26.94
-9.46
-29.64
-6.30
-34.66
-221.05
4.55
-52.38
0.69
-10.83
-60.34
-185.13
-32.26
-25.56
16.86
-34.58
-48.05
-7.74
-25.49
-24.04
-37.17
6.77
-37.91
-32.15
-39.75
-17.22
5.08
-41.77
-74.63
-17.68
-10.50
-20.49
-32.70
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Prazosin
Prednisolone
PREDNISOLONE ACETATE
Prednisone
PRILOCAINE HYDROCHLORIDE
Primaquine Diphosphate
Primidone
Priscoline
Pro-Amatine
Pro-Banthine
Probenecid
PROCARBAZINE HYDROCHLORIDE
PROGESTERONE
Pronestyl
Propofol
Propylthiouracil
Prostaglandin E1
Proxymetacaine
Prozac
PTEROSTILBENE
Pyrazinamide
Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro[CAS]
PYRIDINE-2-ALDOXIME METHOCHLORIDE
Pyrimethamine
QUETIAPINE HEMIFUMARATE
Quinapril hydrochloride
Quinidine hydrochloride monohydrate
R(+)-SCH-23390 hydrochloride
RABEPRAZOLE
Raclopride
RALTITREXED
RAMIPRIL
RAMIPRIL
Ranitidine hydrochloride
Ranolazine dihydrochloride
Reichsteins substanceÂ S
REPAGLINIDE
Resveratrol
Retinoic acid
Ribavirin
RIFABUTIN
Rifabutin
RIFAMPICIN

-74.72
-71.01
-58.18
-59.54
-56.61
-47.21
-17.33
15.88
-45.72
-35.85
-25.57
-10.24
-135.52
-33.25
-96.14
1.80
-281.47
-66.72
-0.35
-111.36
-28.09
-19.57
16.69
4.91
-55.53
-59.85
-43.57
-71.68
-225.07
-38.11
6.53
-24.47
-27.13
-7.39
-15.06
-24.58
24.07
-80.06
-39.84
-43.19
-77.60
-93.76
-13.15

202
Table A.1 Continued.
RIFAPENTINE
RIFAPENTINE
RIFAXIMIN
Riluzole
Rimcazole
RISPERIDONE
RITONAVIR
RIZATRIPTAN BENZOATE
ROFECOXIB
ROLIPRAM
ROLITETRACYCLINE
ROPIVACAINE HCl
ROSIGLITAZONE HCl
ROSIGLITAZONE MALEATE
ROXATIDINE ACETATE HCl
RU 24969
RUFLOXACIN HCl
RUTIN
Rythmol
S(-)-Timolol maleate
SALBUTAMOL SULFATE
Salmeterol
SAQUINAVIR MESYLATE
SB 205607
SDM25N
SECOISOLARICIRESINOL
Sertraline
Sertraline
Sibutramine
SIBUTRAMINE HCl
Simvastatin
SKF 83566
Sonazine
Sotalol hydrochloride
SPECTINOMYCIN DIHYDROCHLORIDE PENTAHYDRATE
Spironolactone
SR 57,227A
Stanozolol
STAVUDINE
STAVUDINE
Stiripentol
Sulfacetamide
Sulfamethoxazole
SULFASALAZINE

-64.54
-93.03
-35.08
-58.55
-8.93
-90.13
-145.33
-35.64
-19.89
-197.91
-89.46
14.31
-29.74
-21.83
-23.89
-100.81
16.34
-7.79
-24.02
-11.27
-57.70
-66.58
0.63
-87.65
-148.22
7.48
30.75
6.39
-74.85
-48.81
-282.50
85.21
-10.09
-14.64
-80.03
-89.91
4.17
-168.50
-43.12
-36.06
24.79
-45.86
-38.02
-7.99
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Sulfinpyrazone
Sulfisoxazole
Sulindac
SUMATRIPTAN SUCCINATE
Symmetrel
SYNEPHRINE
TACROLIMUS
TADALAFIL
Tamoxifen
TAXIFOLIN-(+)
TAXIFOLIN-(+/-)
TEGASEROD MALEATE
TELITHROMYCIN
TELMISARTAN
TEMOZOLOMIDE
Terazosin
Terazosin
TERBINAFINE HCl
Terbutaline Sulfate
Testosterone
Testosterone
TETRACYCLINE
TETRAETHYLTHIURAM DISULFIDE
TFMPP
Thalidomide
Theophylline
THIABENDAZOLE
Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl][CAS]
THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE
TIAGABINE HCl
TIBOLONE
TICLOPIDINE HCl
TINIDAZOLE
Tizanidine hydrochloride
TOCAINIDE
Tofranil
TOLAZAMIDE
Tolbutamide
TOLTERODINE TARTRATE
TOPIRAMATE
TOPOTECAN HCL
TORASEMIDE

-53.83
-37.08
-125.91
10.65
-23.92
-12.39
-176.39
28.66
-86.62
-15.27
-1.15
21.65
-73.24
-84.77
-3.15
-21.67
-8.54
-1025.30
-92.19
-79.38
-133.96
-58.86
-1275.81
16.24
-28.80
-69.10
-2.52
-50.82
58.40
16.34
-36.11
-131.53
-242.87
-19.86
-98.06
-21.83
-286.92
-44.51
39.25
-27.08
-19.99
40.67
-41.10
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TOREMIFENE CITRATE
TOSUFLOXACIN TOSYLATE
Tramadol
TRANILAST
TRAZODONE HYDROCHLORIDE
TREMULACIN
TRIAMCINOLONE ACETONIDE
Triamterene
TRICLABENDAZOLE
Triclosan
Trileptal
TRIMEBUTINE MALEATE
Trimethoprim
TRIPELENNAMINE HYDROCHLORIDE
Tripfluoperazine Hydrochloride
TRIPTOLIDE
TROPICAMIDE
TROPISETRON HCl
TROXIPIDE
TRYPTOLINE
Tyzine
URAPIDIL HYDROCHLORIDE
Urecholine
URSODEOXYCHOLIC ACID
VALACICLOVIR HYDROCHLORIDE
VALDECOXIB
Valproic Acid
VALSARTAN
VARDENAFIL CITRATE
VECURONIUM BROMIDE
VENLAFAXINE HCl
VINCRISTINE SULFATE
VINDESINE SULFATE
VINORELBINE BITATRATE
Viramune
Vistaril Pamoate
VORICONAZOLE
WARFARIN SODIUM
Westcort
XANTHINOL NICOTINATE
Zacopride
ZAFIRLUKAST
Zaleplon
ZERANOL

-16.54
-41.06
-25.90
68.77
-4.12
-315.25
-22.19
1.47
-155.68
-181.17
-10.76
-97.99
-0.16
-34.08
28.64
-5.67
-60.08
-6.79
-24.60
-81.98
-35.39
-26.34
-9.34
-49.48
-20.27
-42.76
-98.54
-40.09
16.37
-25.16
-36.29
-49.39
-61.35
-45.00
-11.00
17.41
-11.99
-12.62
-49.55
-56.27
-5.81
8.66
33.51
-87.34
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Zidovudine
ZILEUTON
Zolmitriptan
ZOLPIDEM TARTRATE
Zonisamide

-52.97
-85.00
-30.51
-33.68
-39.54
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The NIH clinical collections I and II contain drug-like molecules with
documented biological activity and a history of use in human clinical trials. These
properties create a bias for biological activity that is non-specific with regard to
AC2 inhibition. For example, SKF-83566 was validated as a direct small
molecule AC2 inhibitor, but is also known to be a dopamine and serotonin
receptor antagonist (see discussion in chapter 4). Therefore, it is desirable to
identify chemical moieties and functional groups that confer specificity and/or
potency for inhibition of AC2. As such, a modest structure-activity relationship
study was designed by testing analogues of four compounds (SKF-83566,
tranilast, loratadine, and oxymetholone, see Figure A.1 for chemical structures)
that were identified and validated as modulators of AC2 activity (3671-5745,
1683-6987, 8005-4220, 4100-1558, and N050-006 were purchased from
ChemDiv, San Diego, CA). All compounds were tested for the ability to modulate
cAMP accumulation in response to activation of AC isoforms in HEK-hAC2
(activation by 50 nM PMA, 3 μM forskolin, and 300 nM PGE2), HEK-hAC1
(activation by 3 μM A23187), HEK-hAC5 (activation by 300 nM forskolin), and
HEK-wt cells (activation by 3 μM forskolin) as described in chapter 4 (Table A.2).
These experiments represent an initial small-scale structure-activity relationship
study for the compounds that inhibit AC2 activity, while simultaneously counterscreening to examine the AC isoform selectivity of the compounds.
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Figure A.1 Chemical structures of active compounds and their analogues.

Table A.2 AC isoform-selectivity profiles of test compounds in intact-cell studies. AC isoform selectivity was assessed
by testing the ability of test compounds (30 µM) to modulate cAMP responses in HEK-hAC2 cells, HEK-hAC1 cells,
HEK-hAC5 cells, and HEK-wt cells. Data are reported as a percent of the vehicle treatment condition and represent
the Mean ± S.E.M. of three independent experiments. * p < 0.05, ** p < 0.01,*** p < 0.001 compared to vehicle
condition, one sample t-test compared to 100.

AC2

SKF-83566 HBr
(+)-SCH23390 HCl
Nor-S-(-)-SCH 23388 HCl
SKF81297 HBr
SKF82958 HBr
SCH39166 HBr
6264-0080
3671-5745
Oxymetholone
N050-0006
Tranilast
1683-6987
8005-4220
4100-1558
Loratadine
Desloratadine

50 nM
PMA
Mean±SEM
16±0.66***
54±1.1***
77±7.9
86±8.2
81±16
98±11
310±36*
110±18
67±11
89±12
33±5.0**
98±4.8
81±12
88±7.9
50±6.8*
67±4.7*

300 nM
3 µM FSK
PGE2
Mean±SEM Mean±SEM
36±3.3**
20±2.6**
74±1.7**
68±3.6*
71±4.1*
82±9.2
130±9.3
100±20
94±10
82±9
100±1.5
110±8.9
360±25**
360±75
150±9.7*
130±6.4*
56±24
32±1.6***
110±5.7
110±7.6
32±3.7**
55±2.8**
92±2.8
110±16
88±4.7
83±8.2
110±1.8*
160±14
21±1.3***
46±2.3**
110±3.5
85±5.8

AC1
3 µM
A23187
Mean±SEM
100±8.1
120±6.6
81±10
84±16
80±12
ND
33±4.4**
130±15
75±9.7
100±15
96±5.4
94±5.9
96±7.3
75±5.9
120±7.8
78±7.5

AC5
300 nM
FSK
Mean±SEM
61±2.7**
74±5.7*
98±5.3
200±2.4***
120±4.1
ND
330±33*
92±2.2
100±9.7
99±2.9
31±0.31***
110±2.2*
90±7.2
110±5.0
16±0.80***
84±4.0

WT
3 µM FSK
Mean±SEM
85±3.0*
100±14
93±8.8
260±8.4**
210±0.74***
110±14
240±19*
110±3.5
84±11
100±4.4
60±6.4*
130±5.6*
91±1.4*
110±6.5
51±3.2**
89±1.9*
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The development and initial success of a robust cell-based HTS assay for
inhibitors of AC2 (see chapter 4) prompted further screening. In an effort to
identify novel and diverse small molecule inhibitors of AC2, the Spectrum
Collection (MicroSource Discovery Systems Inc.) was screened for inhibition of
PMA-stimulated cAMP in HEK-hAC2 cells as described in chapter 4. The
Spectrum Collection is a diverse chemical collection that contains 2,320
compounds (60% drugs, 25% natural products, and 15% other bioactive
molecules) and provided the opportunity to extend the screening efforts initiated
by screening the NIH clinical collections I and II. The complete results from the
screening of the Spectrum Collection compounds (20 μM) for inhibition of 50 nM
PMA-stimulated cAMP in HEK-hAC2 cells are reported in Table A.3.
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Table A.3 Screening of the Spectrum Collection for inhibition of AC2 activity. The
Spectrum Collection (20 µM) was screened for inhibition of PMA-stimulated (50
nM) cAMP accumulation in HEK-hAC2 cells using the Cisbio HTRF cAMP
dynamic 2 detection methodology. The data represent the percent inhibition of
the PMA-stimulated cAMP response in singlet.

Compound Name
1-(2-METHOXYPHENYL)PIERAZINE HYDROCHLORIDE
1,2alpha-EPOXYDEACETOXYDIHYDROGEDUNIN
1,3,5-TRIMETHOXYBENZENE
1,3-DIDEACETYL-7-DEACETOXY-7-OXOKHIVORIN
1,3-DIDEACETYLKHIVORIN
1,4-NAPHTHOQUINONE
1,7-DIDEACETOXY-1,7-DIOXO-3-DEACETYLKHIVORIN
10-HYDROXYCAMPTOTHECIN
11a-ACETOXYPROGESTERONE
12a-HYDROXY-5-DEOXYDEHYDROMUNDUSERONE
12a-HYDROXY-9-DEMETHYLMUNDUSERONE-8-CARBOXYLIC ACID
13-METHYL-4,4-BISNOR-8,11,13-PODOCARPATRIEN-3-ONE
14-METHOXY-4,4-BISNOR-8,11,13-PODOCARPATRIEN-3-ONE
18alpha-GLYCYRRHETINIC ACID
18-AMINOABIETA-8,11,13-TRIENE SULFATE
1-HYDROXY-3,6,7-TRIMETHOXY-2,8-DIPRENYLXANTHONE
1-MONOPALMITIN
1-PHENYLBIGUANIDE HYDROCHLORIDE
1R,2S-PHENYLPROPYLAMINE
2,2'-AZO-bis-2-AMINOPROPANE
2',2'-BISEPIGALLOCATECHIN DIGALLATE
2,3,4-TRIHYDROXY-4'-ETHOXYBENZOPHENONE
2,3,4'-TRIHYDROXY-4-METHOXYBENZOPHENONE
2,3-DICHLORO-5,8-DIHYDROXYNAPTHOQUINONE
2',3-DIHYDROXY-4,4',6'-TRIMETHOXYCHALCONE
2,3-DIHYDROXY-4-METHOXY-4'-ETHOXYBENZOPHENONE
2,3-DIHYDROXY-6,7-DICHLOROQUINOXALINE
2,3-DIMERCAPTOSUCCINIC ACID
2,4-DICHLOROPHENOXYACETIC ACID
2,4-DICHLOROPHENOXYBUTYRIC ACID
2',4-DIHYDROXY-3,4',6'-TRIMETHOXYCHALCONE
2',4'-DIHYDROXY-4-METHOXYCHALCONE

% Inhibition
-3.07
-40.94
-48.95
20.00
-0.27
99.60
-25.67
37.10
-15.39
-103.88
-1.59
-89.76
-104.77
-10.67
-21.67
12.42
21.46
1.78
-37.14
5.68
18.01
-16.64
12.05
-75.35
-223.55
-65.85
-110.67
-92.54
19.65
-90.34
-54.71
-28.22
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2',4'-DIHYDROXYCHALCONE
2',4-DIHYDROXYCHALCONE
2',4'-DIHYDROXYCHALCONE 4'-GLUCOSIDE
2,4-DINITROPHENOL
2',5'-DIHYDROXY-4-METHOXYCHALCONE
2,5-DI-t-BUTYL-4-HYDROXYANISOLE
2,6-DIHYDROXY-4-METHOXYTOLUENE
2,6-DIMETHOXYQUINONE
21-ACETOXYPREGNENOLONE
2-ACETYLPYRROLE
2-AMINOBENZENESULFONAMIDE
2-AMINOGUANIDINE HEMISULFATE
2-BENZOYL-5-METHOXYBENZOQUINONE
2-HYDROXY-3,4-DIMETHOXYBENZOIC ACID
2-HYDROXY-5 (6)EPOXY-TETRAHYDROCARYOPHYLLENE
2-MERCAPTOBENZOTHIAZOLE
2-METHOXY-5 (6)EPOXY-TETRAHYDROCARYOPHYLLENE
2'-METHOXYFORMONETIN
2-METHOXYRESORCINOL
2-METHOXYXANTHONE
2-METHYL GRAMINE
2-METHYL-4-(PIPERIDIN-1-YLCARBOXY)-5ISOPROPYLPHENYLTRIMETHYLAMMONIUM CHLORIDE
2-METHYL-5,7,8-TRIMETHOXYISOFLAVONE
2-METHYLENE-5-(2,5-DIOXOTETRAHYDROFURAN-3-YL)-6-OXO-10,10-DIMETHYLBICYCLO[7: 2: 0]UNDECANE
2-THIOURACIL
3,16-DIDEOXYMEXICANOLIDE-3beta-DIOL
3,3'-DIINDOLYLMETHANE
3,4',5,6,7-PENTAMETHOXYFLAVONE
3,4-DIDESMETHYL-5-DESHYDROXY-3'-ETHOXYSCLEROIN
3,4-DIMETHOXYCINNAMIC ACID
3,4-DIMETHOXYDALBERGIONE
3,4'-DIMETHOXYFLAVONE
3,6-DIMETHOXYFLAVONE
3,7-DIHYDROXYFLAVONE
3,7-DIMETHOXYFLAVONE
3,7-EPOXYCARYOPHYLLAN-6-OL

-121.12
-121.33
-29.60
-221.20
-355.99
-753.17
0.08
98.02
6.55
-14.10
-25.00
1.26
-42.64
-11.99
-12.54
-138.94
-10.31
8.29
5.61
-150.57
-45.27
19.65
29.32
2.19
-8.15
2.91
-22.31
-66.71
-1.99
14.27
88.27
-165.77
-92.72
22.49
-75.57
1.78
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3,7-EPOXYCARYOPHYLLAN-6-ONE
3-ACETAMIDOCOUMARIN
3-ACETYLCOUMARIN
3alpha-ACETOXYDIHYDRODEOXYGEDUNIN
3alpha-HYDROXY-3-DEOXYANGOLENSIC ACID METHYL ESTER
3alpha-HYDROXY-4,4-BISNOR-8,11,13-PODOCARPATRIENE
3-AMINO-1,2,4-TRIAZOLE
3-AMINO-beta-PINENE
3beta-ACETOXYDEOXODIHYDROGEDUNIN
3beta-HYDROXY-23,24-BISNORCHOL-5-ENIC ACID
3beta-HYDROXYDEOXODIHYDRODEOXYGEDUNIN
3beta-HYDROXYISOALLOSPIROST-9(11)-ENE
3-DEACETYLKHIVORIN
3-DEOXO-3beta-ACETOXYDEOXYDIHYDROGEDUNIN
3-DEOXO-3beta-HYDROXYMEXICANOLIDE 16-ENOL ETHER
3-DEOXY-3beta-HYDROXYANGOLENSIC ACID METHYL ESTER
3-DESHYDROXYSAPPANOL TRIMETHYL ETHER
3H-1,2-DITHIOLE-3-THIONE
3-HYDROXY-3',4'-DIMETHOXYFLAVONE
3-HYDROXY-4-(SUCCIN-2-YL)-CARYOLANE delta-LACTONE
3-HYDROXYFLAVONE
3-HYDROXYTYRAMINE
3-ISOBUTYL-1-METHYLXANTHINE (IBMX)
3-METHOXYCATECHOL
3-METHYLORSELLINIC ACID
3-METHYLXANTHINE
3-NOR-3-OXOPANASINSAN-6-OL
3-OXOURSAN (28-13)OLIDE
4-(3-BUTOXY-4-METHOXYBENZYL)IMIDAZOLIDIN-2-ONE
4,4'-DIISOTHIOCYANOSTILBENE-2,2'-SUFONIC ACID SODIUM SALT
4,4'-DIMETHOXYDALBERGIONE
4-ACETOXYPHENOL
4'-DEMETHYLEPIPODOPHYLLOTOXIN
4-HYDROXY-6-METHYLPYRAN-2-ONE
4-HYDROXYANTIPYRINE
4'-HYDROXYCHALCONE
4'-HYDROXYFLAVANONE

-5.40
-35.65
-138.94
-35.81
1.07
10.19
-16.48
-4.78
-10.45
-12.30
-21.84
-6.63
-65.18
-71.94
-13.90
-0.07
-36.43
-56.41
-20.12
-13.55
-37.15
-12.69
-25.40
-46.70
1.78
6.78
4.61
-64.00
-171.13
-45.60
-702.19
-1.05
-25.67
-21.17
-38.79
-32.24
-59.61
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4-HYDROXYINDOLE
4'-METHOXYCHALCONE
4-METHOXYDALBERGIONE
4-METHYLDAPHNETIN
4-METHYLESCULETIN
4-NAPHTHALIMIDOBUTYRIC ACID
4-NONYLPHENOL
4-O-METHYLPHLORACETOPHENONE
5,7-DIHYDROXY-4-METHYLCOUMARIN
5,7-DIHYDROXYISOFLAVONE
5alpha-ANDROSTAN-3,17-DIONE
5alpha-CHOLESTAN-3beta-OL-6-ONE
5alpha-CHOLESTANOL
5-AMINOPENTANOIC ACID HYDROCHLORIDE
5-CHLOROINDOLE-2-CARBOXYLIC ACID
5-FLUOROINDOLE-2-CARBOXYLIC ACID
5-HYDROXY-2',4',7,8-TETRAMETHOXYFLAVONE
5-METHYLHYDANTOIN
6,2'-DIMETHOXYFLAVONE
6,3'-DIMETHOXYFLAVONE
6,4'-DIHYDROXYFLAVONE
6,7-DICHLORO-3-HYDROXY-2-QUINOXALINECARBOXYLIC ACID
6alpha-METHYLPREDNISOLONE ACETATE
6-AMINONICOTINAMIDE
6-HYDROXYANGOLENSIC ACID METHYL ESTER
6-HYDROXYFLAVONE
6-HYDROXYTROPINONE
7,2'-DIHYDROXYFLAVONE
7,3'-DIMETHOXYFLAVONE
7,4'-DIHYDROXYFLAVONE
7,4'-DIMETHOXYISOFLAVONE
7,8-DIHYDROXYFLAVONE
7-AMINOCEPHALOSPORANIC ACID
7-DEACETOXY-7-OXOKHIVORIN
7-DEACETYLKHIVORIN
7-DESACETOXY-6,7-DEHYDROGEDUNIN
7-DESHYDROXYPYROGALLIN-4-CARBOXYLIC ACID

-25.58
-100.19
-593.06
-9.99
-113.38
16.66
-64.70
-22.11
34.78
12.00
-274.74
26.26
-14.02
-11.53
-2.24
2.62
-86.69
-9.77
-68.45
-17.28
-10.37
24.66
-12.77
-2.19
0.47
-61.41
-26.64
14.40
-49.76
15.46
-2.81
-133.38
-32.45
-68.27
8.93
10.81
-8.07

214
Table A.3 Continued.
7-HYDROXYETHYLTHEOPHYLLINE
7-HYDROXYFLAVONE
7-NITROINDAZOLE
7-OXOCHOLESTEROL
8beta-HYDROXYCARAPIN, 3,8-HEMIACETAL
8-CYCLOPENTYLTHEOPHYLLINE
8-HYDROXYCARAPINIC ACID
ABACAVIR SULFATE
ABAMECTIN (avermectin B1a shown)
ABIENOL
ABIETIC ACID
ACACETIN DIACETATE
ACADESINE
ACAMPROSATE CALCIUM
ACARBOSE
ACEBUTOLOL HYDROCHLORIDE
ACECAINIDE HYDROCHLORIDE
ACECLIDINE
ACEDAPSONE
ACEDOBEN
ACEGLUTAMIDE
ACEMETACIN
ACENOCOUMAROL
ACEPROMAZINE MALEATE
ACESULFAME POTASSIUM
ACETAMINOPHEN
ACETAMINOSALOL
ACETANILIDE
ACETARSOL
ACETAZOLAMIDE
ACETOHEXAMIDE
ACETOHYDROXAMIC ACID
ACETOPHENAZINE MALEATE
ACETOSYRINGONE
ACETRIAZOIC ACID
ACETYL ISOGAMBOGIC ACID
ACETYLCARNITINE

-14.68
5.74
-45.27
-50.80
-36.95
-12.07
-1.19
-13.47
-46.12
-307.12
-140.80
3.52
0.52
10.25
-21.61
-12.92
-13.25
-10.58
-23.80
-20.58
-2.60
-18.04
-13.08
41.78
-9.28
-6.04
23.48
8.83
-11.61
13.90
2.68
17.87
7.80
-26.37
14.96
-31.10
-33.98
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Table A.3 Continued.
ACETYLCHOLINE CHLORIDE
ACETYLCYSTEINE
ACETYLGLUCOSAMINE
ACETYL-L-LEUCINE
ACETYLPHENYLALANINE
ACEXAMIC ACID
ACIPIMOX
ACONITIC ACID
ACONITINE
ACRIFLAVINIUM HYDROCHLORIDE
ACRISORCIN
ACTINONIN
ACYCLOVIR
ADENINE
ADENOSINE
ADENOSINE PHOSPHATE
ADIPHENINE HYDROCHLORIDE
ADONITOL
ADRENOLONE HYDROCHLORIDE
AESCULIN
AGARIC ACID
AGELASINE (stereochemistry of diterpene unknown)
AGMATINE SULFATE
AJMALINE
AKLOMIDE
ALANYL-dl-LEUCINE
ALAPROCLATE
ALBENDAZOLE
ALBUTEROL
ALCLOMETAZONE DIPROPIONATE
ALENDRONATE SODIUM
ALEURETIC ACID
ALEXIDINE HYDROCHLORIDE
ALFLUZOSIN
ALGESTONE ACETOPHENIDE
ALISKIREN HEMIFUMARATE
ALIZARIN

13.15
-0.18
-56.03
-12.74
-29.13
-25.66
5.78
0.74
-0.62
60.54
-19.99
-43.23
-3.55
4.95
-143.95
-35.03
-30.87
-13.78
-35.34
31.99
5.80
-21.88
10.86
1.31
0.32
10.87
4.93
-23.68
-29.04
1.24
-25.22
25.65
-17.11
7.19
-116.80
14.57
-48.10
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ALLANTOIN
ALLOPURINOL
ALLOXAN
ALLYLISOTHIOCYANATE
ALMOTRIPTAN
alpha-CYANO-3-HYDROXYCINNAMIC ACID
alpha-CYANO-4-HYDROXYCINNAMIC ACID
alpha-DIHYDROGEDUNOL
alpha-HYDROXYDEOXYCHOLIC ACID
alpha-MANGOSTIN
alpha-METHYL-L-TYROSINE
alpha-TOCHOPHEROL
alpha-TOCHOPHERYL ACETATE
alpha-TOXICAROL (dl)
ALPINETIN METHYL ETHER
ALPRENOLOL
ALRESTATIN
ALTHIAZIDE
ALTRENOGEST
ALTRETAMINE
ALVERINE CITRATE
AMANTADINE HYDROCHLORIDE
AMBROXOL HYDROCHLORIDE
AMCINONIDE
AMIFOSTINE
AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE
AMINACRINE
AMINOBENZTROPINE
AMINOCAPROIC ACID
AMINOCYCLOPROPANECARBOXYLIC ACID
AMINOETHOXYDIPHENYLBORANE
AMINOETHYLISOTHIOUREA DIHYDROBROMIDE
AMINOGLUTETHIMIDE
AMINOHIPPURIC ACID
AMINOHYDROXYBUTYRIC ACID
AMINOLEVULINIC ACID HYDROCHLORIDE

-10.14
-26.56
-38.79
-40.59
-26.32
-12.69
-22.14
-44.72
-25.00
-78.42
-1.26
-2.62
-9.96
-84.54
-9.99
4.99
-5.76
-18.17
-37.75
-46.56
-12.25
-29.46
18.10
5.86
-28.05
-20.17
5.53
-20.42
-7.07
-7.59
-3.20
-245.61
-2.24
-4.43
-14.06
-11.85
-5.04
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AMINOPENTAMIDE SULFATE
AMINOPTERIN
AMINOPYRINE
AMINOSALICYLATE SODIUM
AMINOTHIAZOLE
AMIODARONE HYDROCHLORIDE
AMIPRILOSE
AMISULPRIDE
AMITRAZ
AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE
AMMONIUM LACTATE
AMODIAQUINE DIHYDROCHLORIDE
AMOXAPINE
AMOXICILLIN
AMPHOTERICIN B
AMPICILLIN SODIUM
AMPIROXICAM
AMPROLIUM
AMPYRONE
AMPYZINE SULFATE
AMSACRINE
AMYGDALIN
ANABASAMINE HYDROCHLORIDE
ANABASINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE
ANASTROZOLE
ANCITABINE HYDROCHLORIDE
ANDROSTA-1,4-DIEN-3,17-DIONE
ANDROSTERONE
ANDROSTERONE ACETATE
ANEBROMPHENIRAMINE MALEATE
ANETHOLE
ANGOLENSIN (R)
ANHYDROBRAZILIC ACID
ANIRACETAM
ANISINDIONE

-11.35
12.62
9.78
-13.99
23.05
-258.09
-40.59
-12.25
-50.85
-8.22
56.23
-7.86
-23.71
7.07
13.90
-8.29
15.31
-32.62
-27.90
3.30
9.37
-20.19
-0.92
-10.67
-0.85
-78.00
2.40
-12.50
-60.76
-196.30
-371.76
20.61
-45.28
-64.73
-16.16
-4.05
7.56
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ANISODAMINE HYDROBROMIDE
ANISOMYCIN
ANTAZOLINE PHOSPHATE
ANTHOTHECOL
ANTHRALIN
ANTHRAQUINONE
ANTIAROL
ANTIMYCIN A (A1 shown)
ANTIPYRINE
APHYLLIC ACID
APIGENIN
APIGENIN DIMETHYL ETHER
APIIN
APIOLE
APOMORPHINE HYDROCHLORIDE
APOTOXICAROL
APRAMYCIN
ARABITOL(D)
ARBUTIN
ARCAINE SULFATE
ARECOLINE HYDROBROMIDE
ARGININE HYDROCHLORIDE
ARIPIPRAZOLE
ARSANILIC ACID
ARSENIC TRIOXIDE
ARTEMETHER
ARTEMISIN
ARTEMISININ
ARTENIMOL
ARTESUNATE
ARTHONIOIC ACID
ASARYLALDEHYDE
ASCORBIC ACID
ASCORBYL PALMITATE
ASIATIC ACID
ASPARTAME
ASPIRIN

6.34
-24.59
1.66
-133.15
-46.12
-63.47
56.56
-185.07
12.11
-42.44
-17.04
-25.04
-22.50
-174.46
0.19
-82.97
13.86
-3.54
-3.75
0.67
8.04
-24.91
-225.19
-16.53
-10.41
26.30
-2.88
-57.80
-5.09
-11.91
-123.25
2.59
40.72
22.67
-12.20
20.78
22.77
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ASTAXANTHIN
ASTEMIZOLE
ASTRAGALOSIDE IV
ATENOLOL
ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM
ATOVAQUONE
ATRACURIUM BESYLATE
ATRANORIN
ATROPINE SULFATE
AURAPTENE
AURIN TRICARBOXYLIC ACID
AUROTHIOGLUCOSE
AVERMECTIN A1a
AVOBENZONE
AVOCADANOFURAN
AVOCADENOFURAN
AVOCADYNE
AVOCADYNE ACETATE
AVOCADYNOFURAN
AVOCATIN A
AVOCATIN B
AZACITIDINE
AZADIRACHTIN
AZAPERONE
AZASERINE
AZATADINE MALEATE
AZATHIOPRINE
AZELAIC ACID
AZELASTINE HYDROCHLORIDE
AZITHROMYCIN
AZLOCILLIN SODIUM
AZOBENZENE
AZTREONAM
BACAMPICILLIN HYDROCHLORIDE
BACCATIN III
BACITRACIN

-26.21
43.15
-21.84
-5.65
-13.55
-8.22
5.03
4.08
-110.98
-19.17
-6.43
-5.26
-11.94
-72.25
-404.39
-14.86
-4.02
38.05
25.46
-3.41
50.49
5.05
5.90
-23.88
-44.02
-36.60
-19.21
-27.69
22.19
13.97
-0.08
-23.14
-61.67
23.85
-16.95
5.99
6.12
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BACLOFEN
BAICALEIN
BAICALIN
BALSALAZIDE DISODIUM
BAMBUTEROL HYDROCHLORIDE
BARBITAL
BATYL ALCOHOL
BECLAMIDE
BECLOMETHASONE DIPROPIONATE
BEKANAMYCIN SULFATE
BEMOTRIZINOL
BENAZEPRIL HYDROCHLORIDE
BENDROFLUMETHIAZIDE
BENFLUOREX HYDROCHLORIDE
BENFOTIAMINE
BENOXINATE HYDROCHLORIDE
BENSERAZIDE HYDROCHLORIDE
BENURESTAT
BENZALKONIUM CHLORIDE
BENZANTHRONE
BENZBROMARONE
BENZETHONIUM CHLORIDE
BENZO[a]PYRENE
BENZOCAINE
BENZOIC ACID
BENZONATATE
BENZOXIQUINE
BENZOYL PEROXIDE
BENZOYLPAS
BENZTHIAZIDE
BENZYDAMINE HYDROCHLORIDE
BENZYL ALCOHOL
BENZYL BENZOATE
BENZYL ISOTHIOCYANATE
BEPHENIUM HYDROXYNAPTHOATE
BEPRIDIL HYDROCHLORIDE
BERBAMINE HYDROCHLORIDE

-6.73
-60.64
6.30
17.38
1.31
-20.14
0.13
-1.14
-36.00
10.76
-6.10
26.21
24.53
-19.43
11.77
3.39
-41.68
12.69
-6.49
-1067.13
-115.15
-43.26
-108.23
21.47
-23.04
-37.01
3.07
-17.87
5.74
7.15
-14.24
-24.54
-16.03
-22.37
13.33
-46.09
-9.92
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BERBERINE CHLORIDE
BERGAPTEN
BERGENIN
beta-AMYRIN ACETATE
beta-CAROTENE
beta-CARYOPHYLLENE ALCOHOL
beta-ESCIN
BETAHISTINE HYDROCHLORIDE
BETAINE HYDROCHLORIDE
BETAMETHASONE
BETAMETHASONE 17,21-DIPROPIONATE
BETAMETHASONE ACETATE
BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE
BETAMIPRON
beta-NAPHTHOL
beta-PELTATIN
beta-SITOSTEROL
beta-TOXICAROL
BETAXALOL HYDROCHLORIDE
BETAZOLE HYDROCHLORIDE
BETHANECHOL CHLORIDE
BETULIN
BETULINIC ACID
BEZAFIBRATE
BICALUTAMIDE
BICUCULLINE (+)
BICUCULLINE(-) METHIODIDE
BIFONAZOLE
BILIRUBIN
BIOCHANIN A
BIOTIN
BIPERIDEN
BISACODYL
BISANHYDRORUTILANTINONE
BISMUTH SUBSALICYLATE
BISOCTRIZOLE

2.95
-32.78
7.56
6.85
-111.70
-6.45
41.97
-14.46
-10.27
-20.63
13.86
-1.80
7.35
6.83
-8.68
-256.18
-11.36
-13.59
-146.05
7.13
5.83
-7.67
17.44
-148.36
1.04
-40.83
-12.12
-35.95
-58.83
-68.13
-46.37
-6.56
-7.53
-146.21
-620.91
-43.00
-56.42
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BISOPROLOL FUMARATE
BISPHENOL A
BISSALICYL FUMARATE
BITHIONATE SODIUM
BITOSCANATE
BIXIN
BLASTICIDIN S
BLEOMYCIN (bleomycin B2 shown)
BOLDINE
BORNEOL
BORNYL ACETATE
BOVINOCIDIN (3-nitropropionic acid)
BRAZILEIN
BRAZILIN
BRINZOLAMIDE
BROMHEXINE HYDROCHLORIDE
BROMINDIONE
BROMO-3-HYDROXY-4-(SUCCIN-2-YL)-CARYOLANE gammaLACTONE
BROMOCRIPTINE MESYLATE
BROMOPRIDE
BROMPERIDOL
BRUCINE
BUCETIN
BUCLADESINE
BUDESONIDE
BUFEXAMAC
BUFLOMEDIL HYDROCHLORIDE
BUMETANIDE
BUPIVACAINE HYDROCHLORIDE
BUPROPION
BUSPIRONE HYDROCHLORIDE
BUSSEIN
BUSULFAN
BUTACAINE
BUTAMBEN
BUTOCONAZOLE
BUTYL PARABEN

10.60
-58.69
1.75
-139.66
11.25
-23.21
19.37
-0.11
10.19
-1.14
-28.15
31.38
13.55
17.12
-2.09
-452.06
4.74
-0.18
-38.09
-10.14
40.08
-11.18
21.31
-2405.69
-16.64
-118.56
7.20
17.98
-27.00
-25.84
5.62
-37.73
-9.96
13.42
-37.52
-44.49
-82.45
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BUTYLATED HYDROXYTOLUENE
CACODYLIC ACID
CADAVERINE TARTRATE
CADIN-4-EN-10-OL
CAFESTOL
CAFESTOL ACETATE
CAFFEIC ACID
CAFFEINE
CALCEIN
CALCIUM GLUCEPTATE
CAMPHOR (1R)
CAMPTOTHECIN
CAMYLOFINE DIHYDROCHLORIDE
CANAVANINE
CANDESARTAN
CANDICIDIN
CANRENOIC ACID, POTASSIUM SALT
CANRENONE
CANTHARIDIN
CANTHAXANTHIN (euglenanone)
CAPECITABINE
CAPOBENIC ACID
CAPREOMYCIN SULFATE
CAPSAICIN
CAPSANTHIN
CAPTAMINE
CAPTAN
CAPTOPRIL
CARAPIN
CARAPIN-8(9)-ENE
CARBACHOL
CARBADOX
CARBAMAZEPINE
CARBARSONE
CARBENICILLIN DISODIUM
CARBENOXOLONE SODIUM
CARBETAPENTANE CITRATE

-450.16
-39.64
13.03
-29.23
11.76
-12.20
-1.19
13.32
24.19
13.61
21.52
-12.33
-102.32
-2.04
-1.28
-163.40
18.36
-34.75
-13.98
-7.31
-5.88
-6.49
-15.75
-18.80
-79.48
-12.24
99.01
-36.27
-6.28
-19.50
-13.81
14.48
7.48
-18.61
11.39
-15.48
-120.51
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CARBIDOPA
CARBINOXAMINE MALEATE
CARBOPLATIN
CARISOPRODOL
CARMINIC ACID
CARMOFUR
CARMUSTINE
CARNITINE (dl) HYDROCHLORIDE
CARNOSIC ACID
CARNOSINE
CARPROFEN
CARSALAM
CARTEOLOL HYDROCHLORIDE
CARVEDILOL
CARVEDILOL PHOSPHATE
CARYLOPHYLLENE OXIDE
CARYOPHYLLENE [t(-)]
CARZENIDE
CASANTHRANOL [cascaroside A shown]
CATECHIN PENTAACETATE
CATECHIN TETRAMETHYLETHER
CEAROIN
CEDRELONE
CEDROL
CEDRYL ACETATE
CEFACLOR
CEFADROXIL
CEFALONIUM
CEFAMANDOLE NAFATE
CEFAMANDOLE SODIUM
CEFAZOLIN SODIUM
CEFDINIR
CEFDITORIN PIVOXIL
CEFEPIME HYDROCHLORIDE
CEFMENOXIME HYDROCHLORIDE
CEFMETAZOLE SODIUM
CEFONICID SODIUM

-48.43
-9.72
-27.67
-17.63
17.85
12.06
-76.58
8.23
-32.45
-33.66
-23.52
-29.51
10.14
-75.51
-177.70
-53.97
-188.99
7.68
-69.10
-139.68
-50.60
-60.02
-258.13
-107.01
-220.43
-3.79
-1.87
18.77
-13.64
1.14
18.91
-1.32
-48.78
5.72
-13.20
-2.44
4.61
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CEFOPERAZONE
CEFORANIDE
CEFOTAXIME SODIUM
CEFOTETAN
CEFOXITIN SODIUM
CEFPIRAMIDE
CEFPODOXIME PROXETIL
CEFPROZIL
CEFSULODIN SODIUM
CEFTAZIDIME
CEFTIBUTEN
CEFTIOFUR HYDROCHLORIDE
CEFTRIAXONE SODIUM TRIHYDRATE
CEFUROXIME AXETIL
CEFUROXIME SODIUM
CELASTROL
CELECOXIB
CELLOBIOSE (D[+])
CEPHALEXIN
CEPHALOSPORIN C SODIUM
CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM
CEPHARANTHINE
CEPHRADINE
CETIRIZINE HYDROCHLORIDE
CETRIMONIUM BROMIDE
CETYLPYRIDINIUM CHLORIDE
CHAULMOOGRIC ACID
CHENODIOL
CHICAGO SKY BLUE
CHINIOFON
CHLORALOSE
CHLORAMBUCIL
CHLORAMINE-T
CHLORAMPHENICOL
CHLORAMPHENICOL PALMITATE
CHLORAMPHENICOL SODIUM SUCCINATE

-2.69
-4.36
-14.87
17.04
-18.35
-5.52
-22.23
3.96
-9.96
3.26
-3.20
-7.64
-0.28
9.24
-5.01
-307.12
16.46
12.87
21.42
18.15
-1.73
18.42
-3.38
6.90
2.30
29.30
-8.92
-23.21
-13.88
109.19
12.73
-3.73
-10.27
15.88
22.42
5.59
-4.35
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CHLORANIL
CHLORCYCLIZINE HYDROCHLORIDE
CHLORHEXIDINE HYDROCHLORIDE
CHLORINDIONE
CHLORMADINONE ACETATE
CHLORMEZANONE
CHLOROCRESOL
CHLOROGUANIDE HYDROCHLORIDE
CHLOROPHYLLIDE Cu COMPLEX Na SALT
CHLOROPYRAMINE HYDROCHLORIDE
CHLOROQUINE DIPHOSPHATE
CHLOROTHIAZIDE
CHLOROXINE
CHLOROXYLENOL
CHLORPHENIRAMINE (S) MALEATE
CHLORPROMAZINE
CHLORPROPAMIDE
CHLORPROTHIXENE HYDROCHLORIDE
CHLORPYRIFOS
CHLORQUINALDOL
CHLORTETRACYCLINE HYDROCHLORIDE
CHLORTHALIDONE
CHLORZOXAZONE
CHOL-11-ENIC ACID
CHOLECALCIFEROL
CHOLEST-4,6-DIEN-3-ONE
CHOLEST-5-EN-3-ONE
CHOLESTAN-3-ONE
CHOLESTANE
CHOLESTEROL
CHOLESTERYL ACETATE
CHOLIC ACID
CHOLIC ACID, METHYL ESTER
CHOLINE CHLORIDE
CHROMOCARB
CHRYSANTHEMIC ACID
CHRYSANTHEMIC ACID, ETHYL ESTER

81.80
-26.97
-67.47
6.83
-1.87
5.90
-49.66
-0.32
70.63
-3.88
-0.03
18.85
-46.56
-81.46
-6.70
25.27
-7.29
50.50
-232.94
19.54
-27.53
-31.98
-25.02
-16.10
-100.33
-19.32
-15.55
-18.91
18.21
-6.70
-15.00
-33.87
-60.12
-4.51
-10.99
-23.61
-3.13
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CHRYSANTHEMYL ALCOHOL
CHRYSAROBIN
CHRYSIN
CHRYSIN DIMETHYL ETHER
CHRYSOPHANOL
CHUKRASIN METHYL ETHER
CIANIDANOL
CICLOPIROX OLAMINE
CILOSTAZOL
CIMETIDINE
CINCHONIDINE
CINCHONINE
CINCHOPHEN
CINNARAZINE
CINOXACIN
CINTRIAMIDE
CIPROFIBRATE
CIPROFLOXACIN
CISAPRIDE
CISPLATIN
CITALOPRAM HYDROBROMIDE
CITICOLINE
CITIOLONE
CITRININ
CITROPTEN
CITRULLINE
CLARITHROMYCIN
CLAVULANATE LITHIUM
CLEMASTINE FUMARATE
CLEMIZOLE HYDROCHLORIDE
CLENBUTEROL HYDROCHLORIDE
CLIDINIUM BROMIDE
CLIMBAZOLE
CLINAFOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLIOQUINOL

-21.70
-535.96
-69.57
-54.22
-300.27
-25.67
-12.01
-56.28
-5.26
19.96
-11.09
-5.08
-1.07
-449.99
-30.08
3.96
22.54
-12.92
-72.57
-57.00
11.23
0.25
11.55
-39.10
12.64
-10.67
-12.60
-4.61
12.35
-14.62
-27.86
2.73
11.60
9.25
7.25
-17.62
-4.00
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Table A.3 Continued.
CLOBETASOL PROPIONATE
CLOFARABINE
CLOFAZIMINE
CLOFIBRATE
CLOFIBRIC ACID
CLOFILIUM TOSYLATE
CLOFOCTOL
CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM
CLONIDINE HYDROCHLORIDE
CLOPERASTINE HYDROCHLORIDE
CLOPIDOGREL SULFATE
CLOPIDOL
CLORGILINE HYDROCHLORIDE
CLORSULON
CLOSANTEL
CLOTRIMAZOLE
CLOVANEDIOL DIACETATE
CLOXACILLIN SODIUM
CLOXYQUIN
CLOZAPINE
COLCHICINE
COLESEVALAM HYDROCHLORIDE (high mol wt copolymer @10mg/ml)
COLFORSIN
COLISTIMETHATE SODIUM
COLISTIN SULFATE
CONESSINE
CONVALLATOXIN
CORALYNE CHLORIDE
CORTISONE
CORTISONE ACETATE
CORYNANTHINE
COTARNINE CHLORIDE
COTININE
COUMARIN
COUMOPHOS

11.91
-56.99
-55.17
-1.59
-6.87
-1.32
-439.91
1.75
-58.86
-13.66
-33.09
-1.76
1.77
-11.58
-1.21
15.34
0.82
-80.48
-62.30
6.76
-104.05
35.04
14.14
-11.24
-3268.26
34.85
-35.98
12.20
-10.67
6.85
-28.25
-33.50
-18.21
-7.90
-3.22
-57.97
0.65
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Table A.3 Continued.
CREATININE
CRESOL
CRESOPIRINE
CROMOLYN SODIUM
CROTAMITON
CRUSTECDYSONE
CRYOFLURANE
CRYPTOTANSHINONE
CURCUMIN
CYANOCOBALAMIN
CYCLAMIC ACID
CYCLANDELATE
CYCLIZINE
CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOCREATINE
CYCLOHEXIMIDE
CYCLOLEUCINE
CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE
CYCLOSERINE (D)
CYCLOSPORINE
CYCLOTHIAZIDE
CYCLOVERATRYLENE
CYPERMETHRIN
CYPROHEPTADINE HYDROCHLORIDE
CYPROTERONE
CYPROTERONE ACETATE
CYROMAZINE
CYSTAMINE DIHYDROCHLORIDE
CYSTEAMINE HYDROCHLORIDE
CYSTEINE HYDROCHLORIDE
CYSTINE
CYTARABINE
CYTIDINE
CYTISINE
d,l-threo-3-HYDROXYASPARTIC ACID
DACARBAZINE

12.64
-19.72
-11.99
0.65
-22.77
-13.13
-26.52
-630.03
-484.54
3.11
9.58
-81.68
-2.93
17.10
-0.18
8.53
10.02
-26.56
-3.93
-7.88
-2.36
4.54
-9.84
-144.72
-22.21
-1.28
6.58
-0.72
-16.96
3.84
19.12
-1.97
2.86
7.99
3.28
-7.53
-25.18
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DACTINOMYCIN
DALBERGIONE
DALBERGIONE, 4-METHOXY-4'-HYDROXYDANAZOL
DANTHRON
DANTROLENE SODIUM
DAPSONE
DARIFENACIN HYDROBROMIDE
DASATINIB
DAUNORUBICIN
DEACETOXY(7)-7-OXOKHIVORINIC ACID
DEACETOXY-7-OXOGEDUNIN
DEACETYLGEDUNIN
DEBRISOQUIN SULFATE
DECAHYDROGAMBOGIC ACID
DECAMETHONIUM BROMIDE
DECOQUINATE
DEFERIPRONE
DEFEROXAMINE MESYLATE
DEGUELIN(-)
DEHYDROABIETAMIDE
DEHYDROACETIC ACID
DEHYDROCHOLATE SODIUM
DEHYDROCHOLIC ACID
DEHYDRODIHYDROROTENONE
DEHYDROROTENONE
DEHYDROVARIABILIN
DEMECLOCYCLINE HYDROCHLORIDE
DEMETHYLNOBILETIN
DENATONIUM BENZOATE
DEOXYADENOSINE
DEOXYANDIROBIN
DEOXYCHOLIC ACID
DEOXYGEDUNIN
DEOXYKHIVORIN
DEOXYSAPPANONE B 7,3'-DIMETHYL ETHER
DEOXYSAPPANONE B 7,3'-DIMETHYL ETHER ACETATE

-25.95
12.50
-30.25
-30.48
-250.19
19.91
2.92
-38.06
-12.94
10.88
-4.39
-92.69
-23.26
-27.48
-445.84
-23.75
-24.58
-28.25
8.60
-92.20
-48.61
25.15
-6.11
8.23
-13.55
-15.76
-287.74
-8.93
-150.16
-9.12
68.04
-10.99
-4.59
-50.92
-8.72
-116.45
-43.29
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DEOXYSAPPANONE B 7,4'-DIMETHYL ETHER
DEOXYSAPPANONE B TRIMETHYL ETHER
DEQUALINIUM CHLORIDE
DERACOXIB
DERRUSNIN
DERRUSTONE
DESACETYL (7)KHIVORINIC ACID, METHYL ESTER
DESACETYLCOLFORSIN
DESIPRAMINE HYDROCHLORIDE
DESLORATADINE HYDROCHLORIDE
DESLORATIDINE
DESONIDE
DESOXYCORTICOSTERONE ACETATE
DESOXYMETASONE
DESOXYPEGANINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE
DEXAMETHASONE
DEXAMETHASONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE
DEXCHLORPHENIRAMINE MALEATE
DEXIBUPROFEN
DEXLANSOPRAZOLE
DEXPANTHENOL
DEXPROPRANOLOL HYDROCHLORIDE
DIACERIN
DIACETAMATE
DIALLYL SULFIDE
DIATRIZOIC ACID
DIAVERIDINE
DIAZOXIDE
DIBEKACIN
DIBENZOTHIOPHENE
DIBENZOYLMETHANE
DIBUCAINE HYDROCHLORIDE
DIBUTYL PHTHALATE
DICHLORISONE ACETATE
DICHLORVOS

-128.48
-113.13
-14.70
-20.01
-28.30
38.95
-7.23
-689.41
1.54
-72.14
35.35
-9.95
-17.81
-2.50
-5.26
-41.55
33.87
12.64
-1.16
-12.52
-36.90
-19.53
0.90
23.31
-10.83
-45.41
-19.50
6.70
-52.63
17.41
-34.02
-202.58
-63.72
-25.02
-46.34
-10.99
-26.61
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DICLAZURIL
DICLOFENAC SODIUM
DICLOXACILLIN SODIUM
DICTAMNINE
DICUMAROL
DICYCLOHEXYLUREA
DICYCLOMINE HYDROCHLORIDE
DIDEACETYL (1,3)-7-DESACETOXY-7-OXO-DEOXYKHIVORINIC ACID
DIENESTROL
DIETHYLCARBAMAZINE CITRATE
DIETHYLSTILBESTROL
DIETHYLTOLUAMIDE
DIFFRACTAIC ACID
DIFLORASONE DIACETATE
DIFLOXACIN HYDROCHLORIDE
DIFLUBENZURON
DIFLUNISAL
DIFUCOL HEXAMETHYL ETHER
DIGITONIN
DIGITOXIN
DIGOXIGENIN
DIGOXIN
DIHYDROCELASTROL
DIHYDROCELASTRYL DIACETATE
DIHYDROERGOTAMINE MESYLATE
DIHYDROFISSINOLIDE
DIHYDROFOLIC ACID
DIHYDROGAMBOGIC ACID
DIHYDROGEDUNIC ACID, METHYL ESTER
DIHYDROGEDUNIN
DIHYDROJASMONIC ACID
DIHYDROJASMONIC ACID, METHYL ESTER
DIHYDROMUNDULETONE
DIHYDROMYRISTICIN
DIHYDROROTENONE
DIHYDROSTREPTOMYCIN SULFATE
DIHYDROXY (3alpha,12alpha)PREGNAN-20-ONE

-10.33
-37.83
-7.81
-46.34
-3.72
-14.07
-2.08
8.34
-24.92
-4.73
7.25
-1.25
-20.97
31.48
-6.58
4.03
-43.34
-3.07
102.13
-9.00
-5.99
5.01
-123.96
-84.14
-24.92
-45.93
-16.00
-179.43
-28.41
-23.26
109.86
-53.32
-77.02
-97.45
-102.56
-8.78
-2.12
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DILAZEP DIHYDROCHLORIDE
DILOXANIDE FUROATE
DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE
DIMERCAPROL
DIMETHADIONE
DIMETHYL 4,4-o-PHENYLENE-BIS (3-THIOPHANATE)
DIMETHYL FUMARATE
DIMETHYLCAFFEIC ACID
DIMINAZENE ACETURATE
DIMPYLATE
DINITOLMIDE
DIOSGENIN
DIOSMETIN
DIOSMIN
DIOXYBENZONE
DIPERODON HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENYLPYRALINE HYDROCHLORIDE
DIPLOSALSALATE
DIPTERYXIN
DIPYRIDAMOLE
DIPYROCETYL
DIPYRONE
DIRITHROMYCIN
DISOPYRAMIDE PHOSPHATE
DISULFIRAM
DJENKOLIC ACID
D-LACTITOL MONOHYDRATE
d-LIMONENE
DOBUTAMINE HYDROCHLORIDE
DOCETAXEL
DOCOSANOL
DOCUSATE SODIUM
DOMPERIDONE
DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE

-14.95
-34.18
-16.56
-5.60
-730.52
24.57
-60.23
-155.37
-4.09
-6.05
-33.09
-7.17
-31.75
11.02
-10.21
-57.09
-9.35
-34.31
14.31
-12.54
22.49
44.24
-14.95
-17.20
8.89
-3.22
-673.59
3.40
-6.94
5.90
4.80
-27.18
12.46
7.07
-68.51
-20.72
6.01
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DORAMECTIN
DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE
DOXIFLURIDINE
DOXOFYLLINE
DOXORUBICIN
DOXYCYCLINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE
D-PHENYLALANINE
DROFENINE HYDROCHLORIDE
DROPERIDOL
DROSPIRENONE
DUARTIN (-)
DUARTIN, DIMETHYL ETHER
DULOXETINE HYDROCHLORIDE
DUTASTERIDE
DYCLONINE HYDROCHLORIDE
DYDROGESTERONE
DYPHYLLINE
EBSELEN
ECAMSULE TRIETHANOLAMINE
ECONAZOLE NITRATE
EDARAVONE
EDETATE DISODIUM
EDITOL
EDOXUDINE
EDROPHONIUM CHLORIDE
EFAROXAN HYDROCHLORIDE
EFLOXATE
ELAIDYLPHOSPHOCHOLINE
ELETRIPTAN HYDROBROMIDE
ELLAGIC ACID
EMBELIN
EMETINE
EMODIN
ENALAPRIL MALEATE

-83.97
-11.94
-63.71
12.00
-9.51
10.86
41.45
38.93
-4.51
-37.92
-15.03
-32.38
-20.41
-66.38
-68.02
-58.70
-31.22
24.95
7.19
29.23
-47.51
12.01
-79.20
-42.09
-11.09
-35.88
37.66
40.41
-29.22
-208.19
50.01
3.39
-26.13
-31.22
0.58
-555.53
-15.23
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ENALAPRILAT
ENILCONAZOLE
ENOXACIN
ENOXOLONE
ENROFLOXACIN
ENTANDROPHRAGMIN
EPHEDRINE (1R,2S) HYDROCHLORIDE
EPI(13)TORULOSOL
EPIAFZELECHIN (2R,3R)(-)
EPIAFZELECHIN TRIMETHYL ETHER
EPIANDROSTERONE
EPICATECHIN
EPICATECHIN MONOGALLATE
EPICATECHIN PENTAACETATE
EPIESTRIOL
EPIGALLOCATECHIN
EPIGALLOCATECHIN 3,5-DIGALLATE
EPIGALLOCATECHIN-3-MONOGALLATE
EPINEPHRINE BITARTRATE
EPIRUBICIN HYDROCHLORIDE
EPITESTOSTERONE
EPOXYGEDUNIN
EPRODISATE DISODIUM
EQUILIN
ERDOSTEINE
ERGOCALCIFEROL
ERGONOVINE MALEATE
ERGOSTEROL
ERGOSTEROL ACETATE
ERGOTAMINE TARTRATE
ERYTHROMYCIN
ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROSE
ERYTHROSINE SODIUM
ESCITALOPRAM OXALATE
ESCULETIN

-26.80
-9.40
30.82
-29.90
8.12
-35.19
-6.61
-53.79
-26.27
2.88
-114.16
-3.00
-12.77
-10.19
12.06
-6.04
14.49
-47.93
-59.39
-18.88
0.13
-66.42
1.21
-115.39
-5.45
-82.78
23.45
-51.70
-46.59
-6.68
-3.90
-15.95
15.39
-0.58
109.92
-64.55
20.43
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ESCULIN MONOHYDRATE
ESEROLINE FUMARATE
ESOMEPRAZOLE POTASSIUM
ESTRADIOL
ESTRADIOL ACETATE
.ESTRADIOL BENZOATE
ESTRADIOL CYPIONATE
ESTRADIOL DIACETATE
ESTRADIOL DIPROPIONATE
ESTRADIOL METHYL ETHER
ESTRADIOL VALERATE
ESTRADIOL-3-SULFATE, SODIUM SALT
ESTRAGOLE
ESTRIOL
ESTRONE
ESTRONE ACETATE
ESTRONE BENZOATE
ESTROPIPATE
ETHACRIDINE LACTATE
ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE
ETHAMIVAN
ETHANOLAMINE OLEATE
ETHAVERINE HYDROCHLORIDE
ETHINYL ESTRADIOL
ETHIONAMIDE
ETHIONINE
ETHISTERONE
ETHOPROPAZINE HYDROCHLORIDE
ETHOSUXIMIDE
ETHOTOIN
ETHOXZOLAMIDE
ETHYL PARABEN
ETHYNODIOL DIACETATE
ETICLOPRIDE HYDROCHLORIDE
ETIDRONATE DISODIUM
ETODOLAC

30.74
-132.98
22.98
-33.29
-64.70
-164.11
-192.32
-112.34
-133.79
-21.80
-155.41
7.24
-84.80
-10.22
-72.10
-390.03
-117.50
3.91
44.59
-164.34
-14.13
-0.49
-22.51
-82.34
-113.74
-10.22
-0.93
1.79
-72.54
9.24
2.88
-3.62
-49.92
-456.27
17.01
-2.08
-16.98
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ETOMIDATE
ETOPOSIDE
EUCALYPTOL
EUCATROPINE HYDROCHLORIDE
EUGENOL
EUPARIN
EUPHOL
EUPHOL ACETATE
EVANS BLUE
EVOXINE
EXALAMIDE
EXEMESTANE
EZETIMIBE
FAMCICLOVIR
FAMOTIDINE
FAMPRIDINE
FAMPROFAZONE
FARNESOL
FAST GREEN FCF
FASUDIL HYDROCHLORIDE
FEBUXOSTAT
FELBINAC
FELODIPINE
FENBENDAZOLE
FENBUFEN
FENBUTYRAMIDE
FENDILINE HYDROCHLORIDE
FENOFIBRATE
FENOFIBRIC ACID
FENOLDIPAM MESYLATE
FENOPROFEN
FENOTEROL HYDROBROMIDE
FENSPIRIDE HYDROCHLORIDE
FENTHION
FERULIC ACID
FEXOFENADINE HYDROCHLORIDE
FILIPIN

-20.90
-8.16
-12.92
-30.68
-165.81
-147.74
-177.13
-27.09
69.06
4.99
-147.14
-56.36
-28.05
23.17
-23.23
-12.44
-140.62
-85.01
109.86
7.93
-16.91
-19.29
-8.61
-4.73
21.84
-85.79
-43.69
-300.63
0.88
1.18
-0.99
-22.43
8.31
-85.97
13.85
-24.58
-32.72
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FINASTERIDE
FIPEXIDE HYDROCHLORIDE
FIPRONIL
FIROCOXIB
FISETIN
FISSINOLIDE
FLAVANONE
FLOPROPIONE
FLORFENICOL
FLOXURIDINE
FLUCONAZOLE
FLUCYTOSINE
FLUDARABINE PHOSPHATE
FLUDROCORTISONE ACETATE
FLUFENAMIC ACID
FlUMAZENIL
FLUMEQUINE
FLUMETHASONE
FLUMETHAZONE PIVALATE
FLUNARIZINE HYDROCHLORIDE
FLUNISOLIDE
FLUNIXIN MEGLUMINE
FLUNIXIN MEGLUMINE
FLUOCINOLONE ACETONIDE
FLUOCINONIDE
FLUORESCEIN
FLUOROMETHOLONE
FLUOROURACIL
FLUOXETINE
FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE
FLURBIPROFEN
FLUROFAMIDE
FLUROTHYL
FLUROXENE
FLUTAMIDE
FLUTICASONE PROPIONATE

5.00
-6.57
-120.30
-5.83
17.01
-74.68
-131.31
-23.45
30.48
-29.51
19.07
-1.25
24.58
18.83
-74.93
1.31
33.31
-14.34
9.14
-123.66
-15.57
15.37
12.34
-2.65
25.73
31.65
0.37
5.39
22.16
54.99
14.98
-32.48
2.67
-8.75
-10.03
2.02
-10.03
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FLUVASTATIN
FLUVOXAMINE MALEATE
FOLIC ACID
FOMEPIZOLE
FOMEPIZOLE HYDROCHLORIDE
FORMESTANE
FORMONONETIN
FOSCARNET SODIUM
FOSFOMYCIN CALCIUM
FOSFOSAL
FRAXIDIN METHYL ETHER
FRIEDELIN
FTAXILIDE
FUCOSTANOL
FULVESTRANT
FUMARPROTOCETRARIC ACID
FURALTADONE
FURAZOLIDONE
FUROSEMIDE
FUSARIC ACID
FUSIDIC ACID
GABAPENTIN
GABOXADOL HYDROCHLORIDE
GADOTERIDOL
GALANGIN
GALANGIN TRIMETHYL ETHER
GALANTAMINE
GALLAMINE TRIETHIODIDE
GALLIC ACID
GAMBOGIC ACID
gamma-AMINOBUTYRIC ACID
GANCICLOVIR
GANGALEOIDIN
GARCINOLIC ACID
GARLICIN
GATIFLOXACIN
GEDUNIN

-45.40
-0.90
-17.81
-9.73
15.83
-179.59
16.59
13.42
-8.52
5.48
-25.75
-7.83
-33.71
31.51
-14.34
-26.30
-64.84
-19.90
24.30
-22.58
29.23
-6.83
5.40
15.82
-21.14
-24.52
-0.84
-18.43
-5.38
-12.66
-30.99
-16.91
-97.80
-17.45
-16.26
16.67
-108.29
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GEDUNOL
GEFITINIB
GEMFIBROZIL
GEMIFLOXACIN MESYLATE
GENETICIN
GENISTEIN
GENTAMICIN SULFATE
GENTIAN VIOLET
GIBBERELLIC ACID
GINKGOLIDE A
GITOXIGENIN
GITOXIGENIN DIACETATE
GITOXIN
GLAFENINE
GLICLAZIDE
GLIMEPIRIDE
GLIPIZIDE
GLUCITOL-4-GUCOPYANOSIDE
GLUCONOLACTONE
GLUCOSAMINE HYDROCHLORIDE
GLUCOSAMINIC ACID
GLUTAMINE (D)
GLUTAMINE (L)
GLUTATHIONE
GLYBURIDE
GLYCOCHOLIC ACID
GLYCOPYRROLATE
GLYCYRRHIZIC ACID, AMMONIUM SALT
GOSSYPETIN
GOSSYPIN
GOSSYPOL
GRAMICIDIN
GRAMINE
GRANISETRON HYDROCHLORIDE
GRISEOFULVIN
GUAIAZULENE
GUAIFENESIN

-11.61
-3.90
-11.26
30.71
-2.99
-121.96
-13.47
110.02
-9.32
-9.92
-19.34
-35.60
-5.19
-127.42
-22.37
-47.07
-7.23
10.92
-12.77
-3.36
-7.00
-9.28
28.35
-3.66
-27.23
-0.53
10.92
-0.40
-39.46
1.49
-141.55
-340.92
8.53
15.28
-95.70
-72.68
-24.82
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GUAIOL(-)
GUANABENZ ACETATE
GUANADREL SULFATE
GUANETHIDINE MONOSULFATE
GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE
HAEMATOMMIC ACID
HAEMATOMMIC ACID, ETHYL ESTER
HAEMATOPORPHYRIN
HAEMATOXYLIN
HAEMATOXYLIN PENTAACETATE
HALAZONE
HALOFANTRINE HYDROCHLORIDE
HALOPERIDOL
HALOTHANE
HARMALINE
HARMALOL HYDROCHLORIDE
HARMANE
HARMINE
HARMOL HYDROCHLORIDE
HARPAGOSIDE
HECOGENIN
HECOGENIN ACETATE
HEDERACOSIDE C
HEDERAGENIN
HELENINE
HELICIN
HEMATEIN
HEMICHOLINIUM BROMIDE
HEPTAMINOL HYDROCHLORIDE
HESPERETIN
HESPERIDIN
HETACILLIN POTASSIUM
HETEROPEUCENIN, METHYL ETHER
HEXACHLOROPHENE
HEXAMETHONIUM BROMIDE
HEXAMETHYLQUERCETAGETIN

-90.01
12.00
8.56
-31.58
-23.67
-1.83
-19.34
-179.06
87.76
11.48
-53.17
-12.73
-5.27
22.98
11.70
29.19
41.13
-37.78
-29.14
-7.60
2.40
-14.21
-49.92
-1.06
31.02
-230.86
-16.85
-18.64
-12.23
-30.69
-9.62
-37.84
25.08
-117.74
-140.70
14.07
-133.71
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HEXESTROL
HEXETIDINE
HEXYLENE GLYCOL
HEXYLRESORCINOL
HIERACIN
HISTAMINE DIHYDROCHLORIDE
HOMATROPINE HYDROBROMIDE
HOMATROPINE METHYLBROMIDE
HOMIDIUM BROMIDE
HOMOPTEROCARPIN
HOMOSALATE
HUMULENE (alpha)
HUPERZINE A
HYCANTHONE
HYDRALAZINE HYDROCHLORIDE
HYDRASTINE (1R, 9S)
HYDRASTININE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE
HYDROCORTISONE
HYDROCORTISONE ACETATE
HYDROCORTISONE BUTYRATE
HYDROCORTISONE HEMISUCCINATE
HYDROCORTISONE PHOSPHATE TRIETHYLAMINE
HYDROCORTISONE VALERATE
HYDROFLUMETHIAZIDE
HYDROLYSIS PRODUCT OF BUSSEIN
HYDROQUINIDINE
HYDROQUININE HYDROBROMIDE HYDRATE
HYDROQUINONE
HYDROXYAMPHETAMINE HYDROBROMIDE
HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE
HYDROXYPROGESTERONE CAPROATE
HYDROXYTOLUIC ACID
HYDROXYUREA
HYDROXYZINE PAMOATE
HYMECHROME

-90.33
-81.36
3.01
-20.50
-10.67
-20.24
19.04
14.96
100.44
-254.80
-244.45
-98.88
-2.19
34.41
28.39
-15.80
18.62
27.36
-18.26
15.44
8.59
-9.23
-4.08
-8.45
-26.17
7.59
12.40
3.20
-23.42
-2.47
8.75
-9.68
-203.26
9.78
3.18
18.15
37.37

243
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HYMECROMONE METHYL ETHER
HYOSCYAMINE
HYPOXANTHINE
IBANDRONATE SODIUM
IBUPROFEN
ICARIIN
IDAZOXAN HYDROCHLORIDE
IDEBENONE
IDOXURDINE
IDRAMANTONE
IFOSFAMIDE
IMEXON
IMIDAZOL-4-YLACETIC ACID SODIUM SALT
IMIPENEM
IMIPRAMINE HYDROCHLORIDE
IMIQUIMOD
INDAPAMIDE
INDOLE-3-CARBINOL
INDOMETHACIN
INDOPROFEN
INOSINE
INOSITOL
IODIPAMIDE
IODIXANOL
IODOQUINOL
IOHEXOL
IOPANIC ACID
IOTHALAMIC ACID
IOVERSOL
IOXILAN
IPRATROPIUM BROMIDE
IPRIFLAVONE
IPRONIAZID SULFATE
IRBESARTAN
IRETOL
IRIDIN
IRIGENIN

-131.59
7.01
-1.78
0.33
-6.26
3.86
-45.18
-168.34
4.84
-2.95
-12.21
-30.03
-14.96
8.23
-68.34
-26.25
2.79
-41.80
13.76
6.76
-28.64
-15.30
-32.38
-2.51
15.50
-10.58
-18.54
-18.61
17.51
1.73
-15.81
-13.23
-5.60
4.74
-6.70
-28.76
-50.85
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Table A.3 Continued.
IRIGENIN TRIMETHYL ETHER
IRIGENIN, 7-BENZYL ETHER
IRIGENIN, DIBENZYL ETHER
IRIGENOL
IRIGINOL HEXAACEATATE
IRINOTECAN HYDROCHLORIDE
IRSOGLADINE MALEATE
ISAXONINE
ISOBERGAPTENE
ISOBUTAMBEN
ISOBUTYLMETHYLXANTHINE
ISOETHARINE MESYLATE
ISOFLUPREDNONE ACETATE
ISOGINKGETIN
ISOKOBUSONE
ISOLIQUIRITIGENIN
ISONIAZID
ISOPEONOL
ISOPIMPINELLIN
ISOPROPAMIDE IODIDE
ISOPROTERENOL HYDROCHLORIDE
ISOROTENONE
ISOSAFROLE
ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE
ISOTECTORIGENIN, 7-METHYL ETHER
ISOTRETINON
ISOVALERAMIDE
ISOXICAM
ISOXSUPRINE HYDROCHLORIDE
ISRADIPINE
ITOPRIDE HYDROCHLORIDE
ITRACONAZOLE
IVERMECTIN
JUAREZIC ACID
JUGLONE
KAEMPFEROL

-18.01
-83.12
-29.04
-54.16
-6.05
23.40
-10.52
-46.23
-0.12
-64.42
-46.70
-108.48
-81.16
1.33
4.16
-35.09
4.13
-2.73
-73.27
10.64
-20.94
-71.23
-28.02
30.36
-14.39
-15.39
-80.73
5.71
3.20
-34.31
-51.71
0.24
-114.11
-151.99
-20.65
-99.47
10.36
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KAINIC ACID
KANAMYCIN A SULFATE
KARANJIN
KASUGAMYCIN HYDROCHLORIDE
KAWAIN
KETANSERIN TARTRATE
KETOCONAZOLE
KETOPROFEN
KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE
KHAYANTHONE
KHELLIN
KHIVORIN
KINETIN
KINETIN RIBOSIDE
KOBUSONE
KOPARIN
KYNURENINE
L(+/-)-ALLIIN
LABETALOL HYDROCHLORIDE
LACCAIC ACID A
LACTOBIONIC ACID
LACTULOSE
LAGOCHILIN
LAMIVUDINE
LAMOTRIGINE
LANATOSIDE C
LANOSTEROL
LANOSTEROL ACETATE
LANSOPRAZOLE
LAPPACONITINE
LARIXINIC ACID
LARIXOL
LARIXOL ACETATE
LATHOSTEROL
L-BUTHIONINE SULFOXIMINE
L-DEOXYALLIIN

3.28
36.98
7.64
14.29
27.60
-6.71
-241.68
-13.29
0.65
-23.97
-38.72
-24.00
-24.41
25.83
-54.96
18.62
-49.17
-38.26
-10.90
-4.26
7.53
-7.22
24.34
-12.35
-13.49
-10.35
-31.92
-44.71
-85.79
-68.21
-14.14
-30.44
-82.35
-125.41
-6.26
-16.80
-15.68
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LECANORIC ACID
LEFLUNOMIDE
LEOIDIN
LETROZOLE
LEUCOVORIN CALCIUM
LEVALBUTEROL HYDROCHLORIDE
LEVAMISOLE HYDROCHLORIDE
LEVCYCLOSERINE
LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE
LEVOCARNITINE PROPIONATE HYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE
LEVODOPA
LEVOFLOXACIN
LEVOMENTHOL
LEVONORDEFRIN
LEVONORGESTREL
LEVOSIMENDAN
LEVOTHYROXINE
LEVULINIC ACID, 3-BENZYLIDENYLLIDOCAINE HYDROCHLORIDE
LIDOFLAZINE
LIGUSTILIDE
LINAMARIN
LINCOMYCIN HYDROCHLORIDE
LINDANE
LIOTHYRONINE
LIOTHYRONINE (L- isomer) SODIUM
LIPOAMIDE
LISINOPRIL
LITHIUM CITRATE
LITHOCHOLIC ACID
L-LEUCYL-L-ALANINE
LOBARIC ACID
LOBELINE HYDROCHLORIDE
LOBENDAZOLE
LOFEXIDINE HYDROCHLORIDE

21.37
6.27
-164.28
-0.62
-10.22
-14.95
-18.37
-6.98
-21.02
7.57
5.20
-14.69
-8.69
23.45
-28.64
-31.08
-64.46
-31.57
3.01
-7.15
-23.59
13.06
-110.50
-6.43
-4.29
-3.14
2.87
0.18
-24.27
21.21
24.58
-89.59
16.25
-1.18
-7.17
-45.05
6.57
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LOMEFLOXACIN HYDROCHLORIDE
LOMERIZINE HYDROCHLORIDE
LOMUSTINE
LONIDAMINE
LOPERAMIDE HYDROCHLORIDE
LORATADINE
LORGLUMIDE SODIUM
LORNOXICAM
LOSARTAN
LOVASTATIN
LOXAPINE SUCCINATE
L-PHENYLALANINOL
LUNARINE
LUPANINE PERCHLORATE
LUPANYL ACID HYDROCHLORIDE
LUPEOL
LUPININE
MADECASSIC ACID
MAFENIDE HYDROCHLORIDE
MALATHION
MANGAFODIPIR TRISODIUM
MANGANESE TETRAKIS(4-CARBOXYPHENYL)PORPHYRIN
CHLORDE
MANGIFERIN
MANGOSTIN TRIMETHYL ETHER
MANNITOL
MAPROTILINE HYDROCHLORIDE
MEBENDAZOLE
MEBEVERINE HYDROCHLORIDE
MEBHYDROLIN NAPHTHALENESULFONATE
MECAMYLAMINE HYDROCHLORIDE
MECHLORETHAMINE
MECLIZINE HYDROCHLORIDE
MECLOCYCLINE SULFOSALICYLATE
MECLOFENAMATE SODIUM
MECLOFENOXATE HYDROCHLORIDE
MECYSTEINE HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE

-37.74
-255.69
-41.80
-24.45
30.36
38.17
-8.23
-8.90
-13.12
-44.37
-2.15
-18.64
-22.90
11.09
-18.30
6.30
3.10
-6.57
-44.13
-476.24
-1.04
-5.97
16.86
-45.49
-3.72
5.83
0.62
40.75
-39.97
21.30
-23.75
-472.39
19.17
-53.54
-0.03
-15.61
-3.00
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MEDRYSONE
MEFENAMIC ACID
MEFEXAMIDE
MEFLOQUINE
MEGESTROL ACETATE
MEGLUMINE
MEGLUTOL
MELATONIN
MELENGESTROL ACETATE
MELEZITOSE
MELIBIOSE
MELOXICAM SODIUM
MELPERONE HYDROCHLORIDE
MELPHALAN
MEMANTINE HYDROCHLORIDE
MENADIONE
MENAQUINONE-4
MENTHONE
MENTHYL BENZOATE
MEPARTRICIN
MEPENZOLATE BROMIDE
MEPHENESIN
MEPHENTERMINE SULFATE
MEPIROXOL
MEPIVACAINE HYDROCHLORIDE
MEPRYLCAINE HYDROCHLORIDE
MEQUINOL
MERBROMIN
MERCAPTOPURINE
MEROGEDUNIN
MEROPENEM
MESALAMINE
MESNA
MESORIDAZINE BESYLATE
MESTRANOL
METACETAMOL
meta-CRESYL ACETATE

-54.33
-104.16
4.94
53.47
-54.20
-17.08
-20.59
-11.51
-110.87
9.79
-19.24
-11.27
-23.27
-19.17
-14.15
93.00
-99.29
-18.49
-1200.51
-66.68
-41.62
8.44
-8.14
-2.46
-22.30
16.60
-65.26
105.70
-13.91
-12.66
31.22
27.95
22.55
2.80
-30.72
4.89
5.01
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METAMECONINE
METAMPICILLIN SODIUM
METAPROTERENOL
METARAMINOL BITARTRATE
METAXALONE
METERGOLINE
METFORMIN HYDROCHLORIDE
METHACHOLINE CHLORIDE
METHACYCLINE HYDROCHLORIDE
METHAPYRILENE HYDROCHLORIDE
METHAZOLAMIDE
METHENAMINE
METHICILLIN SODIUM
METHIMAZOLE
METHIONINE SULFOXIMINE (L)
METHOCARBAMOL
METHOPRENE (S)
METHOTREXATE(+/-)
METHOXAMINE HYDROCHLORIDE
METHOXSALEN
METHOXYAMINE HYDROCHLORIDE
METHOXYVONE
METHSCOPOLAMINE BROMIDE
METHSUXIMIDE
METHYCLOTHIAZIDE
METHYL 7-DESHYDROXYPYROGALLIN-4-CARBOXYLATE
METHYL DEOXYCHOLATE
METHYL ORSELLINATE
METHYL ROBUSTONE
METHYLATROPINE NITRATE
METHYLBENZETHONIUM CHLORIDE
METHYLDOPA
METHYLDOPATE HYDROCHLORIDE
METHYLENE BLUE
METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE

-23.12
-11.38
-1.43
-4.90
-41.43
-256.18
-9.80
-24.46
10.21
2.22
-11.04
1.06
23.03
13.78
-6.34
-8.77
-758.04
23.75
15.54
-74.98
-0.38
-140.43
33.82
-26.05
-6.98
-75.60
-157.39
-22.37
-87.88
-1.45
-55.73
-24.06
5.92
109.92
34.97
1.85
0.70
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METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTHIOURACIL
METHYLXANTHOXYLIN
METHYSERGIDE MALEATE
METICRANE
METITEPINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE
METOPROLOL TARTRATE
METRONIDAZOLE
METYRAPONE
MEVALONIC ACID LACTONE
MEVASTATIN
MEXAMINE
MEXICANOLIDE
MEXILETINE HYDROCHLORIDE
MIANSERIN HYDROCHLORIDE
MICONAZOLE NITRATE
MIDODRINE HYDROCHLORIDE
MIFEPRISTONE
MIGLITOL
MILNACIPRAN HYDROCHLORIDE
MILRINONE
MILTEFOSINE
MIMOSINE
MINAPRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE
MINOXIDIL
MITOMYCIN
MITOTANE
MITOXANTRONE HYDROCHLORIDE
MOCLOBEMIDE
MODAFINIL
MODALINE SULFATE
MOGUISTEINE
MOLINDONE HYDROCHLORIDE
MOLSIDOMINE

9.31
-15.30
-72.09
-11.51
0.17
46.44
-1.81
25.13
-14.90
-31.68
2.50
15.79
0.17
-27.47
-20.56
-11.20
14.01
-197.94
23.55
-106.01
8.77
7.80
1.70
-7.55
18.62
11.90
-30.78
-11.56
-101.21
-747.79
97.53
-5.01
-2.86
-57.43
-19.08
-0.92
-2.93

251
Table A.3 Continued.
MONENSIN SODIUM (monensin A is shown)
MONOBENZONE
MONOCROTALINE
MONTELUKAST SODIUM
MORANTEL CITRATE
MORIN
MOROXYDINE HYDROCHLORIDE
MOXALACTAM DISODIUM
MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE
MOXISYLYTE HYDROCHORIDE
MUCIC ACID
MUNDOSERONE
MUNDULONE
MUNDULONE ACETATE
MUPIROCIN
MUUROLLADIE-3-ONE
MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID
MYOSMINE
N- (9-FLUORENYLMETHOXYCARBONYL)-L-LEUCINE
N,N-HEXAMETHYLENEAMILORIDE
NABUMETONE
N-ACETYLMURAMIC ACID
N-ACETYLNEURAMIC ACID
N-ACETYLPROLINE
NADIDE
NADIFLOXACIN
NADOLOL
NAFCILLIN SODIUM
NAFRONYL OXALATE
NAFTIFINE HYDROCHLORIDE
NAFTOPIDIL
NALBUPHINE HYDROCHLORIDE
NALIDIXIC ACID
NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE

-84.16
-86.14
-1.45
8.11
34.75
0.91
25.64
3.97
-131.04
48.63
-7.47
-12.97
-131.36
-117.53
-291.40
11.17
16.43
-14.40
0.02
-35.34
-75.94
-13.84
-4.83
-6.11
-16.08
-4.24
-40.00
30.42
6.23
12.97
16.04
-63.86
-39.21
8.53
7.37
-4.61
-5.04
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NAPHAZOLINE HYDROCHLORIDE
NAPROXEN(+)
NAPROXOL
NARINGENIN
NARINGIN
NATAMYCIN
NATEGLINIDE
NEFAZODONE HYDROCHLORIDE
NEFOPAM
NELARABIN
NEOMYCIN SULFATE
NEOSTIGMINE BROMIDE
NEROL
NEROLIDOL
NETILMICIN SULFATE
NEVIRAPINE
NIACIN
NIACINAMIDE
NIALAMIDE
NICARDIPINE HYDROCHLORIDE
NICERGOLINE
NICLOSAMIDE
NICORANDIL
NICOTINE BITARTRATE
NICOTINYL ALCOHOL TARTRATE
NIFEDIPINE
NIFENAZONE
NIFLUMIC ACID
NIFUROXAZIDE
NIFURSOL
NIKETHAMIDE
NILUTAMIDE
NIMESULIDE
NIMODIPINE
NIMUSTINE
NIPECOTIC ACID
NISOLDIPINE

1.77
-1.43
-11.58
-5.91
10.47
23.92
0.82
-55.26
-7.51
0.70
-6.70
3.84
-49.31
-12.09
18.89
-8.01
-27.07
12.40
-16.94
-510.40
-57.00
-24.31
20.33
-23.06
-29.41
-125.76
-8.94
-53.03
-141.38
-61.92
11.15
-24.65
-104.07
-36.16
-37.07
-4.02
-238.72
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NITARSONE
NITAZOXANIDE
NITHIAMIDE
NITRENDIPINE
NITROFURANTOIN
NITROFURAZONE
NITROMIDE
NITROXOLINE
NIZATIDINE
N-METHYL (-)EPHEDRINE [1R,2S]
N-METHYLANTHRANILIC ACID
N-METHYLBENZYLAMINE HYDROCHLORIDE
N-METHYL-D-ASPARTIC ACID (NMDA)
N-METHYLISOLEUCINE
NOBILETIN
NOCODAZOLE
NOMIFENSINE MALEATE
NONIC ACID
NONOXYNOL-9
NORCANTHARIDIN
NOREPINEPHRINE
NORETHINDRONE
NORETHINDRONE ACETATE
NORETHYNODREL
NORFLOXACIN
NORGESTIMATE
NORGESTREL
NORHARMAN
NORSTICTIC ACID
NORSTICTIC ACID PENTAACETATE
NORTRIPTYLINE
NOSCAPINE HYDROCHLORIDE
NOVOBIOCIN SODIUM
N-PHENYLANTHRANILIC ACID
NYLIDRIN HYDROCHLORIDE
NYSTATIN
O-BENZYL-l-SERINE

19.99
-61.10
-3.90
-29.12
-12.08
-18.43
-23.78
-85.47
-4.29
-3.64
24.37
3.33
-16.48
-6.56
-101.77
-32.72
2.88
-1.85
-58.57
-56.65
-12.25
-56.45
-70.94
-49.40
20.84
-472.86
-21.03
-34.27
18.31
-184.67
7.73
-19.20
-2.40
-33.90
-16.91
-8.55
-4.09
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OBLIQUIN
OBTUSAQUINONE
OCTISALATE
OCTOCRYLENE
OCTODRINE
OCTOPAMINE HYDROCHLORIDE
OFLOXACIN
OLEANDOMYCIN PHOSPHATE
OLEANOIC ACID
OLEANOLIC ACID ACETATE
OLIGOMYCIN (A shown)
OLMESARTAN
OLMESARTAN MEDOXOMIL
OLTIPRAZ
OMEPRAZOLE
ONDANSETRON
ORBIFLOXACIN
ORLISTAT
ORNIDAZOLE
ORNITHINE
OROTIC ACID
ORPHENADRINE CITRATE
ORSELLINIC ACID
ORSELLINIC ACID, ETHYL ESTER
OSAJIN
OSELTAMIVIR PHOSPHATE
OUABAIN
o-VERATRALDEHYDE
OXACILLIN SODIUM
OXALIPLATIN
OXANTEL PAMOATE
OXAPROZIN
OXCARBAZEPINE
OXEDRINE
OXELAIDIN CITRATE
OXETHAZAINE
OXFENDAZOLE

-45.82
-1452.63
-156.78
-218.18
17.98
21.70
37.31
8.47
-30.95
-66.81
-105.05
16.99
-12.92
-207.03
-2.93
-0.55
0.85
-68.21
-27.00
10.90
-15.03
3.05
-0.78
-64.14
-526.77
24.61
-11.67
-76.02
-7.35
5.85
20.56
-2.36
-18.29
-18.82
-10.52
-43.00
-11.66
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OXIBENDAZOLE
OXICONAZOLE NITRATE
OXIDOPAMINE HYDROCHLORIDE
OXIGLUTATIONE DISODIUM SALT
OXOLAMINE CITRATE
OXOLINIC ACID
OXONITINE
OXTRIPHYLLINE
OXYBENZONE
OXYBUTYNIN CHLORIDE
OXYMETAZOLINE HYDROCHLORIDE
OXYPHENBUTAZONE
OXYPHENCYCLIMINE HYDROCHLORIDE
OXYPHENONIUM BROMIDE
OXYQUINOLINE SULFATE
OXYTETRACYCLINE
OXYTHIAMINE CHLORIDE HYDROCHLORIDE
OZAGREL HYDROCHLORIDE
PACHYRRHIZIN
PACLITAXEL
PAEONOL
PALIPERIDONE
PALMATINE
PALMATINE CHLORIDE
PANCURONIUM BROMIDE
PANGAMIC ACID SODIUM
PANTETHINE
PANTHENOL (dl)
PANTOPRAZOLE
PANTOTHENIC ACID(d) Na salt
PAPAVERINE HYDROCHLORIDE
PARACHLOROPHENOL
PARAMETHADIONE
PARAROSANILINE PAMOATE
PARAXANTHINE
PARGYLINE HYDROCHLORIDE
PAROMOMYCIN SULFATE

6.35
-187.67
-9.98
13.68
-81.85
22.37
-5.41
-16.15
-58.72
-12.42
8.29
-171.53
-11.24
-7.47
-28.80
3.89
-11.15
7.23
14.76
-10.58
-7.59
-5.50
35.20
31.18
14.30
-5.70
-14.86
-7.04
-11.99
-19.44
-73.90
-11.74
23.82
-79.76
-38.05
19.63
6.78
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PAROXETINE HYDROCHLORIDE
PASINIAZID
PATULIN
PAZUFLOXACIN MESYLATE
p-CHLOROPHENYLALANINE
PECTOLINARIN
PEFLOXACINE MESYLATE
PELLETIERINE HYDROCHLORIDE
PEMPIDINE TARTRATE
PENBUTOLOL SULFATE
PENCICLOVIR
PENFLURIDOL
PENICILLAMINE
PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM
PENTACHLOROPHENOL
PENTAGASTRIN
PENTAMIDINE ISETHIONATE
PENTETIC ACID
PENTOLINIUM TARTRATE
PENTOXIFYLLINE
PENTYLENETETRAZOL
PEONIFLORIN
PERGOLIDE MESYLATE
PERHEXILINE MALEATE
PERICIAZINE
PERILLIC ACID (-)
PERILLYL ALCOHOL
PERINDOPRIL ERBUMINE
PERMETHRIN
PERPHENAZINE
PERSEITOL
PERSEITOL HEPTAACETATE
PERUVOSIDE
PEUCENIN
p-FLUOROPHENYLALANINE
PHENACEMIDE

44.58
1.45
-342.17
-27.09
17.71
-40.94
15.01
-27.74
-33.40
-27.87
2.47
-134.52
3.45
-29.00
8.29
-872.61
-4.22
-20.93
25.54
-7.49
4.80
3.75
-16.85
-21.16
28.96
-2.39
-21.83
-94.09
13.69
-103.25
66.40
8.23
8.17
-10.68
-12.05
-10.99
15.88
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PHENACETIN
PHENACYLAMINE HYDROCHLORIDE
PHENAZOPYRIDINE HYDROCHLORIDE
PHENELZINE SULFATE
PHENETHYL CAFFEATE (CAPE)
PHENFORMIN HYDROCHLORIDE
PHENINDIONE
PHENIRAMINE MALEATE
PHENOLPHTHALEIN
PHENOTHIAZINE
PHENOTHRIN
PHENOXYBENZAMINE HYDROCHLORIDE
PHENSUCCIMIDE
PHENTERMINE
PHENTOLAMINE HYDROCHLORIDE
PHENYL AMINOSALICYLATE
PHENYLBUTAZONE
PHENYLBUTYRATE SODIUM
PHENYLEPHRINE HYDROCHLORIDE
PHENYLETHYL ALCOHOL
PHENYLMERCURIC ACETATE
PHENYLPROPANOLAMINE HYDROCHLORIDE
PHENYTOIN SODIUM
PHLORACETOPHENONE
PHLORETIN
PHLORIDZIN
PHTHALYLSULFACETAMIDE
PHTHALYLSULFATHIAZOLE
PHYSCION
PHYSOSTIGMINE SALICYLATE
PHYTOL
PHYTONADIONE
PICEID
PICROPODOPHYLLIN
PICROPODOPHYLLIN ACETATE
PICROTIN
PICROTOXININ

-33.29
-24.50
-10.03
3.71
-137.03
8.17
2.40
-11.09
-34.52
-186.10
-151.67
-324.11
-5.96
-28.55
-0.05
18.80
-1.95
-19.51
-24.92
15.98
101.37
3.32
-25.36
-6.78
-121.32
19.65
-5.38
-8.37
-484.54
-3.29
-184.67
-29.46
-24.10
-48.28
-10.90
-5.12
3.04

258
Table A.3 Continued.
PIDOTIMOD
PILOCARPINE NITRATE
PIMAGEDINE HYDROCHLORIDE
PIMETHIXENE MALEATE
PIMOZIDE
PIMPINELLIN
PINACIDIL
PINDOLOL
PIOGLITAZONE HYDROCHLORIDE
PIPAMPERONE
PIPEMIDIC ACID
PIPENZOLATE BROMIDE
PIPERACETAZINE
PIPERACILLIN SODIUM
PIPERAZINE
PIPERIC ACID
PIPERIDOLATE HYDROCHLORIDE
PIPERINE
PIPERONYL BUTOXIDE
PIPERONYLIC ACID
PIPLARTINE
PIPOBROMAN
PIRACETAM
PIRENPERONE
PIRENZEPINE HYDROCHLORIDE
PIRIBEDIL HYDROCHLORIDE
PIROCTONE OLAMINE
PIROMIDIC ACID
PIROXICAM
PISCIDIC ACID
PIZOTYLINE MALATE
PLUMBAGIN
PODOFILOX
PODOPHYLLIN ACETATE
PODOTOTARIN
POLYMYXIN B SULFATE
POMIFERIN

-18.73
-10.38
-7.49
9.60
-275.76
-33.80
5.20
6.33
-25.59
27.69
-3.73
-1.62
32.62
4.76
-14.30
5.62
16.41
6.20
-7.37
4.81
-131.31
47.44
2.54
-37.75
4.84
-4.73
-54.55
1.91
3.81
-4.43
3.52
-23.88
-7.28
-83.68
-13.20
9.80
-366.96
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Table A.3 Continued.
POTASSIUM p-AMINOBENZOATE
PRALIDOXIME CHLORIDE
PRALIDOXIME MESYLATE
PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOXINE HYDROCHLORIDE
PRANOPROFEN
PRASTERONE
PRASTERONE ACETATE
PRASUGREL
PRAVASTATIN SODIUM
PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE
PREDNICARBATE
PREDNISOLONE
PREDNISOLONE ACETATE
PREDNISOLONE HEMISUCCINATE
PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE
PREGABALIN
PREGNENOLONE SUCCINATE
PRENYLETIN
PRIDINOL METHANESULFONATE
PRILOCAINE HYDROCHLORIDE
PRIMAQUINE PHOSPHATE
PRIMIDONE
PRIMULETIN
PRISTIMERIN
PROADIFEN HYDROCHLORIDE
PROBENECID
PROBUCOL
PROCAINAMIDE HYDROCHLORIDE
PROCAINE HYDROCHLORIDE
PROCARBAZINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE
PROCYCLIDINE HYDROCHLORIDE
PROFLAVINE HEMISULFATE
PROGESTERONE

-21.37
29.77
11.52
14.42
-1.39
0.85
-17.36
-107.41
-19.55
8.69
-2.57
-2.15
-21.54
6.08
-23.41
-6.56
16.46
-8.70
1.18
7.57
14.18
13.74
-5.04
-80.31
-7.44
-140.80
-166.52
-9.73
-36.27
22.18
2.54
-3.50
-1.60
31.52
-15.13
58.47
-113.08
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Table A.3 Continued.
PROGLUMIDE
PROMAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE
PRONETALOL HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE
PROPENTOFYLLINE
PROPIOLACTONE
PROPOFOL
PROPOXUR
PROPOXYCAINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE (+/-)
PROPYLTHIOURACIL
PROSCILLARIDIN
PROTIONAMIDE
PROTIRELIN
PROTOPORPHYRIN IX
PROTOVERATRINE A
PROTRYPTYLINE HYDROCHLORIDE
PROXYPHYLLINE
PRULIFLOXACIN
PSEUDO-ANISATIN
PSEUDOEPHEDRINE HYDROCHLORIDE
PTAEROXYLIN
PUERARIN
PUROMYCIN HYDROCHLORIDE
PURPURIN
PURPUROGALLIN
PURPUROGALLIN-4-CARBOXYLIC ACID
PUTRESCINE DIHYDROCHLORIDE
PYRANTEL PAMOATE
PYRAZINAMIDE
PYRETHRINS
PYRIDOSTIGMINE BROMIDE
PYRIDOXINE
PYRILAMINE MALEATE

-23.71
28.74
-27.00
-18.38
13.15
-50.68
-0.62
3.28
-7.35
-70.70
-23.18
-10.51
17.49
-9.23
-9.05
3.92
-5.37
55.79
1.31
26.94
5.52
-10.14
5.84
-9.68
-225.22
13.05
-7.27
-122.18
-49.43
-28.05
-15.12
24.39
-3.07
-447.81
7.48
-1.32
-22.79
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Table A.3 Continued.
PYRIMETHAMINE
PYRITHIONE ZINC
PYRITHYLDIONE
PYRITINOL
PYROCATECHUIC ACID
PYROGALLIN
PYRONARIDINE TETRAPHOSPHATE
PYRROMYCIN
PYRVINIUM PAMOATE
QUASSIN
QUEBRACHITOL
QUERCETIN
QUERCETIN 5,7,3',4'-TETRAMETHYL ETHER
QUERCITRIN
QUETIAPINE
QUINACRINE HYDROCHLORIDE
QUINALIZARIN
QUINAPRIL HYDROCHLORIDE
QUINAPRILAT
QUINESTROL
QUINETHAZONE
QUINIC ACID
QUINIDINE GLUCONATE
QUININE ETHYL CARBONATE
QUININE SULFATE
QUINOLINIC ACID
QUINPIROLE HYDROCHLORIDE
QUIPAZINE MALEATE
RABEPRAZOLE SODIUM
RACEPHEDRINE HYDROCHLORIDE
RACTOPAMINE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE
RAMIFENAZONE
RAMIPRIL
RAMOPLANIN [A2 shown; 2mM]
RANITIDINE
RANOLAZINE

31.31
69.94
4.39
-14.86
2.63
-345.99
24.19
-207.03
-41.27
-20.56
-31.55
-92.20
-57.93
-4.04
12.75
50.63
9.84
-18.88
21.98
-119.97
0.25
-3.88
-0.46
-32.47
-5.53
-8.72
-16.82
5.50
-2.93
-2.16
-18.52
-8.44
10.31
1.53
-110.63
-36.29
0.19
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Table A.3 Continued.
RASAGILINE
RAUWOLSCINE HYDROCHLORIDE
REBAMIPIDE
REPAGLINIDE
RESERPINE
RESORCINOL
RESORCINOL MONOACETATE
RESVERATROL
RESVERATROL 4'-METHYL ETHER
RETINOL
RETINYL ACETATE
RETINYL PALMITATE
RETUSIN
RETUSIN 7-METHYL ETHER
RHETSININE
RHIZOCARPIC ACID
RHODINYL ACETATE
RHODOCLADONIC ACID
RHOIFOLIN
RIBAVIRIN
RIBOFLAVIN
RIBOFLAVIN 5-PHOSPHATE SODIUM
RIBOSTAMYCIN SULFATE
RIFAMPIN
RIFAXIMIN
RILUZOLE
RIMANTADINE HYDROCHLORIDE
RISEDRONATE SODIUM
RISPERIDONE
RITANSERIN
RITODRINE HYDROCHLORIDE
RITONAVIR
RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE
ROBUSTIC ACID
ROCCELLIC ACID
ROFECOXIB

-20.07
7.83
18.98
4.34
11.94
-3.86
1.77
-4.68
-33.46
-70.56
-182.40
-23.76
3.61
-7.47
-16.10
-30.07
-194.45
4.74
-4.61
-19.21
69.85
-94.57
-13.80
-7.66
-8.06
-39.32
15.34
-0.83
-36.06
-15.04
-16.57
1.31
95.31
2.55
75.72
-17.28
-10.27
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Table A.3 Continued.
ROLIPRAM
ROLITETRACYCLINE
RONIDAZOLE
ROPINIROLE HYDROCHLORIDE
ROSIGLITAZONE MALEATE
ROSMARINIC ACID
ROSOLIC ACID
ROSUVASTATIN CALCIUM
ROTENONE
ROTENONIC ACID, METHYL ETHER
ROXARSONE
ROXATIDINE ACETATE HYDROCHLORIDE
ROXITHROMYCIN
RUFLOXACIN HYDROCHLORIDE
RUTILANTINONE
RUTIN
SACCHARIN
SAFROLE
SALICIN
SALICYL ALCOHOL
SALICYLAMIDE
SALICYLANILIDE
SALIDROSIDE
SALINOMYCIN, SODIUM
SALMETEROL XINAFOATE
SALSALATE
SALSOLIDINE
SALSOLINE
SALSOLINOL HYDROBROMIDE
SALVINORIN A
SANGUINARIUM SULFATE
SANTONIN
SAPPANONE A DIMETHYL ETHER
SARAFLOXACIN HYDROCHLORIDE
SAXAGLIPTIN
SCLAREOL
SCLAREOLIDE

-120.30
-36.48
-32.72
3.45
10.08
7.41
-57.04
-27.38
-45.82
-138.44
-18.60
-21.81
1.04
22.86
-696.28
-0.69
11.51
-102.39
-42.43
-14.71
-3.65
-204.66
19.89
-152.61
-71.41
16.55
8.47
1.82
-4.64
-105.89
-38.43
-30.35
-113.75
-6.79
11.70
-29.41
-140.92
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Table A.3 Continued.
SCOPOLAMINE HYDROBROMIDE
SCOPOLETIN
SECNIDAZOLE
SECURININE
SELAMECTIN
SELEGILINE HYDROCHLORIDE
SEMUSTINE
SENNOSIDE A
SENNOSIDE B
SERATRODAST
SEROTONIN HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE
SHIKIMIC ACID
SIBUTRAMINE HYDROCHLORIDE
SILDENAFIL CITRATE
SILIBININ
SIMVASTATIN
SINAPIC ACID
SINAPIC ACID METHYL ETHER
SINENSETIN
SINOMENINE
SIROLIMUS
S-ISOCORYDINE (+)
SISOMICIN SULFATE
SITAGLIPTIN
SITOSTERYL ACETATE
SKATOLE
SMILAGENIN
SMILAGENIN ACETATE
SNAP (S-NITROSO-N-ACETYLPENICILLAMINE)
SODIUM FLUOROACETATE
SODIUM MONOFLUOROPHOSPHATE
SODIUM NITROPRUSSIDE
SODIUM OXYBATE
SODIUM PHENYLACETATE
SODIUM PHENYLBUTYRATE
SODIUM SALICYLATE

-1.32
24.78
-11.38
-79.90
-158.83
-34.14
-108.88
1.40
-20.10
-99.16
2.01
6.11
-8.07
-44.14
-0.55
-245.16
-128.76
25.53
8.53
0.52
-15.70
-77.69
2.65
-32.18
-51.49
-12.12
-83.28
-60.25
-16.36
9.61
-43.62
5.21
-0.83
-0.48
-68.10
13.28
-10.78
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Table A.3 Continued.
SODIUM TETRADECYL SULFATE
SODIUM THIOGLYCOLATE
SOLANESOL
SOLANESYL ACETATE
SOLASODINE
SOLIDAGENONE
SOLIFENACIN SUCCINATE
SORBITOL
SOTALOL HYDROCHLORIDE
SPAGLUMIC ACID
SPARFLOXACIN
SPARTEINE SULFATE
SPECTINOMYCIN HYDROCHLORIDE
SPERMIDINE TRIHYDROCHLORIDE
SPERMINE
SPHONDIN
SPIPERONE
SPIRAMYCIN
SPIRONOLACTONE
SR-2640
STAVUDINE
STICTIC ACID
STIGMASTA-4,22-DIEN-3-ONE
STIGMASTEROL
STREPTOMYCIN SULFATE
STREPTOZOSIN
STROPHANTHIDIN
STROPHANTHIDINIC ACID LACTONE ACETATE
STRYCHNINE
STRYCHNINE METHIODIDE
SUCCINYLSULFATHIAZOLE
SUCRALFATE SODIUM (10mM 10% aq DMSO)
SUCRALOSE
SULBACTAM
SULBENTINE
SULCONAZOLE NITRATE
SULFABENZAMIDE

-6.12
27.91
-115.03
-28.68
0.52
-94.47
-37.43
-18.61
-1.25
20.33
0.28
-2.02
9.80
-24.10
-16.94
-11.84
-29.41
-0.56
-28.41
-28.46
2.94
6.65
-16.94
-18.30
-11.59
-1.87
-20.97
6.98
10.88
15.79
5.13
-58.78
10.98
10.92
-79.20
-72.73
-4.00
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Table A.3 Continued.
SULFACARBAMIDE
SULFACETAMIDE
SULFACHLORPYRIDAZINE
SULFADIAZINE
SULFADIMETHOXINE
SULFADOXINE
SULFAGUANIDINE
SULFAMERAZINE
SULFAMETER
SULFAMETHAZINE
SULFAMETHIZOLE
SULFAMETHOXAZOLE
SULFAMETHOXYPYRIDAZINE
SULFAMONOMETHOXINE
SULFANILATE ZINC
SULFANITRAN
SULFAPHENAZOLE
SULFAPYRIDINE
SULFAQUINOXALINE SODIUM
SULFASALAZINE
SULFATHIAZOLE
SULFINPYRAZONE
SULFISOXAZOLE
SULFISOXAZOLE ACETYL
SULINDAC
SULISOBENZONE
SULMAZOLE
SULOCTIDIL
SULPIRIDE
SUMATRIPTAN SUCCINATE
SUPROFEN
SURAMIN HEXASODIUM
SUXIBUZONE
SYMCLOSENE
SYRINGIC ACID
TACRINE HYDROCHLORIDE
TACROLIMUS

-7.37
11.64
-35.01
-4.51
-19.07
14.01
-8.15
-2.79
29.00
6.45
-3.22
9.14
-9.48
-14.08
-3.76
-11.78
-14.04
17.68
11.09
13.38
-16.98
-4.15
13.71
-225.21
-76.58
9.32
-13.80
-34.47
4.67
-14.25
10.52
12.07
-5.75
-6.03
-22.72
-4.51
-39.24
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Table A.3 Continued.
TADALAFIL
TAMOXIFEN CITRATE
TANDUTINIB
TANGERITIN
TANNIC ACID
TANSHINONE IIA
TANSHINONE IIA SULFONATE SODIUM
TAPENTADOL HYDROCHLORIDE
TAURINE
TAZOBACTAM
TEGASEROD MALEATE
TEICOPLANIN [A(2-1) shown]
TELENZEPINE HYDROCHLORIDE
TELITHROMYCIN
TELMISARTAN
TEMEFOS
TEMOZOLAMIDE
TENATOPRAZOLE
TENIPOSIDE
TENOXICAM
TENYLIDONE
TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE
TERBUTALINE HEMISULFATE
TERCONAZOLE
TERFENADINE
TERPENE HYDRATE
TESTOSTERONE
TESTOSTERONE PROPIONATE
TETRACAINE HYDROCHLORIDE
TETRACHLOROISOPHTHALONITRILE
TETRACYCLINE HYDROCHLORIDE
TETRAHYDROGAMBOGIC ACID
TETRAHYDROSAPPANONE A TRIMETHYL ETHER
TETRAHYDROZOLINE HYDROCHLORIDE
TETRAMIZOLE HYDROCHLORIDE
TETRANDRINE

16.25
-52.87
-9.88
-38.20
43.89
-218.61
-49.88
0.01
-15.62
6.96
28.44
-17.53
-4.52
2.35
-7.79
4.40
-16.37
2.36
-52.24
12.19
-143.05
-0.69
-1117.66
4.13
-60.28
17.60
12.12
-53.81
-167.68
7.37
38.66
29.71
-155.12
-48.52
-8.03
-26.24
-44.94
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Table A.3 Continued.
TETROQUINONE
THALIDOMIDE
THEAFLAVIN
THEANINE
THEOBROMINE
THEOPHYLLINE
THERMOPSINE PERCHLORATE
THIABENDAZOLE
THIAMINE
THIAMPHENICOL
THIAMYLAL SODIUM
THIMEROSAL
THIOCTIC ACID
THIODIGLYCOL
THIOGUANINE
THIOGUANOSINE
THIOPENTAL SODIUM
THIORIDAZINE HYDROCHLORIDE
THIOSTREPTON
THIOTEPA
THIOTHIXENE
THIRAM
THONZONIUM BROMIDE
THONZYLAMINE HYDROCHLORIDE
THYMOPENTIN
THYMOQUINONE
TIAPRIDE HYDROCHLORIDE
TIBOLONE
TICARCILLIN DISODIUM
TICLOPIDINE HYDROCHLORIDE
TIGOGENIN
TILARGININE HYDROCHLORIDE
TILETAMINE HYDROCHLORIDE
TILMICOSIN
TILORONE
TIMOLOL MALEATE
TIMONACIC

-32.56
-13.90
18.62
-1.99
-1.67
3.01
22.68
-15.55
-19.66
-7.46
14.75
75.93
15.77
6.22
27.41
2.62
1.27
44.31
-3.36
19.60
36.75
16.35
33.87
1.04
-31.48
104.76
21.34
-67.78
-34.80
-33.35
-0.25
-12.82
14.75
3.13
7.93
9.44
10.84
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Table A.3 Continued.
TINIDAZOLE
TIOCONAZOLE
TIOPRONIN
TIOXOLONE
TIRATRICOL
TOBRAMYCIN
TOCAINIDE HYDROCHLORIDE
TODRALAZINE HYDROCHLORIDE
TOLAZAMIDE
TOLAZOLINE HYDROCHLORIDE
TOLBUTAMIDE
TOLFENAMIC ACID
TOLMETIN SODIUM
TOLNAFTATE
TOLONIUM CHLORIDE
TOLPERISONE HYDROCHLORIDE
TOLTRAZURIL
TOMATIDINE HYDROCHLORIDE
TOMATINE
TOPIRAMATE
TOPOTECAN HYDROCHLORIDE
TOREMIPHENE CITRATE
TOTAROL
TOTAROL ACETATE
TOTAROL-19-CARBOXYLIC ACID, METHYL ESTER
TRACAZOLATE
TRAMADOL HYDROCHLORIDE
TRAMIPROSATE
TRANDOLAPRIL
TRANEXAMIC ACID
TRANILAST
TRANYLCYPROMINE SULFATE
TRAVOPROST
TRAZODONE HYDROCHLORIDE
TRETINOIN
TRIACETIN
TRIACETYLRESVERATROL

-22.68
-97.63
-41.87
-177.79
-69.75
38.60
-37.18
5.59
-9.24
-19.29
30.92
-212.92
6.84
-49.79
110.45
9.07
-25.31
-28.77
102.87
3.41
60.75
-44.59
-862.37
-826.37
-755.34
-91.43
4.34
3.11
12.84
-14.25
54.21
5.58
-17.24
5.37
-117.23
16.51
-109.70
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Table A.3 Continued.
TRIAMCINOLONE
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE
TRIAMTERENE
TRICHLORFON
TRICHLORMETHIAZIDE
TRICHLORMETHINE HYDROCHLORIDE
TRICLABENDAZOLE
TRICLOSAN
TRIENTINE HYDROCHLORIDE
TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLUPROMAZINE HYDROCHLORIDE
TRIFLURIDINE
TRIGONELLINE
TRIHEXYPHENIDYL HYDROCHLORIDE
TRILOSTANE
TRIMEBUTINE MALEATE
TRIMEDLURE
TRIMEPRAZINE TARTRATE
TRIMETAZIDINE DIHYDROCHLORIDE
TRIMETHADIONE
TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM
TRIMETHYLCOLCHICINIC ACID
TRIMETOZINE
TRIMIPRAMINE MALEATE
TRIOXSALEN
TRIPELENNAMINE CITRATE
TRIPROLIDINE HYDROCHLORIDE
TRIPTOPHENOLIDE
TRISODIUM ETHYLENEDIAMINE TETRACETATE
TROCLOSENE POTASSIUM
TROLOX
TROPICAMIDE
TROPISETRON HYDROCHLORIDE
TROXERUTIN
TRYPTAMINE

-19.98
14.80
10.70
14.47
1.40
-4.65
-18.90
-40.18
-461.75
-7.01
-15.55
22.31
-0.28
18.26
12.87
-108.87
-62.49
-112.71
-13.39
-9.75
3.91
-30.30
15.17
6.17
6.72
-23.58
-75.94
-5.38
11.29
-109.10
20.22
-5.52
-9.17
-23.32
19.03
6.28
-25.58
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Table A.3 Continued.
TRYPTOPHAN
TUAMINOHEPTANE SULFATE
TUBOCURARINE CHLORIDE
TULOBUTEROL HYDROCHLORIDE
TYLOSIN TARTRATE
TYLOXAPOL
TYRAMINE
TYROTHRICIN
UBIDECARENEONE
UMBELLIFERONE
UNDECYLENIC ACID
URACIL
URAPIDIL HYDROCHLORIDE
UREA
URETHANE
URIDINE
URIDINE TRIPHOSPHATE TRISODIUM
URSINOIC ACID
URSOCHOLANIC ACID
URSODIOL
USNIC ACID
UTILIN
VALACYCLOVIR HYDROCHLORIDE
VALERYL SALYCILATE
VALGANCICLOVIR HYDROCHLORIDE
VALINOMYCIN
VALPROATE SODIUM
VALSARTAN
VANCOMYCIN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE
VECURONIUM BROMIDE
VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE
VERATRIC ACID
VERATRINE SULFATE
VESAMICOL HYDROCHLORIDE
VIDARABINE

7.37
5.64
15.01
-5.97
-15.21
-58.16
-10.99
84.13
2.84
7.70
-15.54
3.14
-21.20
-0.95
5.65
-7.92
-24.68
3.61
-149.90
-4.00
-32.33
-35.60
16.30
-46.14
11.73
-225.04
13.92
-19.71
12.52
-15.73
4.67
12.69
-4.96
5.05
8.90
-10.78
-19.46
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Table A.3 Continued.
VINBLASTINE SULFATE
VINCRISTINE SULFATE
VINORELBINE
VINPOCETINE
VIOMYCIN SULFATE
VISNAGIN
VORICONAZOLE
VORINOSTAT
VULPINIC ACID
WARFARIN
XANTHONE
XANTHOPTERIN
XANTHOXYLIN
XANTHURENIC ACID
XANTHYLETIN
XYLAZINE
XYLOCARPUS A
XYLOMETAZOLINE HYDROCHLORIDE
XYLOSE
YOHIMBIC ACID HYDRATE
YOHIMBINE HYDROCHLORIDE
ZALCITABINE
ZALEPLON
ZAPRINAST
ZIDOVUDINE [AZT]
ZILEUTON
ZINC UNDECYLENATE
ZIPRASIDONE MESYLATE
ZOLMITRIPTAN
ZOMEPIRAC SODIUM
ZOPICLONE
ZOXAZOLAMINE

-32.74
-21.89
-71.32
-2.93
28.84
-8.12
-45.42
-153.07
-3.20
-13.64
-100.74
24.22
-7.97
1.43
-82.39
-0.47
-31.38
-28.90
12.29
-6.79
-10.06
0.01
33.32
6.34
-5.33
-51.13
-14.47
-291.85
18.79
-10.41
41.07
-61.79
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Several compounds that were identified in the small molecule screen of
the Spectrum Collection (6944-0074 and G856-6223 are structural analogues of
robustic acid and were purchased from ChemDiv, San Diego, CA) for inhibitors of
AC2 activity in HEK-hAC2 cells were further characterized for the ability to
modulate cAMP accumulation in response to activation of AC isoforms in HEKhAC2 (activation by 50 nM PMA, 3 μM forskolin, and 300 nM PGE2), HEK-hAC1
(activation by 3 μM A23187), HEK-hAC5 (activation by 300 nM forskolin), and
HEK-wt cells (activation by 3 μM forskolin) as described in chapter 4 (Table A.4).
.

Table A.4 AC isoform-selectivity profiles of test compounds in intact-cell studies. AC isoform selectivity was assessed
by testing the ability of test compounds (30 µM) to modulate cAMP responses in HEK-hAC2 cells, HEK-hAC1 cells,
HEK-hAC5 cells, and HEK-wt cells. Data are reported as a percent of the vehicle treatment condition and represent
the Mean ± S.E.M. of three independent experiments. * p < 0.05, ** p < 0.01,*** p < 0.001 compared to vehicle
condition, one sample t-test compared to 100.

AC2

Amlodipine Besylate
Nifedipine
Nicardipine HCl
6944-0074
G856-6223
Fluphenazine diHCl
Methiothepin Maleate
Perphenazine
(-)-Riboflavin
Deoxyadenosine
BisI

50 nM
PMA
Mean±SEM
66±13
180±22
270±48
220±27*
200±51
78±12
69±11
65±6.1*
88±24
64±4.2*
2.3±1.4***

300 nM
3 µM FSK
PGE2
Mean±SEM Mean±SEM
90±3.0
75±2.8*
160±8.3*
260±14**
110±9.0
230±28*
100±8.7
210±13*
110±3.9
170±10*
180±18
93±7.5
220±2.0*** 76±8.1
170±13*
81±8.5
64±27
86±29
93±7.1
100±5.1
88±3.5
90±9.3

AC1
3 µM
A23187
Mean±SEM
140±14
110±16
150±24
130±9.5
120±8.2
62±5.0*
45±1.8**
59±5.6*
76±8.3
94±6.3
81±4.3*

AC5
300 nM
FSK
Mean±SEM
110±4.8
130±11
110±2.0*
120±6.3
110±11
84±6.4
96±7.0
93±2.3
150±40
94±4.1
95±4.9

WT
3 µM FSK
Mean±SEM
110±15
150±11*
120±13
170±11*
160±7.4*
99±5.2
120±8.1
110±4.9
260±50
85±5.2
100±1.5
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